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Abstract 
 
Sulfur amino acids have critical function as intracellular redox buffers and maintain 
homeostasis in the external milieu by combating oxidative stress. Synthesis of 
glutathione (GSH) is regulated at a substrate level by cysteine, which is synthesized by 
homocysteine via the transsulfuration pathway. Oxidative stress and diminished 
glutathione pools play a sustained role in the pathogenesis of acute pancreatitis.  
 
One of the aims of this study was to experimentally address the temporal relationship 
between plasma sulfur amino acid levels in patients suffering from acute pancreatitis. 
The data indicated low concentration of cysteine initially, at levels similar to those of 
healthy controls. Glutathione was found reduced whilst cysteinyl-glycine and γ-
glutamyl transpeptidase activity were increased in both mild and severe attacks. As the 
disease progressed, glutathione and cysteinyl-glycine were further increased in mild 
attacks and cysteine levels correlated with homocysteine and γ-glutamyl transpeptidase 
activity. The progress of severe attacks was associated with glutathione depletion, 
reduced γ-glutamyl transpeptidase activity and increased cysteinyl-glycine, that 
correlated with glutathione depletion. The corollary that ample supply of cysteine and 
cysteinly-glycine does not contribute towards glutathione synthesis in acute pancreatitis 
poses an important issue that merits resolution. Heightened oxidative stress and 
depletion of glutathione rationalized the progression of disease in severe attacks.  
 
An upsurge that reactive oxygen species can shift redox state of cells is determined by 
the ratio of the abundant redox couples reduced and oxidized glutathione (GSH: GSSG) 
in cell. The study reported a novel methodology for quantification of total oxidized 
glutathione (tGSSG) and total glutathione (tGSH) in whole blood using reverse phase 
high performance liquid chromatography. The novelty of the method is ascertained by 
the use of a mercaptan scavenger 1, methyl-2-vinyl-pyridinium trifluromethanesulfonate 
for the total oxidized glutathione determination. The results reported permit quantitation 
of tGSSG and tGSH and was applied to a control group.  
 
Finally, the study was also focussed in developing a liquid chromatography-mass 
spectrometric method to evaluate free and conjugated bile acids in patients suffering 
from various degrees of cholestatic-hepatobiliary disorders. The study reported low 
levels of ursodeoxycholic acid (UDCA) and slightly high levels of lithocholic acid 
(LCA). All the primary bile acids seem to be conjugated with glycine and taurine amino 
acid.  
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CHAPTER 1. Introduction 
1.1. Oxidative stress 
 
Evolution of organisms to adapt to oxygenated environment has heralded a permanent 
transformation in the development of effective cellular strategies to detect and detoxify 
metabolites of molecular oxygen widely known as reactive oxygen species (ROS). The 
term ROS encompasses a wide variety of chemical species that include oxygen centred 
radicals. Although, ROS have been known to actively participate in a diverse array of 
biological/ physiological process (such as regulation of vascular tone, normal cell 
growth, senescence, apoptosis) (Droge, 2002), they are also known to trigger a 
divergent response. The outcome of which reflects the subtle difference in the level and 
duration of the oxidant burst that accompanies oxidative stress (Frein et al., 2005).   
The concept of oxidative stress has become interventional after the discovery of 
molecular oxygen by Joseph Priestley in 17th Century. Ever since its discovery, 
molecular oxygen has been a topic of intense debate and almost a paradox. Since then 
amassed wealth of scientific knowledge have suggested the formation and role of 
various free radicals produced during and after biochemical reactions in aerobic species. 
Further oxidation, describes an oxidative event that can or cannot be a reversible 
reaction and the term stress, delineates a deviation from the normal physiological 
process. Thus, the term “oxidative stress” is characterized as a persistent oxidative shift 
towards a pathophysiological event in the absence of a counterbalancing regulatory 
response called redox regulation. Redox, on the other hand, is a regulatory process, 
inducing a protective response against oxidative damage caused by accumulation of free 
radicals. Thus, the cells use redox process to reset to the original state of redox 
homeostasis after temporary exposure to ROS.   
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Nevertheless, the survival of the cell during and/ or after a stress insult is dependent 
upon the ability of the cell to adapt or resist the stress. Exposure of cells to high levels 
of ROS for prolonged time perturbs the normal redox regulation and shifts the cells into 
a state of oxidative stress. Free radicals thus formed during these processes create a 
stress environment in the cells resulting in a pattern of cumulative damage and/ or cell 
injury (Figure 1.1). 
 
Figure 1.1. Schematic representation of production of free radicals as results various 
biochemical pathways and possible mechanism of cell injury. (Adapted from: (James et 
al., 2004) 
1.1.1. Free radicals, their formation and types 
 
Free radicals are electrically charged molecular species capable of independent 
existence that contains an unpaired electron in their atomic orbital (Halliwell and 
Gutteridge, 1988). These species are highly reactive and unstable due to the presence of 
 = Oxidative stress
    Cell  
Injury 
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unpaired electron(s) thus, behaving as oxidants or reductants as they can either donate 
or extract an electron from other molecules.  
Free radicals are formed when covalent bonds between entities are broken and one 
electron remains with each newly formed atom. Oxygen centred free radicals contain 
two unpaired electrons in the outer shell. When free radicals acquire an electron from a 
surrounding compound or molecule, a new free radical is formed in its place. The newly 
formed radical in an attempt to return to its ground state acquires or loses electron(s) 
with anti-parallel spins from cellular structures or molecules thus continuing the 
formation. A number of mechanisms within the body and external sources lead to 
formation of free radicals (Figure 1.2). 
There are numerous types of free radicals formed within the body such as: superoxide 
anions (O2-), hydroxyl radical (•OH), and hydrogen peroxide (H2O2).  
Superoxide (O2-) are abundant and 2% of the oxygen consumed by cells are converted 
into O2-(Ward, 1988). They are formed when oxygen acquires an additional electron, 
leaving the molecule with only one unpaired electron. This radical is not particularly 
reactive relative to other species. However, either by spontaneous action or through 
enzymatic action of superoxide dismutases, it is converted into H2O2 and O2 (Fridovich, 
1995). In biological systems, O2- can be converted (nonenzymatically) to hydrogen 
peroxide (H2O2) (Fridovich, 1978, Deby and Goutier, 1990). H2O2 can also be formed 
directly from O2 through the two-electron transfer by a number of oxidases (e.g. urate 
oxidase, monoamine oxidase, and xanthine oxidase). Compared with oxygen radicals, 
H2O2 is relatively stable and can easily diffuse across cellular membranes. In the 
presence of reduced transition metal ions such as copper or iron, H2O2 can undergo 
reduction to the hydroxyl anion via the Fenton reaction, yielding the hydroxyl radical 
(•OH) (Halliwell and Gutteridge, 1988). •OH radical can also arise from the hemolytic 
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fission of H2O2 by ultraviolet light, the hydrolysis of water by ionizing radiation, or the 
metabolic reactions of certain chemicals (Halliwell, 1999). Thus, •OH is probably the 
most potent oxygen radical and can react non-specifically with any biological 
molecules. 
 
Figure 1.2. Possible endogenous and exogenous sources of free radicals and their 
effects on the cellular physiology. Possible cellular responses to counteract oxidative 
stress and regulate physiological homeostasis.    (Adopted from (Finkel and Holbrook (2000).  
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1.1.2. Cellular sources of oxidants and oxidative stress response by organism 
Four keys sources in aerobic organisms generate ROS, 1) the mitochondrial electron 
transpor, 2) peroxisomal metabolism 3) cytochrome P450 reactions and 4) phagocytotic 
cells. Mitochondrial respiratory chain produces the majority of ROS through NADH 
dehydrogenase and ubiquinone-cytochrome c reductase thus contributing towards the 
production of O2- radicals (Turrens, 1997). During respiratory process, the oxygen 
radicals capture electrons and leak out of electron transport cycle leading to the 
formation of O2- radical. Peroxisomes contain a number of H2O2 generating oxidases, 
including fatty acyl-CoA oxidase and urate oxidase. These enzymes remove two 
electrons from substrates and ultimately transfer the electrons to O2 to form H2O2.  
The cytochrome P450 enzymes also generate generous portions of ROS in the cell. 
These enzymes are primarily mixed-function oxidases found in the microsomes. The 
endogenous substrates of these enzymes include fatty acids, steroids, prostaglandins, 
leukotrienes, and thromboxanes (Puntarulo and Cederbaum, 1998). In addition, the 
P450s are able to act on a variety of xenobiotic compounds. The catalytic mechanism of 
cytochrome P450s involves several steps of one-electron transfers among NADPH, the 
substrates and O2. Such steps, if uncoupled, may generate O2
·- superoxide anion and 
H2O2 as by-products (Puntarulo and Cederbaum, 1998). Neutrophils and macrophages 
are able to enhance the uptake of oxygen and use it to generate a mixture of free 
radicals, including O2-, H2O2, and nitric oxide (Robinson and Badwey, 1994). These 
oxidants are part of the defence mechanism to allow immune cells to kill invading 
pathogens. 
 
In order to counteract the oxidants, the cells in time with evolution have developed an 
impressive repertoire of strategies to detect and detoxify the metabolites of ROS. A 
number of stress response mechanisms in the cell, either in a cooperative or in an 
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antagonistic manner have evolved to adapt to the stress response. Many of these 
pathways and/ or response have led to the evolution of innate cellular protective 
mechanisms contrary to oxidation. These innate free radical defence mechanisms are 
maintained by the intracellular redox regulating molecules (Go and Jones, 2005, 
Rubartelli and Sitia, 2009, Nkabyo et al., 2005) and these molecules primarily function 
to create an intra and extracellular reducing environment. Thus, redox describes all the 
chemical reactions in which the atoms have their oxidation state changed. The redox 
systems, that include the glutathione (GSH) and thioredoxin (TRX) system, function 
primarily to contribute towards a reducing environment. In addition to these molecules, 
there are certain cellular antioxidant enzyme systems that contribute towards 
maintaining redox homeostasis by counteracting the ROS. Some of these antioxidant 
enzymes are superoxide dismutases (SOD), catalase, glutathione transferases (GST’s), 
and glutathione peroxidise (GP). These protein antioxidant enzymes are combined with 
non-protein intracellular scavengers namely GSH, ascorbate and vitamin E (Table 1.1). 
 
Table 1.1. Schematic representation of ROS produced, damage caused and antioxidant 
defence to counteract the oxidant production.   
 
Oxidative stress Damage caused by ROS Antioxidant 
defences 
Hydroxy radical Adds bases to DNA, damage to lipid 
bilayer, mitochondrial damage 
SOD, GPx, GR 
Hydrogen peroxides Diffuses nuclear membrane causing DNA 
damage, capable of penetrating plasma 
membrane  
GPx, catalase 
Superoxide’s Membrane diffusible GR and SOD 
ONOO- Homolysis to NO2 and OH radicals Vitamin E 
4-Hyrdoxynonenal Aldehyde product of lipid peroxidation Lipoic acid 
Xenobiotics Endogenous origin GST’s and GPx 
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1.1.3. The emerging concept of redox regulation 
 
A mechanism in the body subject the cells to follow redox regulation to achieve redox 
homeostasis, as redox balance is fundamental for a cell existence. Under normal 
physiological conditions, the human body is inevitably submitted to oxidative reactions 
through various biochemical pathways. However, to counteract this, large batteries of 
antioxidants swiftly repair and replace the likely harm. These antioxidant systems 
maintain the redox balance/ homeostasis by scavenging the oxidant species.  
Under instances where the free radical activity suddenly increases as a consequence of 
either primary (e.g. excess radiation exposure) or secondary, (e.g. tissue damage by 
trauma) insults, the antioxidant defence will be weakened. Under these circumstances, 
the cells fail to tolerate these abruptive changes over long period leading to macroscopic 
shifts in redox potentials that divulge a failure in the stress responses (Jones, 2006). As 
a result, pathophysiological events such as accumulation of free radicals, lipid 
peroxidation products, DNA strand break following oxidation of proteins occurs, 
overwhelming cell leading to cell damage/ death. This damage can be apoptotic, 
necrotic or reversible, irreversible in nature.  
Many current perspectives favour the evidence for the existence of a redox regulatory 
network intimately linked with cellular functions in both normal and pathological 
conditions (Finkel, 2003). These redox regulatory reactions describe a reversible phase 
during which oxidative reactions like zinc finger oxidation, methionine sulfoxidation, 
glutathiolation, S-nitrosation return to a resting state by reductive pathways including 
changes in oxidation states of metals (Frein et al., 2005).  
Accumulated measurable evidence of such insults caused by free radical accretion 
instigating stress initiation, contribute to many consequences of aging and major disease 
process including cardiovascular (Stocker and Keaney, 2004), pulmonary diseases 
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(Cantin, 2004), diabetes (Bonnefont-Rosselot, 2004), neurodegenerative diseases (Vina 
et al., 2004) and cancer (Berger, 2005) are abundant. Also, increased oxidative stress 
presents an important mechanism in the genesis and progression of several diseases in 
humans (Halliwell, 1993). One of the classic examples of such a progressive 
inflammatory disease is acute pancreatitis.   
1.1.4. Redox regulation in body systems 
 
Redox regulation is exhibited in cells/ tissues that are subjected to oxidative/reductive 
stress and the response imparted reflects the state of the redox couples in the cells. As 
stated erstwhile by Sir Hans Krebs, “Redox state describes the ratio of interconvertible 
oxidized and reduced form of specific redox couple emphasizing on NAD+/ NADPH 
redox couple”. However the statement later was slightly modified with a contemporary 
definition – “Redox state not only describes the state of a particular redox pair but 
describes the redox environment of the cell and defines the half-cell reduction potential 
and the reducing capacity of the redox couples”– NADP+/ NADPH, GSH/GSSG and 
reduced and oxidized thioredoxin (TRXss/TRX(SH2). Therefore, the reducing capacity 
of the cell is important in maintaining the redox environment (Schafer and Buettner, 
2001).  
The three major redox systems in the body as mentioned above are interdependent with 
each other. GSH/GSSG and TrxSS/ Trx (SH2) use NADPH as a source for their 
reducing equivalents. The GSH/GSSG system forms the representative principal redox 
buffer of the cell because of its concentration, which is far higher than the other two-
redox buffers. Thus, the overall redox environment is the contribution of GSH/GSSG 
ratio.  
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1.1.5. Role of amino thiols in redox regulation 
 
Amino thiols have a critical function as intracellular redox buffers and extend an 
important purpose as extracellular redox system. Low molecular weight thiol-containing 
amino acids have an essential role in maintaining the cells redox state. Oxidation of 
GSH, Cys and Met is one among cellular response to an increase ROS production 
(Schafer and Buettner, 2001).  
1.2. Sulfur amino acid metabolism 
 
Methionine (Met) and cysteine (Cys) are considered the principal sulfur-containing 
amino acids. Met is an essential amino acid initiating protein synthesis in eukaryotes. 
Cys plays a critical role as a precursor amino acid for proteins in maintaining protein 
structure by virtue of its ability to form disulfide bonds. Met is an essential amino acid 
obtained significantly from the diet while Cys is a semi-essential amino acid as it can be 
produced de novo by the site specific transsulfuration pathway (Finkelstein, 1990). 
Dietary amino acids are mainly absorbed in the apical membrane system and enter the 
plasma circulating as free amino acids. The metabolic cycling of Met is central to many 
important methylation reactions in the body. Met and Cys are metabolically linked via 
the transsulfuration pathway, allowing Met to serve as a source for Cys synthesis.  
Much of the interest in sulfur amino acid metabolism in the past decade has been 
focussed on the possible role of homocysteine (Hcy) in various cardiovascular and 
neurological diseases (Janosikova et al., 2003, Graham et al., 1997). However, more 
recently Cys, has been implicated in cellular redox function and as a possible indicator 
of oxidative damage (El-Khairy et al., 2001, El-Khairy et al., 1999). Cys has pleotropic 
roles in the body. Most importantly, the sulfur atom in Cys in vivo has an ability to 
occur in ten different oxidation states. These different oxidation states perhaps helps in a 
range of cysteine modifications in peptides and proteins (Giles et al., 2003).  
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Transmethylation provides a pathway for methionine metabolism beginning with its 
activation of S-adenosylmethionine (SAM) (Figure 1.3). SAM plays a vital role in Met 
metabolism. Met is converted to SAM in presence of methionine adenosyl transferases 
(MAT) and is ATP dependent. In mammals, SAM serves as a source a primary methyl 
donor for various biological methylations in the body (Williams and Schalinske, 2007). 
The utility of SAM as a methyl donor lies in its active high-energy sulfonium ion and 
the electrophilic nature of its carbon atoms adjacent to sulfur atoms (Brosnan and 
Brosnan, 2006). SAM dependent methylations are essential in various biosynthetic 
cellular components like phospholipids, proteins, DNA, RNA, creatine, carnitine 
(Stipanuk, 2004). SAM is converted to S-adenosylhomocysteine (SAH) by 
methyltransferases. SAH is hydrolyzed to homocysteine upon losing adenosine by SAH 
hydrolase. These sequences of reactions constitute the transmethylation and are 
ubiquitously present in all the cells. Hcy either undergoes remethylation or is 
metabolised irreversibly to form Cys (Figure 1.3). 
Thus, transmethylation claims Hcy back to methionine cycle, which occurs through two 
reactions, both of which are equally important in converting Hcy to Met (Finkelstein, 
1990). In the first reaction, a methyl group is transferred from betaine (oxidation 
product of choline) to Hcy in the presence of BHMT independent of folate, to form Met 
and dimethylglycine (DMG). The second reaction uses folate and the methionine 
synthase to transfer the methyl group from 5-methyltetrahydrofolate (5-MTHF) to 
vitamin B12 to form methylcobalamin. The methylcobalamin in turn transfers the 
methyl group to Hcy to produce Met (Kharbanda, 2007). A deficiency in these vitamins 
(Vitamin B12, folic acid, riboflavin and pyridoxine) is associated with elevated plasma 
Hcy levels. Thus, Hcy functions as a co-substrate for two methyltransferase reactions.  
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Figure 1.3. The transmethylation and transsulfuration pathways. 
 
Met Syn - Methionine synthase, THF - Tetrahydrofolate, 5-CH3-THF–5-Methyl 
tetrahydrofolate, CH2-THF- Methylene tetrahydrofolate reductase, MTHFR-methylene 
tetrahydrofolate reductase, CBS-Cystathionine β-synthase, MAT- methionine adenosyl 
transferases, DMG-dimethyl glycine, BHMT- Beatine homocysteine 
methyltransfereases.  
(Modified from Kenyon et al. (2002) and Mosharov et al (2000). 
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Hcy metabolism via remethylation versus transsulfuration seems to be highly 
coordinated in response to cellular SAM concentration or the need to generate methyl 
methionine groups (Selhub and Miller, 1992). For instance, excess dietary methionine 
intake in the liver, increases SAM concentration facilitating transsulfuration while 
limiting homocysteine remethylation. On the other hand, lower concentrations of SAM 
enhance methionine conservation. Thus, SAM facilitates a balance in allowing 
homocysteine to undergo either remethylation or transsulfuration. In order to perform 
this function, SAM is both an allosteric inhibitor of MTHFR and allosteric activator of 
cystathionine β-synthetase (CBS). Hence, low cellular concentrations of SAM, induces 
the synthesis of MTHF suppressing cystathionine synthesis resulting in the conservation 
of homocysteine for methionine synthesis. Conversely, higher SAM levels, diverts 
homocysteine through transsulfuration as cystathionine synthesis is stimulated 
following an inhibition of MTHF. This metabolic junction i.e. formation of Hcy, 
structures a delicate balance in the cells for providing SAM for methyl transfers and 
glutathione for redox buffering in the body (Martinov et al., 2000).  
1.2.1. Transsulfuration Pathway 
The transsulfuration pathway constitutes a major route for Cys biosynthesis and thus is 
central in controlling the intracellular redox milieu via GSH. A depletion in Cys not 
only alters GSH homeostasis but also inhibits protein synthesis (Jones et al., 2004). The 
major role of the transsulfuration pathway is to convert Met to Cys via Hcy (Figure 1.3). 
In other words, the sulfur group in Met is donated for GSH synthesis thus, essentially 
maintaining the sulfur balance. The body equilibrium favours SAH synthesis to keep the 
transmethylation pathway in motion, however, CBS competes with methyltransferases 
for Hcy to keep the transsulfuration in motion. Thus, the enzymes at this metabolic 
nexus compete to salvage Hcy and are tightly regulated to meet cellular needs. This 
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tightly regulated pathway is hence, subjected and is sensitive to redox changes 
(oxidative stress) in the body implying that transsulfuration is independent of 
methylation / remethylation status when the body has an increased need for Cys to 
promote glutathione synthesis (Zou and Banerjee, 2005). Thus, the transsulfuration 
pathway can be streamlined as an auto-corrective response of the cell that lead to an 
increased level of GSH synthesis challenged by oxidative stress. 
Under oxidizing conditions, methionine synthase activity is diminished due to oxidative 
liability of its co-factor, cobalamin (Chen et al., 1995). Under these conditions SAM 
exerts a reciprocal regulation to activate CBS (Finkelstein, 1975, Taoka et al., 1998), 
decreasing the activity of methylenetetrahydrofolate reductase (MTHFR), thus 
depressing transmethylation. CBS, on the other hand, exerts a twofold increase in its 
activity under oxidizing conditions to flux Hcy through transsulfuration pathway to 
compromise with diminishing glutathione pool. Thus, CBS forms a highly regulated 
enzyme in humans. It was suggested that the heme-binding terminal in the mammalian 
CBS functions as redox sensor (Taoka et al., 2002, Meier et al., 2001). A reduction of 
the heme moiety was associated with decreased enzyme activity while an oxidation 
increased the flux of the enzyme (Zou and Banerjee, 2003). This juncture poses a 
critical indication in the cells, to preferentially increase transsulfuration and to generate 
more Cys for GSH synthesis during oxidative stress.  
The hypothesis that CBS is activated under oxidizing conditions was confirmed from 
the studies conducted using cultured cells. Cells treated with H2O2 elicited a time and 
dose-dependent increase in transsulfuration flux (Masharov, 2000) followed by an 
increased consumption of radio-labelled Met into GSH. This posits that redox 
regulation is important in modulating the Hcy flux to autocorrect the function during 
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oxidative stress. Thus, Hcy forms a key junction metabolite in both the transmethylation 
and transsulfuration pathways.  
Studies have shown that 50% of GSH is formed from Cys that is derived from Hcy in 
the human liver cells through the transsulfuration pathways. However, the 
transsulfuration pathway occurs completely only in the liver, kidney, pancreas and small 
intestine as they exhibit both CBS and cystathionine γ-lyase activity. Tissues that do not 
express the transsulfuration pathway depend on dietary Cys or on the transsulfuration 
pathway products of other tissues for GSH synthesis. Other catabolic products of the 
transsulfuration pathway include taurine and Coenzyme A (Vitvitsky et al., 2003, 
Mosharov et al., 2000)  
During the transsulfuration cycle, Hcy undergoes a condensation reaction with serine in 
presence of heme-dependent CBS and vitamin B6 (pyridoxine) forming cystathionine. 
The formation of cystathionine irreversibly marks the end of transmethylation pathway. 
Cystathionine forms Cys and α-keto butyrate in presence of cystathionine-γ-lyase. Cys 
either formed from transsulfuration or supplied from diet serves as a precursor for 
protein synthesis and several other essential molecules like GSH, taurine, coenzyme A 
and inorganic sulfur. While high plasma concentrations of Cys can prove toxic to cells, 
it however remains a limiting amino acid for cellular glutathione pools (Vitvitsky et al., 
2003).  
1.3. Glutathione 
 
After its rediscovery in 1921, GSH was extensively studied only because of its 
ubiquitous distribution (Colowick et al., 1954, Hopkins, 1921). The reactivity of the 
sulfhydryl group was considered less important. However, the uniqueness of glutathione 
along with its sulfhydryl group was not known until 1969 (Kosower and Kosower, 
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1969). Since then GSH is considered an inevitable non-enzymatic scavenger (Sies, 
1978).  
 
GSH is a tripeptide composed of Cys, glutamic acid and glycine (Figure 1.4). It exists in 
reduced (GSH) and oxidized form (GSSG). The two characteristic structural chemistry 
that make GSH potent are the γ-glutamyl linkage between glutamyl acid and Cys that 
prevents its degradation by proteases and the –SH group. The peptide bond between the 
amino group of Cys and the carboxyl group of glutamate renders GSH resistant to most 
of the peptidases except γ-glutamyl transpeptidase (γ-GT).  
The reactive thiol group (-SH) of Cys is maintained in reduced state as it has a facile 
electron-donating capacity. The electronic structure of the sulfur atom in GSH permits 
an overlap during the formation of transition states and dissipation of electrons 
transferred from radicals, under lays the reactivity of thiol group towards nucleophilic 
addition and redox reactions. The ability of sulfur atom to donate electrons to other 
compounds makes GSH a well-known reductant (Josephy, 2006).  
 
Further, this structural chemistry plays an important role in cellular stability and is 
intimately associated with glutathione functions. This major low molecular weight (307 
kDalton) non-protein thiol is ubiquitously found in all living cells but abundantly found 
in cells/tissues vulnerable to oxidative stress (Meister, 1995b). GSH is found mainly in 
the cell cytoplasm (80-90%) and in the organelles that include lens of the eye, 
mitochondria, liver, peroxisomes, nuclear matrix. 
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Figure1.4. (A) Structure of glutathione (GSH) and (B) glutathione disulfide (GSSG). 
 
 
1.3.1. Glutathione biosynthesis and γ-glutamyl cycle 
 
GSH biosynthesis is closely associated with Met metabolism via the transsulfuration 
pathway (Figure 1.3). GSH synthesis from its constituent amino acids occurs 
intracellularly in two closely linked steps, which are ATP dependent and enzymatically 
controlled (Anderson, 1997, Lomaestro and Malone, 1995). The first step involves the 
formation of γ-glutamyl cysteine. The amino group in Cys and γ-carboxyl group in 
glutamate combine in the presence of the enzyme called glutamate cysteine ligase 
(GCL). This catalytic mechanism proceeds by phosphorylation of γ-carboxylate of 
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glutamate by ATP. The nucleophilic amino group in Cys attacks the γ-glutamyl 
phosphate intermediate forming γ-glutamyl cysteine (See reaction 1), 
L-glutamate + L-Cys + ATP → γ-glutamyl cysteine + ADP + Pi                     (1) 
The enzyme GCL is the rate limiting, inhibited by GSH following a regulation in 
response to oxidative stress suggesting a significant feedback mechanism 
physiologically (Richman and Meister, 1975). The enzyme is specific for the γ-glutamyl 
moiety and is regulated in two steps; a) feedback competitive inhibition of the γ-
glutamate binding site by GSH (Richman and Meister, 1975) and b) availability of Cys 
(Vina et al., 1978).  
The enzyme GCL is heterodimeric in mammals with catalytic (GCLC, 72.8 kDa) and 
modifier (GCLM, 30.8 kDa) subunits. It has been reported that the association of both 
of the subunits is necessary for GSH biosynthesis under normal physiological 
conditions of glutamate and GSH (Griffith, 1999). However, it was cited that over 
expression of GCLM increases cellular GSH by 2 fold, rendering cells resistant to 
oxidative stress (Tipnis et al., 1999 ). Contrarily, a down-regulation of this subunit 
decreased GSH levels in cultured pancreatic islet cells (Kijima et al., 1998). 
Acute depletion of GSH can lead to a short-term increase in GSH synthesis. This is 
because of a transient increased activity in pre-existing GCL by decreasing the feedback 
inhibition by GSH which results in short-term increase in GSH synthesis (Richman and 
Meister, 1975). The enzyme is inhibited by S-alkyl moiety buthonine sulfoxamine 
(BSO) that binds to the active site of the enzyme that accepts Cys. The formation of 
glutathione conjugates and ROS have been shown to induce increased transcription of 
the GCL leading to increased glutathione biosynthesis (Wild and Mulcahy, 2000). 
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The second step in the GSH biosynthetic pathway involves the coupling of γ-
glutamylcysteine with glycine by the catalytic action of glutathione synthetase. The 
transfer of the γ-phosphate of ATP to the carboxylate of γ-glutamylcysteine generates an 
acylphosphate intermediate. The α-amino group of the glycine then attacks the 
phosphorylated intermediate, displacing the inorganic phosphate to form GSH. Human 
glutathione synthetase is a homodimer. Glutathione synthetase rapidly converts γ-
glutamyl cysteine to GSH (See reaction 2) in vivo and its activity is several fold higher 
than GCL in liver. However, in other tissues, like the skeletal muscles, the activity is 
comparable to GCL, suggesting that glutathione synthetase activity may affect the 
intracellular GSH levels. There is a notion that the over expression of GSH synthetase 
fails to increase GSH levels, while an induction of GCL increases GSH levels (Mulcahy 
et al., 1995).  
γ-glutamylcysteine + L-glycine + ATP → GSH + ADP + Pi                                  (2) 
GSH undergoes metabolism via the γ-glutamyl cycle (Figure 1.5). This cycle was 
proposed by Alton Meister and co-workers, describes six major reactions that constitute 
the γ-glutamyl cycle accounting for functional metabolism and reclaim of GSH. The 
breakdown of GSH is catalysed by an ectoenzyme, γ-GT, an abundant enzyme found in 
major fractions in the external surface of the cell membrane. The enzyme distribution in 
the organs and tissues is similar in several species, highest in kidney and low in adult 
liver (Orlowski and Meister, 1965). This is the first enzyme in the salvage pathway of 
GSH. γ-GT is synthesized in liver as an inactive 60-kDa polypeptide. Cleavage of this 
proenzyme yields an active heterodimer comprising a 40-kDa and a 20-kDa subunit.  
The concentration of GSH is highest in liver followed by kidney, small intestine and 
pancreas (Githens, 1991). Regulation of GSH levels within organs is looked in terms of 
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entire organism, since some organs are net synthesizers of GSH while others are net 
exporters. The liver is both a synthesizer and exporter of GSH. The liver exports large 
quantities of GSH into the blood. The blood plasma contains 20-30 μM GSH with high 
turnover rate (Meister and Anderson, 1983). The kidneys either take up GSH from 
plasma via the metabolism of GSH by γ-GT reaction or direct up take of intact GSH 
into kidney cells (Anderson et al., 1980, Griffith and Meister, 1979).  
 
 
Figure 1.5. The γ-glutamyl cycle.  
(Adapted from: Redox Biochemistry, Banerjee R, 2007, p18) 
Organs with high γ-GT activity can utilize plasma GSH. On the other hand, liver and 
other organs with low γ-GT activity are net exporters of GSH into the plasma (Meister 
and Anderson, 1983). Hence, liver GSH depletion is followed by GSH depletion in 
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other tissues. The plasma and erythrocyte concentration are thought to reflect the 
synthetic capacity of the liver. Intracellular GSH levels in cells that do not export GSH 
directly, regulates GSH by controlling the levels of γ-GCS. A study in vitro has 
indicated that a high concentration of GSH itself inhibits the enzyme. Although, high 
levels of GSH inhibit γ-GCS, glutamic acid however, competes with GSH for binding at 
the regulatory site of the enzyme (Richman and Meister, 1975). Thus, GSH regulates its 
own synthesis (Meister, 1995a).  
γ-GT cleaves the γ-glutamyl amide bond in GSH. The ectoenzyme γ-GT in ATP 
dependent manner cleaves extracellularly the peptide linkage between glutamate and 
Cys transferring the glutamyl residue to cystine, which is a disulphide form of Cys 
generating cysteinyl-glycine (Cys-Gly). Extracellular dipeptidase cleaves Cys-Gly to 
yield Cys and glycine. Dipeptidase is involved in both γ-glutamyl cycle and in 
detoxification process in normal physiology. These products Cys and glycine re-enter 
the cells through specific amino acid transporters. This transport of Cys is crucial as Cys 
is a limiting amino acid in the de novo GSH synthesis (Dickinson and Forman, 2002). 
The carrier amino acid is often cystine facilitating the re-entry of γ-glutamyl-amino acid 
into the cell, thereby recycling Cys. 5-oxoproline is formed as a residue of γ-glutamyl-
amino acid by 5-oxoprolinases, which yields glutamate. Thus entire cycle assist in the 
synthesis and recycle of GSH (Griffith et al., 1978).  
The γ-glutamyl cycle thus, provides all the properties that fulfil the requirements for the 
amino acid transport system. The fact that γ- glutamyl amino acids are formed in or on 
the cell membrane by the interaction of γ-GT, forms the corner stone for the hypothesis 
that γ-GT acts as a carrier for amino acids transport where they are subsequently 
released into the intracellular milieu by the action of γ-glutamyl cyclotransferases 
(Orlowski and Meister, 1970). 
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1.3.2. Hepatic glutathione transport 
 
Liver has the greatest content of GSH and maintenance of hepato-cellular GSH is a 
dynamic process. A steady state hepatic cellular GSH concentration is achieved by a 
balance between: 1. The rate of synthesis catalysed by γ-GCS and GSH synthetase and 
its utilization through GSH peroxidises and alkylating reactions by GST’s. 2. The rate at 
which it is exported from the hepatocytes (Figure 1.6). Hepatic GSH synthesis is largely 
dependent or limited by the availability of Cys (Betty and Reed, 1980). A complete 
transsulfuration cycle taking place in liver contributes towards Cys formation, which is 
otherwise derived from diet or protein breakdown. Thus, Cys is rapidly incorporated 
into GSH. Hepatic GSH is thought to play a central role in inter-organ GSH 
homeostasis by providing Cys to extra-hepatic tissues. Following sinusoidal efflux from 
liver into the blood stream, GSH is hydrolyzed at tissue sites by two membrane-bound 
enzymes: γ-GT and dipeptidase. Hydrolysis of GSH results in the liberation of Cys, 
which is then taken up into the cells to synthesize GSH and/or proteins. Liver releases 
GSH in both reduced and oxidized forms. The hepatocytes have distinct plasma 
membrane domains for sinusoidal and canlicular transport. Sinusoidal GSH release to 
the plasma is by carrier-mediated transport. This was supported by studies on isolated 
hepatocytes, which have demonstrated that Met selectively inhibits GSH efflux, 
suggesting that Met shares the same carrier (Aw et al., 1984). Thus, Met maintains 
hepatic GSH by inhibiting its efflux and serving as a Cys precursor.  
 
On the other hand, canalicular GSH transport occurs by specific carrier mediated 
transport (Ballatori and Truong, 1992). This efflux, studied in the perfused liver model, 
was exclusively GSSG (Kaplowitz et al., 1985). Studies on rat bile have indicated high 
GSSG levels. In order resolve this apparent contradiction, Abbot et al, detected 1-2 mM 
GSH and low transpeptidase activity in pure bile (Abbott, 1983). This canalicular GSH 
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efflux across the canalicular plasma membrane into bile significantly contributes to bile 
formation (Ballatori and Truong, 1992, Grattagliano et al., 2005). A significant 
proportion of this GSH in bile is degraded by γ-GT in the biliary epithelial brush border. 
Hepatic GSH also plays a central role in inter-organ GSH homeostasis by supplying 
plasma GSH through sinusoidal efflux (Ookhtens and Kaplowitz, 1998). A decrease in 
GSH has been found in association with a variety of oxidative stress-mediated liver 
diseases such in various cholestatic hepato-biliary diseases.  
 
 
 
 
Figure 1.6. Regulation of hepatic glutathione.  
 
 
Reactions: 1. γ-glutamyl-Cys synthetase, 2. GSH synthetase, 3. GSH peroxidises, 4. 
GSSG reductase, 5. Thioltransferases, 6. Glutathione -S-transferases. (Adopted from 
(Kaplowitz et al., 1985). 
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1.3.3. Role of glutathione in health and disease 
 
GSH has a critical role in the maintenance of reduced environment by maintaining a 
balanced cellular redox potential (Townsend et al., 2003). It has numerous roles in the 
both physiological and biochemical pathways in the body (Figure 1.7). It participates in 
many biological reactions related to cellular function, protection against oxidative 
damage, detoxification of endogenous and exogenous compounds, storage and transport 
of Cys, regulation of membrane transporters, as well as cell growth and DNA synthesis 
(Manciu et al., 2003, Meister, 1995a, Sies, 1999).  
 
 
Figure 1.7. Role of glutathione in the body and in health and disease.  
 
1.3.4. Redox regulation by glutathione  
 
Redox phenomena have a profound role in life processess. GSH is one of the major pro-
homeostatic modulator of intracellular –SH groups on proteins (Hidalgo et al., 1990, 
Ondarza, 1989). Enzymes involved in glucose metabolism are regulated by redox 
balance largely defined by the –SH groups (Ondarza, 1989). The –SH group in GSH 
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sets the redox stage for metallothioneins which are able to bind to heavy metals and 
subsequently are removed from the body (Hidalgo et al., 1990). Thus, the homeostasis 
of various cellular environments is finely tuned by the reducing power of GSH.  
A redox status of a cell describes the ratio of inter-convertable reduced/oxidized forms 
of a molecule. The thiol group of GSH is oxidized to form a disulfide;  
2GSH       GSSG + 2H+ + 2e- 
The 2GSH/GSSG is considered to be the major thiol-disulphide redox couple of the cell 
(Gilbert, 1990). The 2GSH/GSSG ratio is tightly regulated and strongly is the favour of 
GSH. In the endoplasmic reticulum, where, GSH is implicated in protein disulphide 
bond formation, the GSH/GSSG ratio is 3:1 (Hwang et al., 1992). Over 99% of cellular 
GSH in the mitochondria and cytosol however, is maintained in the reduced state 
(GSH), essentially though GSSG reductase (GR) (Meredith and Reed, 1982). These 
enzymes belong to a group of a flavoprotein disulfide oxidoreductase family. This 
reaction is fast and irreversible providing cells with high GSH/GSSG ratio. GR is found 
to have high affinity for their substrates (GSSG) and other mixed disulfides. This 
enzyme uses NADPH to convert GSSG to GSH to replenish the GSH levels under 
cellular stress conditions.  
GSSG + H+ + NADPH   2GSH + NADP+  
As GSH potently modulates cell signalling in an oxidation-dependent fashion, it is 
crucial for the cells to have efficient ways to replenish reduced levels. Impaired GR 
activity and/ or excessive GSSG accumulation may react with protein sulfhydryl via a 
mixed disulfide reaction, thereby impairing protein function (DeLucia et al., 1975). 
Alternatively, if GSSG is not reduced to GSH, the former is removed from the cell as it 
can readily permeate through the cell lipid membrane (Bannai, 1984).  
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The reaction mechanism of GR involves, i) receiving two electrons from NADPH and is 
tightly bound to FAD, ii) transfer the reducing equivalents to the disulfide formed by 
the two Cys residues in the active site of the same subunit, iii) the electrons are 
transferred to GSSG and interact with the reduced Cys residues, iv) finally the enzyme 
releases two GSH molecules (Argyrou and Blanchard, 2004). A steady state production 
of NADPH depends on the supply of glucose and its flux through the pentose phosphate 
pathway, mitochondrial production and shuttle within the two pathways. Changes in the 
pentose phosphate activity can affect NADPH supply and consequently GSH/GSSG 
status. Thus, the ratio of GSH/GSSG is tied with NADPH levels, which is in turn 
determined by the energy status of the cell (Figure 1.8).  
 
Figure 1.8. Association GSH: GSSG ratio with NADPH levels in pentose phosphate 
pathway. 
During an oxidative insult, the GSH/GSSG ratio shifts the redox state resulting in a 
positive potential (Filomeni et al., 2003, Schafer and Buettner, 2001). The export of 
GSSG under these circumstances prevents positive potential increase thereby protecting 
the sensitivity of the cells towards disturbed equilibrium. This exhibits a protective 
mechanism for the cells and tissues from oxidative stress. Mechanisms that alter GSH 
levels and the GSH/GSSG ratio also alter the cellular redox state. Cellular redox state 
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can be altered by an increase in ROS (RNS) generation as seen during inflammation/ 
metabolism of drugs/ xenobiotics that decreases the GSH/GSSG ratio. Higher threshold 
levels of drugs and xenobiotic compounds can lead to extreme depletion in the GSH 
levels thus, drastically shifting the cellular redox status. Therefore, it is critical for the 
cells to have efficient ways to replenish this loss in GSH levels and maintain the 
GSH/GSSG ratio.  
1.3.5. Antioxidant function of GSH 
 
One of the major functions of GSH involves its antioxidant properties. Reduced GSH is 
capable of directly scavenging radicals and peroxides by being oxidized to either GSSG 
or to a mixed disulfide (Sies, 1999). GSH can also reduce H2O2 and lipid peroxide in 
the presence of GSH peroxidise (GPx) (Zhang et al., 1989). GSSG is then converted 
back to GSH in presence of GR and NADPH to complete the cycle. 
 
2GSH + H2O2         GPx         GSSG + 2H2O 
GSSG + NADPH + H+           GR           2GSH + NADP+ 
 
The GPx are a class of selenocysteine containing proteins. In addition to scavenging 
free radicals, GSH is essential in maintaining the intracellular redox balance and the 
essential thiol status of proteins. To achieve this, GSH (or GSSG) undergoes thiol-
disulfide exchange in a reversible reaction catalyzed by thiol-transferases. Meanwhile, 
GSH reduces (or GSSG oxidizes) the sulfhydryl groups of the proteins. Whereas many 
proteins are active when the key sulfhydryl are in the thiol form, others require them to 
be in the oxidized disulfide form (Cotgreave and Gerdes, 1998). The equilibrium is 
determined by the redox state of the cell, which depends on the concentrations of GSH 
and GSSG. 
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GSH is also considered as the storage and transfer form of Cys. Circulating GSH is 
stable in that it reacts very slowly with oxygen. Cys, on the other hand, is unstable 
extracellularly and rapidly auto-oxidized to cystine, producing potentially toxic oxygen 
free radicals (Olney et al., 1990). To avoid the toxicity of auto-oxidation, most of the 
nonprotein Cys is stored as GSH. After GSH is exported from the cell, it can be quickly 
converted to Cys through the γ-glutamyl cycle. The resulting Cys is then used elsewhere 
for protein synthesis and for the biosynthesis of taurine and other sulfur metabolites. 
The liver, which provides more than 80% of plasma GSH, plays a major role in the 
homeostasis of GSH and Cys . 
 
1.3.6. Role of glutathione in detoxification and mercapturic acid pathway  
 
GSH also plays a major role in detoxifying many reactive metabolites by either 
spontaneous conjugation or by a reaction catalyzed by the glutathione S-transferases 
(GST). Compounds with electrophilic centres readily conjugate with GSH, catalyzed by 
GST (Ouwerkerk-Mahadevan et al., 1997). GST’s are a group of antioxidant enzymes 
that play a critical role in providing protection against the electrophiles and metabolities 
of oxidative stress. In mammals, GST’s play a vital role in the detoxification of harmful 
electrophilic compounds of both endogenous and exogenous origin. Liver receives 
toxins absorbed by the intestine through the portal vein. Many of these toxins undergo 
oxidation by adding a functional group that is attacked by GST’s. This is followed by a 
sequential cleavage of residues of GSH (glutamic acid and glycine moieties) and 
acetylate the amino group of the remaining Cys moiety prior its export.  
 
Kidney forms the primary site for the conversion of GSH conjugates to Cys conjugates. 
In the kidneys, degradation by peptidase to Cys conjugates occurs and is eliminated in 
the urine. This conversion of GSH-conjugates to Cys conjugates constitutes the 
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mercapturic acid pathway. GSH conjugates form Cys-Gly S-conjugates catalyzed by γ-
GT and Cys-S-conjugates catalyzed by dipeptidase (Commandeur et al., 1995). The 
resulting Cys-S-conjugates are acetylated at the amino position of Cys in kidney or 
transported to the liver via Cys-S-conjugate N-acetyltransferases to form N-
acetylcysteine or mercapturic acid metabolites (Figure 1.9). 
 
 
 
Figure 1.9. Mercapturic acid pathway. (X=Electrophilic compounds react with GSH to 
yield conjugates and it can be xenobiotics, leukotrienes, steroids, prostaglandins). 
(Adopted from (Lu, 1999). 
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GST and GSH peroxidises. Depletion of GSH due to oxidative stress is more profound 
in the cells with higher GST activity (Rahman et al., 2005a, Kraus and Kloft, 1980) 
compared with those with low or no GST activity. It is reported that, GSTT-1 genotype 
may be a significant factor in the pathogenesis of AP and the possession of the 
functional GSTT-1*A genotype appears to be associated with a severe attack of AP 
(Rahman et al., 2005).  
1.4. Pancreatitis 
 
Pancreas is a retroperitoneal gland located on the posterior of the abdominal cavity 
functioning both as an exocrine and endocrine gland. The exocrine portion of the 
pancreas is mainly concerned with the secretion of digestive enzymes that are required 
for the digestion of lipids and proteins. A highly coordinated timed release (in volume 
and content) of the pancreatic juice from the acinar cells, to suit the body’s digestive 
requirements, reflects a complex synergy of actions of both hormonal and neural 
pathways. The endocrine pancreas is composed of small clusters of cells embedded in 
the exocrine tissue-the highly vascularised islets of Langerhans cells. These islets of 
Langerhans cells are of two types – the alpha cells those that secret glucagon and the 
beta cells that produce insulin. Glucagon and insulin function simultaneously.  
Diseases of the pancreas can irreversibly affect both the exocrine and endocrine 
secretions thereby leading to insufficient production of digestive enzymes thus 
impairing fat and protein absorption and bring an imbalance in the blood sugar level by 
affecting the production of insulin secreted from the endocrine pancreas. Some of the 
common pancreatic disorders are diabetes mellitus, malabsorption of lipid or proteins, 
pancreatitis and pancreatic tumours.  
 
Pancreatitis is an inflammatory process of the pancreas associated with severe upper 
abdominal pain with nausea and vomiting. The initial stage of pancreatitis does not 
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affect digestion or the normal blood sugar levels. However, a single severe attack of 
pancreatitis can trigger series of events which can destroy the pancreatic acinar cells 
causing bleeding in the gland thereby leading to tissue damage, impaired enzyme 
secretion that could auto-digest the organ (Mergener and Baillie, 1998). Clinical 
judgement upon admitting patients with pancreatitis has often proved unreliable in 
predicting the severity of pancreatitis. In an attempt to predict morbidity and mortality, 
a number of prognostic scoring systems have been developed. This was first coined in 
1974 by John HC Ranson, who introduced the concept of a prognostic scoring system 
for early identification of patients with severe pancreatitis (Ranson et al., 1974). 
Multifarious scoring systems have evolved since then, attempting to identify an “at risk” 
group that may potentially benefit from aggressive medical or surgical management 
(Karimgani et al., 1992).  
According to UK recommendations, severity stratification should be made in all 
patients within 48 hours. It is recommended that all patients should be assessed by the 
Glasgow score and CRP (Anonymous, 1998). The APACHE-II score is equally accurate 
and may be used for initial assessment. A dynamic CT scan is recommended to be 
performed on all severe cases between three and ten days after admission. 
1.4.1. Acute pancreatitis- a model of oxidative stress 
 
Acute pancreatitis (AP) is defined as an acute inflammatory process of the pancreas, 
with variable involvement of other regional tissues or remote organs. AP initially starts 
with an unrecognised aetiology. A localized inflammatory process in the pancreas is 
capable of spreading or involving remote organ systems. The typical severe abdominal 
pain appearing suddenly and radiating back is associated with non-specific symptoms 
like nausea, vomiting and pyrexia. AP remains a disease with considerable morbidity 
and mortality, with up to a quarter of patients developing life-threatening complications. 
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In humans, AP leads to severe acinar damage, extensive interstital edema, hemorrhage 
and migration of neutrophils into the damaged pancreatic gland (Aho et al., 1982). 
There is increasing evidence to suggest that the local and systemic manifestations of AP 
are related to the activation of cellular oxidant generating pathways and oxidative stress 
(Altomare et al., 1996, Kikuchi et al., 1997, Schulz et al., 1999).  
AP develops as an inflammatory disorder with a complex cascade of immunological 
events associated with it. The disease progression is viewed in three stages; with a local 
inflammation of the pancreas, following a generalized inflammatory response and 
eventually multiorgan dysfunction (Bhatia et al., 2001a, Bhatia, 2000, Bhatia, 2002). 
Despite this, the exact mechanism of development and pathogenesis of AP remains 
poorly understood, partly because the process is fully established when patients are 
present with AP.  
AP can be either mild or severe: 
Mild AP is defined as that associated with minimal organ dysfunction and an uneventful 
recovery, and it lacks the features of severe AP. Severe AP is defined as that associated 
with organ failure and/or local complications, such as abscess, pseudocyst or necrosis. 
However, in certain conditions of severe AP, a single attack may be followed by a 
complete recovery or a life threatening illness.  
AP accounts for 3% of all cases of abdominal pain admitted to hospital in the UK (de, 
1991). Epidemiological evidence suggest an increase in the incidence of AP reflecting 
increased consumption of alcohol among the younger generation (Wilson and Imrie, 
1990). A majority of patients fall under mild attacks while 25% of patients of AP suffer 
severe attacks. At least about 30-50% of patients with severe attacks are known to die 
due to secondary infections and/ or organ failure (Bhatia et al., 2001a, Bhatia, 2002).  
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1.4.2. Current biochemical methods of diagnosis 
 
Commonly employed methods of diagnosis include biochemical tests (serum amylase, 
lipase, and trypsinogen). AP is usually confirmed by assay of circulating higher than 
control (or healthy) levels of digestive enzymes (amylase, lipase, trypsinogen and C-
reactive protein). The causes for AP can be major like a block in the biliary tract by 
gallstones leading to a mechanical obstruction or alcoholism, which accounts for ≥ 80% 
upon admission to the hospital. Minor causes like cystic fibrosis, pancreatic trauma, 
peptic ulcers, cardiopulmonary bypass producing an insult to the gland, carcinoma of 
pancreas and viral infections like mumps, hepatitis and certain bacterial infections like 
mycoplasma attribute for 20% of AP.  
1.4.3. Oxidative stress in acute pancreatitis 
 
Mounting evidence has accumulated that oxidative stress plays pivotal role in the 
pathophysiology of AP. Oxygen radicals mediate an important step in the initiation of 
AP (Schoenberg et al., 1995). However, there are no direct evidences so far that free 
radicals are the prime culprits for the onset of human AP as there has always been an 
inevitable delay in the patients arriving at the hospital. This delay has excluded the 
investigation of preliminary mechanisms of the initiation of acinar cell injuries during 
the onset of AP (Tsai et al., 2005).  
Much of the evidence supporting the role of ROS in AP has largely been experimental, 
and supported by three lines of evidence: (1) heightened free radical production; (2) 
depletion of antioxidant systems; and (3) amelioration of pancreatic injury by free 
radical scavengers (Sanfey et al., 1985). These three evidences are germane to the 
present clinical setting. However, the difficulty in relating this work to the clinical 
condition is that much of the observed responses vary from one experimental model to 
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the next, although the caerulin model has been the most widely used (Dabrowski et al., 
1999). 
1.4.4. Evidence of heightened free radical production 
 
The first line of evidence was adduced by measuring the products of lipid peroxidation 
in various animal models (Braganza, 1990, Schoenberg et al., 1995). Excessive 
accumulation of lipid peroxidation products was seen in caerulin induced-AP 
(Dabrowski et al., 1988). In the caerulin model, Dabrowski (1988) also showed that 
severe oxidative stress is associated with a depletion of SOD in the pancreas to 16% of 
normal activity. A number of reports suggest that lipid peroxidation parallels a 
reduction in pancreatic sulfhydryl compounds that include key antioxidant enzymes 
such as GPx (Dabrowski and Chwiecko, 1990), SOD and catalase (Nonaka et al., 1990). 
Direct evidence of oxygen free radical activity by chemiluminescence was demonstrated 
in caeruline and taurocholate induced AP model (Gough, 1990). Most of these studies 
provided unequivocal evidence that oxidant stress was involved at a very early stage in 
the evolution of experimental AP. 
1.4.5. Depletion of antioxidant systems 
 
Depletion of antioxidant system in pancreatitis was investigated in the cearulein model 
(Dabrowski et al., 1991, Luthen and Grendell, 1994). The study concluded that 
depletion of non-protein sulfhydryl (GSH) correlates with an increase in lipid 
peroxidation products and depletion of protein thiols. Although the depletion of total 
GSH was a consistent observation in caerulin and taurocholate models (Luthen and 
Niederau, 1995, Schoenberg et al., 1994), its relationship with the pathogenesis of AP 
has not been fully explored. Furthermore, the idea that GSH depletion is the initial step 
in the development of AP has not gone undisputed, because Fu et al (1997), could not 
induce AP in a caerulin rodent model through GSH depletion with diethylmalonate (Fu 
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et al., 1997). These observations suggested that oxidative stress was not solely 
responsible for initiating pancreatitis. 
1.4.6. Amelioration of pancreatic injury by free radical scavengers 
 
The third line of evidence of ameliorating pancreatic injury by free radical scavengers 
was demonstrated a decade ago in an ex vivo canine pancreas (Sanfey et al., 1985). The 
study involved initiation of AP by free radical infusion or by partial duct occlusion with 
secretin stimulation. Addition of allupurinol resulted in a decrease in interstitial oedema 
and hyperamylaseaemia by inhibiting the production of superoxide anion by inhibiting 
xanthine oxidase. In general, various results upon pre-treatment with antioxidant 
enzymes were reviewed many times (Schoenberg et al., 1995, Braganza, 1990, Sweiry 
and Mann, 1996). Treatment with glutathione monoethylester partially abrogates GSH 
depletion, acinar cell lesions and hyperamylaseaemia in a rodent model of caerulin AP, 
while Cys pro-drug l-2-oxothiazolidine-4-carboxylate produced variable results (Luthen 
et al., 1997). The pro-drug was cleaved by 5-oxoprolinase in an ATP-dependent 
reaction to form L-Cys and subsequently increases GSH levels.  
Table 1.2 suggests ways in which GSH may be depleted in pancreas. 
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Table 1.2. List of possible etiologies of GSH depletion in the pancreas.  
 
Source of depletion Etiology Mechanism 
Decreased synthesis 
 
SAA deficiency 
Protein deficiency 
GGT inhibition 
 
 
 
Poor diet 
Poor diet 
AT-125 
 
 
 
Lack of substrate (Cys) 
Lack of substrate (Cys) 
↓ transport of precursor 
Enhanced oxidation 
 
Oxidant stress (↑O•2-,  
↑H2O2) 
 
 
 
Hypoxia 
 
 
 
 
Mitochondrial dysfunction, XO 
 
 
↓ GSH peroxidise activity 
 
Vitamin C deficiency 
 
Vitamin E deficiency 
 
 
 
 
 
 
 
Selenium deficiency 
 
Poor diet 
 
Poor diet 
 
↑ unsaturated fat 
high-fat diets 
Hypoxia 
 
Activation producing (↑O•-2, ↑H2O2) 
 
Generation of free radicals via 
↑H2O2 
 
↑ cytosolic free radicals 
 
↑ membrane free radicals 
↑ lipid peroxides, CYP induction 
↑H2O2 generating membrane free 
radicals 
 
 
 
 
 
↑ lipid peroxidation 
 
 
Dietary and 
environmental, 
xenobiotic, drugs 
 
Direct injury to membrane by toxins 
or metabolites 
 
 
Biliary reflux 
 
 
Lipid peroxidation products of bile, 
surfactants 
 
Inflammation 
 
 
Generation of O•2-, H2O2 by 
leucocytes 
Increased consumption 
 
Oxidant stress 
GSH conjugation 
 
 
 
Hypoxia 
↑ xenobiotic exposure 
 
 
 
 
↑ efflux of excess GSSG from cell 
Binding of GSH to metabolite and 
efflux of conjugate from cell 
 
Adopted from (Wallig, 1998). 
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1.5. Bile acids  
Bile, an organic fluid, is largely a heterogeneous group of water-soluble compounds 
characterized by steroid scaffolding with carboxylic group located in the side chains. 
Bile is essentially a mixture of catabolic products of cholesterol. Newly synthesized bile 
acids from the liver are secreted into the lumen of the small intestine where they act as 
emulsifiers of cholesterol, dietary lipids and fat-soluble vitamins. From the intestine, the 
bile acids are transported back to the liver via the portal circulation and resecreted into 
the bile . About 95% of bile acids are recovered in the gut during the enterohepatic 
circulation and about 5% loss of bile acids is replaced by the synthesis in the liver. Bile 
acid synthesis is tightly regulated ensuring that there is catabolism of sufficient amounts 
of cholesterol to maintain the homeostasis and provide adequate emulsification in the 
intestine.      
1.5.1. Bile acid biosynthesis 
An approximate of 500 mg of cholesterol is converted to bile acid each day in an adult 
liver. Cholesterol is an important biological molecule and an precursor of bile acid 
formation. It has roles in membrane structure as well as being a precursor for the 
synthesis of the various steroid hormones and bile acids. Both dietary cholesterol and 
that synthesized de novo are transported through the circulation in lipoprotein particles 
such as LDL, HDL. The synthesis and utilization of cholesterol is tightly regulated in 
order to prevent over-accumulation and abnormal deposition within the body. Bile acid 
synthesis is the major pathway for cholesterol catabolism in mammals. The pathway for 
bile acid biosynthesis involves 17 different enzymes (Table 1.3) most of which are 
expressed in the liver. The four main steps involved in the synthesis of bile acids are: 1. 
Initiation, 2. Modification in the ring structures, 3. Oxidation and shortening of the side 
chain and 4. Conjugation of bile acids with an amino acid. Figures 1.12 a, b, c and d 
illustrate those steps.  
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Table 1.3. Enzymes involved in bile acid biosynthesis. 
 
Reaction Enzyme Subcellular 
location 
Family 
1 Cholesterol 7α-hydroxylase ER P450 (CYP7A1) 
2 Cholesterol 24-hydroxylase ER P450 (CYP46A1) 
3 Cholesterol 25-hydroxylase ER Diiorn co-factor 
4 Sterol 27-hydroxylase Mitochondria P450 (CYP27A1) 
5 Oxysterol 7α-hydroxylase ER P450 (CYP39A1) 
6 Oxysterol 7α-hydroxylase ER P450 (CYP7B1) 
7 3β-Hydroxy-Δ5-C27steroid 
oxidoreductase 
ER Specific for C27 
substrates 
8 Sterol 12α-hydroxylase ER P450 (CYP8B1) 
9 Δ 4-3-oxosteroid5-β-reductase Cytoplasm Aldo-Keto reductase 
(AKR1D1) 
10 3α-hydroxysteroid dehrogenase Cytoplasm Aldo-Keto reductase 
(AKR1C4) 
11 Sterol 27-hydroxylase Mitochondria P450 (CYP27A1) 
12 Bile acid CoA ligase ER Uses log-chain FA’s 
13 2-Methylacyl-CoA racemase ER, 
Peroxisome 
Acts on 2-methyl FA’s 
14 Branched chain acyl-CoA oxidase Peroxisome ACOX2 
15 D-bifunctional protein Peroxisome Multiple enzyme activity 
16 Peroxisomal thiolase 2 Peroxisome Multiple isoforms 
17 Bile acid CoA: amino acid N-
acyltransferase 
Peroxisome Liver selective 
*ER – Endoplasmic reticulum 
 
1.5.2. Initiation (Step1)  
Figure 1.10a shows the enzymatic steps involved in step 1. Bile acid synthesis begins by 
one of the several pathways. Cholesterol is converted to 7α-hydroxycholesterol by 
cholesterol 7α-hydroxylase (Figure 1.10a, reaction 1), a microsomal enzyme expressed 
only in liver. 7α-hydroxycholesterol is totally committed for bile acid production 
(Einarsson et al., 1973). This constitutes the classical pathway in the bile acid 
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biosynthesis. However, mice deficient in cholesterol 7α-hydroxylase produce bile acids 
from an alternative pathway, which led to the identification of three enzymes required to 
synthesize bile acids. Hydroxylation of cholesterol at three different positions on the 
side chain produce oxysterols at C24, C25 and C27–hydroxycholesterol in the presence 
of cholesterol 24-hydroxylase, cholesterol 25-hydroxylase and sterol 27-hydroxylase.  
 
Cholesterol 24-hydroxylase synthesizes oxysterol 24(S) hydorxycholesterol (Figure 
1.10a, reaction 2). Humans produce 6-7 mg of C24-hydroxycholesterol per day 
(Bjorkhem et al., 1998), of which ∼3.5 mg is catabolized to bile acids (Bjorkhem et al., 
2001). Hence, the enzyme cholesterol 24-hydroxylase, contributes little towards bile 
acid synthesis. Cholesterol 25-hydroxylase (Figure 1.10a, Reaction 3) is expressed in 
low levels in endoplasmic reticulum and Golgi apparatus in most tissues (Fuchs, 2003). 
This enzyme forms the substrate for oxysterol 7α-hydroxylases, which produces 7α-
hydroxylated oxysterols that are funneled into steps for bile acid biosynthesis. 27-
hydroxy cholesterol is the most abundant oxysterol in human plasma  synthesized by the 
sterol-27 hydroxylase (Figure 1.10a, Reaction 4). About 25% of the bile acid pool 
originates from sterol-27 hydroxylase.  
Oxysterols undergo 7α-hydroxylation in order to be converted to bile acids. Two 
members of the microsomal P450 enzymes (CYP39A1 and CYP7B1) catalyze this 
sequence of steps. The CYP39A1 acts on oxysterol 24(S) hydorxycholesterol (Figure 
1.10a, Reaction 5). The 25 and 27-hydroxycholesterol are converted to bile acid 
intermediates and catalyzed by CYP7B1 oxysterol 7α-hydroxylase (Figure 1.10a, 
Reaction 6).  
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Figure 1.10a. Enzymatic steps involved in the initiation of the bile acid biosynthesis (Step 1).   
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1.5.3. Ring structure modification (Step 2) 
The steps involved in this pathway are shown in Figure 1.10.b. In this step, the 7α-
hydroxylated intermediates those derived from cholesterol and oxysterols are converted 
to their 3-oxo Δ4 forms in the presence of a microsomal 3β-hydroxy-Δ5-C27 steroid 
oxidoreductase or C27-3β-HSD. The complex reaction catalyzed by this enzyme 
involves isomerization of the double bonds from the 5th to the 4th position and oxidation 
of the 3β-hydroxyl to a 3-oxo group (Figure 1.10a, Reaction 7). The enzyme acts only 
on sterols with 7α-hydroxyl group. Therefore, loss of this enzyme blocks all the bile 
acid synthesis, as there is only one C27-3β-HSD (Schwarz et al., 2000, Wikvall, 1981).  
 
The products of C27-3β-HSD-steroid oxidoreductase forms 7α-4-hydroxy-4-cholesten-
3-one (4-cholestene -7α-ol-3-one) which is a common precursor for both cholic acid 
(CA) and chenodeoxycholic acid (CDCA). However, if the intermediate acted upon by 
sterol 12α-hydroxylase (Figure 1.10b, Reaction 8), is converted ultimately to CA (right 
arm of the reaction pathway, Figure 1.10b). In the absence of 12α hydroxylation, 
CDCA is formed (left arm of the reaction pathway, Figure 1.10b). CA and CDCA are 
the two primary bile acids.  
 
The 12α-hydroxylated intermediates, produced from C27-3β-HSD and those that escape 
12α-hydroxylation, undergo reduction of the double bond by the enzyme Δ4-3-
oxosteroid 5β-reductase (Figure 1.10b, Reaction 9). The last step of the ring structure 
modification involves reduction of the 3-oxo group, which is catalyzed by 3α-
hydoxysteroid dehydrogenase (Figure 1.10b, Reaction 10).   
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Figure 1.10b. Enzymatic steps leading to changes in sterol ring structure in the bile acid 
biosynthesis (Step 2). 
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1.5.4. Side chain oxidation (Step 3)  
 
The steps involved in side chain oxidation reactions are shown in Figure 1.10c. The 
products of ring structure modification undergo oxidation and shortening of the sterol 
side chain and this is performed by sterol 27-hydorxylase (Figure 1.10c, Reaction 11). 
This is the same enzyme that initiates bile acid synthesis (See Figure 1.10a, Reaction 4). 
The enzyme introduces a hydroxyl group (at C27), oxidizes the hydroxyl group to an 
aldehyde and finally to carboxylic acid. The products from the above reaction exit 
mitochondria and are subjected to shortening of the side chain. This shortening of the 
side chain takes place in the peroxisomes catalyzed by bile acid coenzyme A ligase 
(Figure 1.10c, Reaction 12). The intermediates of bile acid coenzyme A ligase undergo 
isomerization i.e. the C25(R) position is converted to C25 (S) by 2-
methylacylcoenzyme A racemase (Figure 1.10c, Reaction 13).  
 
The products from the above reaction are subjected to dehydrogenation by a branched 
chain enzyme acyl-coenzyme A oxidase to yield 24, 25-trans unsaturated derivatives 
(Figure 1.10c, Reaction 14). They then undergo hydration and oxidation by a D-
bifunctional protein (Figure 1.10c, Reaction 15). A peroxisomal thiolase cleaves the 
C24 – C25 bond to form propionyl – coenzyme A and a C24-coenzyme A bile acid 
intermediate (Figure 1.10c, Reaction 16).     
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Figure 1.10c. Side chain oxidation in bile acid biosynthesis (Step 3). 
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1.5.5. Conjugation with amino acids (Step 4) 
 
The terminal step before the exit of bile acids into the bile involves conjugation with 
amino acids in the liver, usually with glycine or taurine in an amide linkage to C24 
catalyzed by the bile acid coenzyme A and amino acid-N-acyltransferase (Figure 1.10d, 
Reaction 17). N-acyltransferase is located in the peroxisomes and the amino acids 
glycine and taurine (in humans) taurine (mice) and bile acid coenzyme A thioester are 
the substrates (Falany et al., 1997). The ratio of conjugation of the amino acids with bile 
acids in the humans is dependent on the relative abundance of the two amino acids. The 
conjugated bile acids are then stored in the gall bladder and subsequently secreted into 
the duodenum via the bile duct.  
 
 
Figure 1.10d. Conjugation of bile acids (Step 4).  
 
 
Figures 1.10a, b, c and d adopted from (Russell, 2003). 
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This conjugation increases the amphipathicity and enhances the water solubility of the 
molecules thus making them impermeable to the cell membranes. Conjugated and free 
bile acids do not cross cell membranes thus, specific transport systems are essential for 
moving the bile acids in and out of the cells (Love and Dawson, 1998). The classical 
pathway preferentially forms CA while the alternative pathway produces CDCA.  
 
During the enterohepatic circulation, the primary bile acids, CA and CDCA synthesized 
in the liver are converted to secondary bile acids deoxycholic acid (DCA), lithocholic 
acid (LCA) and ursodeoxycholic acid (UDCA) by the action of intestinal microflora. 
The primary bile acids are metabolized and follow deconjugation by the intestinal 
bacteria that remove the hydroxyl group in the 7th position from the steroid molecule. 
The principally formed secondary bile acids are DCA, LCA and UDCA. LCA is highly 
insoluble and largely excreted in the stools adhered to dietary fiber (Dowling, 1973). 
DCA is partially reabsorbed from the colon as it passes to liver where it is conjugated 
with glycine or taurine before joining the primary bile acids that are already in the 
enterohepatic circulation.  
 
A defect on bile acid synthesis can be related to deficiencies of the enzymes CYP7B1, 
3β-hydroxy-Δ5-C27 steroid oxidoreductase and 3-oxo-Δ4-steroid 5β-reducatse leading to 
liver diseases (Fuchs and Stange, 1999). Clinical manifestations of these deficiencies 
include progressive cholestasis, fat malabsorption and various neurological symptoms. 
Deficiency in CYP7A1 on the contrary, is not associated with liver diseases in adults 
but lead to hyperlipidemia, premature atherosclerosis and gall stone formation 
(Pullinger et al., 2002).  
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1.5.6. Physiology of bile formation 
 
Bile formation is a vital process driven by the osmotic gradient generated by the active 
secretion of the non-permeant solutes into the canalicular lumen (Ballatori and Truong, 
1992, Sperber, 1959). Both endogenous organic solutes like the bile salts and inorganic 
ions and their secretion from the blood to the bile has been identified as a major osmotic 
driving force in the bile formation. Bile salts and their conjugates have been noted to 
account for 40-50% of bile flow (Boyer, 1986). Bicarbonate ions, electrolytes, GSH and 
its conjugates constitute the rest (Ballatori and Truong, 1992, Graf, 1983, Hardison and 
Wood, 1978). The concentration of bile acids in the bile is up to 1000-fold necessitating 
active transport by the hepatocytes against the gradient (Tomer and Shneider, 2003).  
Hepatocytes are polarized cells with two plasma membrane domains; a basolateral 
(sinusoidal) and an apical (canalicular) domain (Suchy et al., 1997). Uptake of biliary 
constituents into the hepatocytes occurs at the basolateral membrane, which is in contact 
with sinusoidal blood. The uptake is mainly sodium dependent driven by Na+ gradient 
generated by Na+/K+ ATPase. The Na+ taurocholate co-transporting polypeptide 
(NTCP) accounts for the major hepatocellular uptake for the conjugated bile salts 
(Hagenbuch et al., 1991, Jacquemin et al., 1994). Sodium independent transport is 
mediated by organic anion transporting polypeptides (OATP). ATP-dependent multi 
drug resistant proteins mediate the basolateral efflux of bile salts across the canalicular 
membrane. 
1.5.7. Determination of bile levels in hepatobiliary diseases  
 
Liver as an organ is involved in variety of synthetic, degradative and excretory 
functions. Although, the liver is made up of three types of cells (hepatocytes, biliary 
epithelial cells and the Kupffer cells) the hepatocytes are mainly involved in most of the 
metabolic activities. Hence, to meet the diverse demand by these metabolic pathways, a 
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number of enzymes are engineered for assisting these pathways. Hepatobiliary and 
intestinal diseases disturb these metabolic pathways giving rise to altered enzyme or 
bile acid synthesis and / or secretion, which are reflected in the serum, plasma or in the 
blood stream. The majority of bile acids are contained in the enterohepatic circulation, 
very little exist outside this circulation under normal healthy conditions (Hofmann, 
1999).  
In an abnormal condition as in hepatic and obstructive biliary diseases, bile metabolic 
rates are altered thereby increased levels of bile in serum, blood, plasma and urine can 
occur. Determination of primary and secondary bile acids in the serum and other 
biological matrices is a good indicator for the diagnosis of hepatobiliary diseases, 
disorders in lipid metabolism and other gastro-intestinal dysfunction (Street et al., 1983, 
Staggers et al., 1990). Bile acid analysis is becoming essential in many clinical biliary 
abnormalities. 
1.6. HPLC in bioanalysis 
 
1.6.1. Principles of HPLC  
 
Optimising a HPLC method is required in order to ensure data quality in 
pharmacological assays. A HPLC system validation under good laboratory practices 
(GLP) is routinely followed to obtain highest quality data. The main aspects of GLP are: 
System suitability tests (SST) - verifies the functionality of the chromatographic system 
on a day-to-day basis. According to International Conference on Harmonisation (ICH) 
and Center for Drug Research and Evaluation (CDER), SST forms an integral part of 
any analytical procedure. The parameters that include in any SST are resolution, tailing 
factor (T), theoretical plate number (N) and plate height (H).    
Resolution (Rs): Separation in chromatographic systems occur when the rate of 
migration of components differs. This is defined by resolution which calculates the 
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distance between two adjacent solute zones centre divided by average peak width 
(Lindsay, 1992).  
Theoretical plates/ Plate number (N) or plate height (H): This describes the column 
efficiency and quality of a chromatographic system. The efficiency of a 
chromatographic column is assessed by the time spent by the solute in the column. The 
longer the time spent, more dispersed it becomes. This efficiency is calculated in 
quantities called plate number or plate height (H). N is used to compare the efficiencies 
of different systems as it indicates column performance.  
Other aspects of SST include are describes as follows: 
Initial system qualification- verifies the functional performance of each component of 
the HPLC instrument (Dong et al., 2001, Dowling, 1973) which includes: 
The pumping systems: the pumping module has an ability to maintain reproducible 
consistent and accurate flow of the mobile phase, which is necessary for high resolution 
and high-speed analyses. A good pumping system should be able to generate stable flow 
of the mobile phase, which minimizes detector noise. Anomalies in flow rate can affect 
retention time and resolution.       
Gradient accuracy: Gradient accuracy defines the ability of the pumps to deliver 
accurately the required percentage of mobile phase at various time points within the run. 
This is a critical to achieving proper chromatographic resolution and reproducibility.  
Pressure Test: The pressure test elucidates the proper functioning of the check valve and 
the tubing system with the pumps. An appropriate pressure is a pre-requisite for stable 
mobile phase flow. 
Injector Module/ Auto-sampler: The injector module includes the injector and the 
needle seat. Injector describes the ability of the needle to draw prescribed volume of 
sample at each replicate injection made. This reflects on the peak area and peak height 
gained at each injection. Anomalies in the injection volume can lead to inaccurate 
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quantitation. Needle seat contamination/ carryover, on the other hand, can lead to 
contamination from the previous injection to the next injection. This could affect 
quantitation. Contamination can be avoided by injecting blanks in between the samples. 
This can be effective after injecting samples containing high concentration of analyte.   
Detector Module: A detector constantly monitors the mobile phase emerging from the 
column. Detectors function based on the principle of wavelengths. Each component 
emerging from the column is detected at a particular wavelength followed by its 
emission at different wavelength. Wavelength deviations/ wavelength accuracy 
problems can lead to less sensitive response. Further, it is necessary to programme the 
detector output to obtain specific response.  
Method validation- verifies the performance of entire analytical procedure.  
1.6.2. Detection techniques in HPLC analysis 
 
The main detection mode systems used in liquid chromatography are visible 
wavelength, electrochemical, UV, photodiode array and fluorescent detectors. Visible 
wavelength detectors are those used for measuring colour of sample component 
obtained by colorimetric reactions. Electrochemical detector measures the current 
associated with the oxidation or reduction of solutes. UV detectors detect solutes that 
absorb UV or visible light. Photodiode array detectors use diodes to measure narrow 
bands of wavelength. Fluorescence detection involves introducing a fluorophore 
conjugated to the analyte of interest.  
1.7. Mass spectrometry in bioanalysis 
 
1.7.1. Principles of mass spectrometry 
 
Mass spectrometry is used to identify ions based on their mass-to-charge ratio (m/z) and 
their relative abundances. A mass spectrometer can be coupled to a separation method. 
The separation method can be either GC (GC-MS) or liquid chromatography (LC-MS). 
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The use of LC-MS has become one of the choicest analytical techniques. Its main 
features are high sensitivity, high resolution, wide dynamic range, cover wide chemical 
diversity, robustness and feasibility to elucidate the molecular weight and structure of 
unknown compounds. A mass spectrometer has includes three fundamental parts- an ion 
source, the analyser and the detector.  
1.7.2. Electrospray ionization  
 
Several ionization techniques can be used at the LC-MS interface. Commonly used 
sources are atmospheric-pressure chemical ionisation (APCI) and electrospray 
ionisation (ESI). Both of these require high voltage and heat which can generate ions 
from solutions of the analyte. The introduction of ESI has proven to be a great tool in 
biochemistry, allowing the mass spectrometric characterization and sequencing of 
peptides, proteins and other biopolymers of great importance to human life and 
medicine.  
ESI ionises a liquid sample at atmospheric pressure. A high voltage (3- 4kV) produces 
nebulisation of the solution producing charged droplets. These charged droplets get 
smaller as the heated drying gas causes the solvent to evaporate. Individual ions are 
formed in the process that are then, separated by the mass analyzer (Figure 1.14). ESI is 
described as a soft ionisation technique because it does not fragment biomolecules . The 
main drawback of ESI is its liability for ion suppression. This is due to matrix effects 
that occur through competition between undetected matrix components co-eluting with 
the analyte of interest that can interfere during the ionisation process. 
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Figure 1.11. Illustration of the electrospray ionisation process. (Adapted from . 
1.8. Aims and objectives 
 
AP is an inflammatory disease. Extensive research on various animal models and 
human studies have shown and proved the role of oxygen-derived free radicals in the 
pathogenesis of AP. Depletion of non-protein thiols and antioxidant GSH in the 
pancreas is an early feature in both the cases. The hypothesis is that “oxidant stress” 
caused by free radicals and depletion of antioxidant systems (including GSH) in the 
pancreatic acinar cell, sets into motion a series of changes leading to AP. In order to 
investigate the role of GSH, it is important to understand the kinetics of the 
transsulfuration pathway in normal and disease conditions. The precursor amino acids 
for GSH synthesis are transported via the γ-glutamyl cycle, therefore any derangement 
in transsulfuration pathway invariably affects the availability of GSH.  
Determination of GSH and GSSG is challenging because GSH is prone to auto-
oxidation, giving erroneous GSSG values. The ratio GSH: GSSG are used to evaluate 
the oxidative stress status in biological systems. Oxidative stress can be assessed by 
measurement of the GSH: GSSG ratio in blood. Alterations in this ratio have been 
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demonstrated in various disease states including AP. Therefore, it is important to 
determine the GSH: GSSG ratio accurately.     
Bile acids are major components of the bile. Synthesis and subsequent excretion of bile 
salts in the feces represent a significant mechanism for elimination of excess dietary 
cholesterol. The concentrations of bile salts are important prognostic and diagnostic 
indicators of any hepato-biliary/intestinal dysfunction.  
The main aims of this thesis were to: 
¾  To investigate the temporal relationship between the plasma amino thiols Cys, 
Hcy, Cys-Gly and kinetics of GSH during the attack of AP.  
¾  To develop an accurate method for the determination of GSSG and tGSH levels 
in whole blood.  
¾  Study the profile of bile acids from patients suffering from various hepato-
biliary diseases.  
 
The specific objectives were to: 
1. Collaborate with clinicians at hospital, who recruited patient criteria for both AP and 
bile acid studies.  
2. Set up an HPLC method with fluorescence detection to profile the sulfur amino acids 
and analyse their profiles in AP. 
3. Identify a reliable scavenger for GSH and develop an HPLC method for the analysis 
of GSSG and tGSH. 4. Set up an LC/MS method for the analysis of bile salts in clinical 
samples and use it to analyse their profiles in patients with cholestatic heapto-biliary 
diseases, an a pilot study.   
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CHAPTER 2. Materials and Methods  
2.1. Materials 
 
2.1.1. Sulfur amino acid analysis 
 
(D, L)-homocyseteine (Hcy), L-cysteine (Cys), cysteinyl-glycine (Cys-Gly), and 
mercaptopropionylglycine (MPG) were obtained from Sigma Aldrich (Dorset, UK). Tri 
n-butylphosphine (TBP) and 7-flurobenzofurazane-4-sulfonic acid ammonium salt 
(SBD-f) and sodium acetate-3-hydrate (CH3COONa.H2O) were purchased from Fluka, 
(Dorset UK). Dimethylformamide (DMF) was purchased from Riedl-deHaen GmbH & 
CO. KG (Zeelze, Germany). Tris (hydroxylmethyl) amino methane (TRIS), sodium di-
hydrogen phosphate monohydrate, sodium hydroxide (NaOH) and 
ethylenediaminetertraacetic acid (EDTA). HPLC-grade acetonitrile was obtained from 
Merck (Nogent-sur-Marne, France). HPLC-grade acetic acid and HPLC grade methanol 
were obtained from Fischer (Loughborough, UK). 
 
2.1.2. Glutathione analysis  
 
Reduced Glutathione (GSH), oxidized glutathione disulphide (GSSG), Glutathione 
ethyl ester (GEE), metaphosphoric acid (MPA), o-phthalaldehyde powder (OPA), OPA 
readymade reagent, dithiothreitol (DTT), 1-methyl-2-vinylpyridium 
trifluromethanesulfonate (M2VP), N-ethylmaleimide (NEM), potassium tetraborate and 
sodium acetate-3-hydrate (CH3COONa. 3H2O) were obtained from Sigma-Aldrich 
(Dorset, UK). Tris (hydroxylmethyl) amino methane (TRIS) and sodium di-hydrogen 
phosphate monohydrate were obtained from BDH (Poole, England). HPLC-grade 
acetonitrile was obtained from Merck (Nogent-sur-Marne, France). HPLC grade acetic 
acid and HPLC grade methanol were obtained from Fischer (Loughborough, UK). 
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2.1.3. Bile salts analysis 
 
Sodium salts of taurocholic acid (TCA), taurolithocholic acid (TLCA), 
taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA), 
tauroursodeoxycholic acid (TUDCA), glycocholic acid (GCA), glycodeoxycholic acid 
(GDCA), glycochenodeoxycholic acid (GCDCA), glycoursodeoxycholic acid 
(GUDCA), cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), 
ursodeoxycholic acid (UDCA), lithocholic acid (LCA) and ammonium acetate were 
obtained from Sigma-Aldrich (Dorset, UK). Glycolithocholic acid (GLCA) was 
procured from Calbiochem. HPLC grade methanol was obtained from Fischer 
(Loughborough, UK). Formic acid was obtained BDH, (Poole England). The internal 
standard cholic acid d-4 was obtained from QMX laboratories, Canada. Solid phase 
extraction (SPE) cartridges (C18-E, 500 mg, 6 mL) were purchased from Phenomenex 
(Macclesfield, UK). 
 
2.1.4. Other consumables  
 
All HPLC buffers for the present study were filtered through 0.45 µM, 47mm Millipore 
Nylaflo® nylon membrane filters (Pall Gelman). HPLC vials, vial inserts (250 μL, 
colourless flat bottom), septas (8mm x 0.010 PTFT), screw-cap lids and. Eppendroff s 
and disposable pipette tips were supplied by Sarstedt, Germany. Glass pasture pipettes 
(6’’) and extraction glass tubes were purchased from Western Laboratories Services Ltd 
(Aldershot, Hampshire, UK). Broad range (4.5-10.0) pH indicator paper strips were 
purchased from Merck, UK. 4 mL vacutainer® plastic tubes were provided from Becton 
Dickson, Rutherford, NJ. Nitrogen gas was supplied by BOC gases, UK. Water was 
filtered using a resistance of 18Ω to provide Milli Q grade quality. 
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2.2. Equipment 
 
2.2.1. General laboratory apparatus 
 
An analytical balance and micro-balance (Sartorious Basic, BP110) to 4 decimal places 
was used for preparation of all standards. For HPLC and ESI/LC-MS analysis, all buffer 
mobile phases were prepared using a calibrated pH meter (Basic Denver Instruments). 
The pH meter were calibrated with standard pH 4 and pH 7 solutions prepared by 
dissolving standard pH 4 and pH7 tablets in Milli Q grade water. Vortex mixtures 
(Jensons Scientific, UK). Desktop Centrifuge (Micro Centaur, Quality laboratory 
equipments London, UK), oven and an SPE vacuum manifold and SPE drying 
attachment for vacuum manifold were purchased from Phenomenex, Macclesfield, UK.  
 
2.2.2. HPLC for sulfur amino acid and glutathione study 
 
A 1050 series Hewlett Packard equipped with a Hewlett Packard 1050 pumping 
systems and Prime Multi Channel Data Station for Windows TM, HPLC Technology, 
Herts, UK was used for analysis for both studies. A Millipore Waters 470 
programmable Scanning Fluorescence Detector was used for detecting fluorescent 
derivatives. A Hypersil C-18 reversed-phase ODS-2 silica column (250x4.6 mm: 5 µm 
particle size) (Chrompack, Les Ulis, France) and Alletech Allsphere TM ODS-2 guard 
cartridges (7.5x4.6mm, 5µm) were used for both assays. The HP 3396A integrator was 
operated in parallel (with Prime Multi Channel Data station) under following 
conditions: Attenuation 3, chart speed =0.5mm-1, area of rejection=5000, threshold=2.0 
and peak width 0.04 mm.  
2.2.3. LC/MS for bile salt analysis 
 
The LC-MS analysis for bile salts was performed using a Waters Alliance 2695 HPLC 
pump coupled to an electrospary (ESI), single quadrupole mass spectrometer (Waters, 
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Elstree, Hertsfordshire, UK) operated in negative mode. Full scan spectra were taken in 
the mass range of m/z 200-600. Instrument control and data acquisition were performed 
using the Masslynx TM V4.0 software. The chromatographic analysis on a C18 column 
(Gemini, 5μ, 150 x 2mm; Phenomenex). Sample injections were performed with a 
Waters 2690 auto sampler and the sample chamber temperature was set at 8oC. The 
column was maintained at ambient temperature.  
2.3. Clinical samples  
2.3.1. Acute pancreatitis study 
 
Human plasma samples from patients, who satisfied the criteria for acute pancreatitis, 
were supplied from The Leeds Teaching Hospitals, NHS Trust, Leeds UK. The samples 
were collected according to the protocol approved by the local ethics committee. The 
plasma samples were collected in 1 mL eppendroffs and kept in -80ºC. 
2.3.1.1. Clinical Criteria for acute pancreatitis classification 
 
All the clinical criteria for the AP patients were assessed by Dr Z Rahman at The Leeds 
Teaching Hospitals NHS Trust, Leeds, U.K in accordance with the Atlanta criteria of 
1992 and The Acute Physiology and Chronic Health Evaluation – II score (APACHE-
II) and Acute Physiology Scores (APS) at 24-hrs after the onset of abdominal pain and 
at 48 and 72 hours (Knaus et al., 1981). A control cohort of healthy, age matched 
subjects, with no history of AP, chronic disease, or malignancy was recruited from 
among the in-hospital medical and nursing staff. Samples for biochemical analyses 
collected at 24 and 72 h after the onset of abdominal pain were analysed immediately 
for erythrocyte GSH, γ-GT activity and disease severity determination at LGI, Leeds, 
UK, by Dr Z Rahman.  
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2.3.2. Glutathione study 
 
Human whole blood samples were supplied from St. Luke’s General Hospital, Leeds, 
UK and Leeds General Infirmary (LGI), Leeds, UK, by Dr Rahman SH. The samples 
were collected according to the protocol approved by the local ethics committee. 
2.3.3. Bile salts 
 
Human bile samples from patients suffering from cholestatic hepato-biliary diseases 
were collected at the Leeds General Infirmary (LGI), Leeds, UK, by Dr Rahman SH. 
The samples were collected according to the protocol approved by the local ethics 
committee. The samples were collected in 5 mL plastic screw top specimen containers 
and stored in -80ºC.  
 
2.4. Biochemical analyses 
 
2.4.1. Total erythrocyte glutathione determination 
 
Total reduced erythrocyte glutathione (GSH) concentration was determined 
colorimetrically using the GSH-400 (OXIS, BIOMED; Nycomed Amersham plc, 
Buckinghamshire, UK). Assay using 1 ml of erythrocyte pellet separated from an 
EDTA treated 5ml sample of peripheral venous blood. The assay was performed 
according to the manufacturer’s instructions by Dr Rahman SH. 
2.4.2. γ-Glutamyl transpeptidase activity 
 
Venus blood after an overnight fast was used for the determination of serum activity of 
γ-glutamyl transpeptidase (γ-GT). Enzyme activity was determined through a 
colorimetric method based on the recommendation of European Committee for Clinical 
Laboratory Standards (Klauke et al., 1993). Serum γ-GT greater than 50 IU/L was 
defined as an elevated γ-GT. The assay was performed by Dr Rahman SH. 
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2.4.3. C-reactive protein assay 
 
A further 5 ml sample of heparin treated venous blood was obtained from all patients 
every 24 hours for at least 4 days from the onset of pain, from which C-reactive protein 
(CRP) levels were measured using an enzyme-linked immunosorbent assay (ELISA) 
(DAKO, High Wycombe, UK). The assay was performed by Dr Rahman SH. 
2.5. Sulfur amino acid analysis  
2.5.1. Reagents 
 
2.5.1.1. Reducing solution (TBP) 
 
1 mL of Tri n-butylphosphine (TBP) was thoroughly mixed with 9 mL of 
dimethylformamide in a fume cupboard. This solution was made fresh each time and 
discarded after use.  
2.5.1.2. Protein precipitating solution (TCA) 
 
1 g of trichloroacetic acid (TCA) and 3.72 mg EDTA were dissolved in 10 mL water 
using 10 mL volumetric flask. The final concentration of TCA was 100mg/ mL and that 
of EDTA was 37.2 mg/ mL. The solution was stored at 4˚C for one week.  
2.5.1.3. Borate buffer   
 
3.82 g of potassium tetraborate and 0.15 g of EDTA were dissolved in water. The 
solution was made up to 100 mL in volumetric flask. The solution was stored at 4˚C for 
one week. 
2.5.1.4. Mercaptopropinyl glycine (MPG) 
 
19.6 mg of MPG was weighed and dissolved in a 100 mL volumetric flask with water. 
The concentration of this solution was 1.2 mM.  
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2.5.1.5. Sodium hydroxide solution 
 
This solution was made by dissolving 6.2 g NaOH in 100 mL water using a volumetric 
flask. The solution was stored at 4˚C for one month.  
2.5.1.6. SPD-f derivatizing solution 
 
A solution of 1 mg/mL SPD-f was prepared fresh every time in borate buffer. The 
volume of this solution was adapted to the number of samples to be derivatized. The 
solution is light sensitive and was kept at 4˚C in a covered container for up to 7 days.  
2.5.2. HPLC mobile phase solutions 
 
 
Buffer A: (0.1 M acetate buffer, pH 4)  
13.6 g of sodium acetate 3- hydrate was dissolved in 900 mL Milli Q Water to make a 
0.1M acetate buffer. The pH of the buffer was adjusted to pH 4 by the addition of HPLC 
grade glacial acetic acid, drop wise. The solution was then transferred to 1000 mL 
volumetric flask and the volume was made up with Milli Q water. The buffer was 
filtered through 0.45 μM Millipore filter and degassed for 10 min. 
 
Buffer B (0.1 M acetate buffer, pH 4, 5% MeOH)  
13.6 g of sodium acetate 3- hydrate was dissolved in 800 mL Milli Q water. The pH of 
the buffer was adjusted to pH 4 by the addition of glacial acetic acid, drop wise. 50 mL 
HPLC grade MeOH was added. The solution was then transferred to a 1000 ml 
volumetric flask and made up with Milli Q water. The buffer was filtered through 0.45 
μM Millipore filter and degassed for 10 min. 
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2.5.3. Sulfur amino acid solutions 
 
2.5.3.1. Stock solutions 
 
1.2 mM stock solution of each sulfur amino acid standard and the internal standard 
(MPG) were made. HCY (4.2 mg), CYS (3.62 mg), CYS-GLY (5.35 mg), GSH (9.2 
mg) and MPG (4.9 mg) were dissolved in 25 mL water using volumetric flasks. These 
stock solutions were aliquoted in 1 mL eppendroff tubes and stored at -20˚C for one 
month. 
2.5.3.2. Preparation of sulfur amino acid combined standard  
 
1 mL of each one of the 1.2 mM standard stock solutions was taken in a 10 mL 
volumetric flask. The final volume was made up to 10 mL with water. This solution is 
was the combined standard of all sulfur amino acid at a concentration of 0.12 mM each 
and was made fresh every time.  
2.5.3.3. Standard solutions of sulfur amino acids for the calibration line 
 
The combined standard (0.12 mM) was further diluted as shown in the table below to 
obtain a linear range of concentrations. These were used as calibration points.  
 
Dilution 7 6 5 4 3 2 1 
Volume of 
0.12 mM 
combined 
standard (µL) 
1000 750 500 250 125 63 31 
Milli Q water 
(µL) 
0 250 500 750 875 938 969 
Final 
concentration 
(μM) 
120 90 60 30 15 7.5 3.75 
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2.5.3.4. Preparation of sulfur amino acid single standards 
 
Single standards of all the amino acids were made from the 1.2 mM stock standards 
(Section 2.5.3.1) and this was used as to determine the retention time for compound. 
Each standard was diluted to a final concentration at 60 μM (50 μL of 1.2 mM stock 
solution added and mixed with 950 μL water.  
2.5.3.5. Preparation of the internal standard (I/S) 
 
20 μL of the 1.2 mM stock solution of MPG (I/S) was mixed with 980 μL water to make 
a working solution of the internal standard at a concentration of 24 μM.  
2.5.3.6. Derivatization of sulfur amino acids 
 
60 µL of biological sample (or standard) were mixed with 40 μL of MPG (24 µM) and 
10 μL of TBP solution. This step was performed in the fume cupboard. The samples 
were mixed and then incubated at 4˚C in the dark for 30 min. 100 μL of TCA solution 
was then added to each sample solution and the solutions were centrifuged at 2817 x g 
(6000 rpm) for 10 min.  
50 μL of the resulting supernatant was transferred into an eppendroff containing 125 μL 
of borate buffer and 10 μL of NaOH. The samples were then derivatized by the addition 
of 50 μL of SBD-f solution and incubated in the oven at 60˚C for 60min. The 
derivatized samples were left to cool to room temperature for 10 min and analyzed 
immediately by HPLC.  
2.5.3.7. HPLC analysis of sulfur amino acids 
 
HPLC analysis was based on a gradient system with two solvents: Buffer A and Buffer 
B. the gradient was programmed as shown in the table below. The injection volume was 
20 μL, the flow rate was 1 mL/min with a overall runtime of 29 min. 
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Time (min) % Buffer A % Buffer B 
0 100 0 
2 50 50 
12 50 50 
14 0 100 
22 0 100 
23 100 0 
29 100 0 
 
 
The fluorescence detector was operated at attenuation 2.0 gain x 100 and at excitation 
wavelength of 385 nm and emission wavelength of 515 nm. The integrator was operated 
under the following conditions: Attenuation 2, chart speed= 0.5 mm/min, Area of 
rejection= 5000, Threshold= 2.0 and Peak width= 0.04.  
2.6. Glutathione Analysis by HPLC 
2.6.1. Reagents 
 
2.6.1.1. 1-Methyl-2-vinyl-pyridium trifluromethane sulfonate (M2VP)  
A 15 mM M2VP was made (2 mg/ 500 μL) in 0.01M HCl solution. This was prepared 
fresh every time before use.  
2.6.1.2. N-ethylmaleimide (NEM) 
 
A 15 mM NEM solution was prepared fresh (9 mg/ 500 μL) in 0.01M HCl solution. 
This was prepared fresh every time before use.  
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2.6.1.3. Dithiothreitol solution  
 
A 25 mM DTT (19 mg/5 mL) solution was made in water, fresh every time before use.  
The solution can also be stored for 3-5 days at 4ºC.  
2.6.1.4. TRIS buffer  
 
A 0.1 M TRIS buffer (121 mg/100 mL) was prepared in water and kept at 4ºC for up to 
10 days.  
2.6.1.5. Sodium phosphate buffer  
 
A 500 mM of sodium dihydrogen phosphate (6.89 g/100 mL) was prepared in water. 
This solution was stored at 4ºC for one week.  
2.6.1.6. Metaphosphoric acid solution 
 
A 6% (w/v) solution of MPA acid solution was prepared by dissolving 6 gm of MPA in 
100 mL water. The MPA solution was stored at 4ºC for one week.  
2.6.1.7. Potassium tetraborate solution 
 
A 0.4 M potassium tetraborate solution was prepared by dissolving 1.2 in 10 mL of 
water. This solution has a pH of 9.90 unadjusted.  
2.6.1.8. OPA reagent  
 
The OPA reagent was purchased as a complete ready-made reagent. It contained Brij 
35, methanol, o-phthaldialdehyde, 2-mercaptoethanol, potassium hydroxide and boric 
acid with a of pH 10.4. The solution is light sensitive and can be oxidized when exposed 
to air. Hence, the reagent bottle was flushed with nitrogen every time after use, sealed in 
parafilm and store at 4ºC as advised in material data sheet.   
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2.6.1.9. Preparation of OPA solution from powder 
 
A 5 mg/mL OPA solution was made by dissolving 50 mg of OPA powder in 0.5 mL 
HPLC grade methanol. The volume was made up to 10 mL with freshly prepared 0.4 M 
potassium tetraborate solution. This OPA solution can be stored for a 1week at 4ºC or 
for four weeks at -20ºC. 
2.6.2. Preparation of GSH, GSSG and GEE standards 
 
Stock solution of GSH (10 mM; 37 mg/ 10mL), GSSG (1 mM; 32 mg/ 5 mL) and GEE 
(1 mM; 1 mg/ 3 mL) were prepared in 0.01M HCl. These solutions were aliquoted (100 
µL) in eppendroff tubes and stored at -20ºC up to 1 week. Working standard solutions 
of GSH (5 mM, 2 mM, 1 mM, 500-10 μM) and GSSG (500-10 μM) were prepared 
daily from these stock solutions by diluting the solutions with 0.01M HCl. All the 
standard and working standard solutions for GSH or GSSG were prepared in 0.01M 
HCl to protonate the reactive thiolate anions.    
2.6.3. Preparation HPLC mobile phase solutions 
 
Buffer A (50 mM acetate buffer, 10 % acetonitrile, pH 6.2) 
6.80 g of sodium acetate-3-hydrate was dissolved in 900 mL water. The pH of the 
solution was adjusted to 6.2 using glacial acetic acid. 100 mL of HPLC grade 
acetonitrile was added. The aqueous solution and the organic solvent were mixed 
thoroughly on a magnetic stirrer. The buffer was filtered through 0.45 μM Millipore 
filter and degassed for 10 min.   
  
Buffer B (50 mM acetate buffer, 80% acetonitrile, pH 6.2) 
6.80 g of sodium acetate-3-hydrate was dissolved in 200 mL water. The pH of the 
solution was adjusted to 6.2 using glacial acetic acid. This solution was mixed with 800 
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mL HPLC grade acetonitrile and mixed thoroughly on a magnetic stirrer. The buffer 
was filtered through 0.45 μM Millipore filter and degassed for 10 min.   
2.6.4. Collection of blood samples 
 
Blood samples were collected in 4 mL vacutainer tubes coated with K2EDTA as 
anticoagulant by vein puncturing healthy volunteers. Immediately, 100 μL of the blood 
sample were placed in 1 mL eppendroff containing 10 µL of M2VP (15 mM) solution 
and mixed thoroughly. These samples were used for tGSSG analysis. The concentration 
of M2VP in the blood samples was 1.3 mM. Another aliquote of blood (100 µL) was 
collected 1 mL eppendroff. These samples were used for tGSH analysis. All samples 
were frozen immediately in an upright position and kept at -80ºC.  
 
2.6.5. Total GSH (tGSH) assay 
 
100 µL of whole blood collected for tGSH assay was thawed on ice. 50 µL of 100 µM 
GEE (internal standard) was then added followed by 100 µL of 25 mM DTT. The 
samples were mixed gently and then incubated at 4ºC for 30 min. 800 µL of ice-cold 
MPA solution was then added to each sample. The resulting solution was mixed and left 
on ice for 10-15 min to complete the precipitation of proteins. The solutions were then 
centrifuged at 7826 x g (10,000 rpm) for 10 min. 100 µL of the clear supernatant was 
transferred to a clean eppendroff and mixed with 200 µL of 0.1M TRIS, pH 8.5. 100 µL 
of this neutralized solution was then mixed with 100 µL of freshly made OPA solution 
(from OPA powder). The samples were mixed and left in dark for 10 min at room 
temperature to derivatize. 800 µL of 500 mM phosphate buffer, pH 7.00 was then added 
to the sample to adjust the pH to 9.0. 20 µL of this derivatized sample were taken for 
HPLC analysis immediately.  
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2.6.6. Oxidized GSH (GSSG assay) 
 
100 µL of whole blood collected with M2VP (1.3 mM), was thawed on ice. 50 µL of 
100 µM GEE (internal standard) was added followed by 100 µL of 25 mM DTT. The 
samples were mixed gently and incubated at 4ºC for 30 min. 800 µL of ice-cold MPA 
solution was then added. The solution was mixed and left on ice for 10-15 min to 
complete precipitate the proteins. The resulting solution was centrifuged at 7826 x g 
(10,000 rpm) for 10 min. 100 µL of the clear supernatant was transferred to a clean 
eppendroff and mixed with 200 µL of 0.1M TRIS, pH 8.5. 100 µL of this neutralized 
sample was then mixed with 100 µL of freshly made OPA solution (from OPA powder). 
The samples were mixed and left in dark for 10 min at room temperature to derivatize. 
800 µL of 500 mM phosphate buffer, pH 7.00 was then added to the sample to adjust 
the pH to 9.0. 20 µL of this derivatized sample were taken for HPLC analysis 
immediately.  
2.6.7. HPLC analysis for tGSH and tGSSG 
 
The HPLC analysis was based on a gradient system with two buffers, Buffer A and 
Buffer B. The gradient was programmed as shown below. The flow rate was 1 mL/min 
with an overall runtime of 29 min.  
 
Time (min) % Buffer A 
10% acetonitrile 
% Buffer B 
80% acetonitrile 
0 90 10 
10 80 20 
15 50 50 
16 0 100 
20 0 100 
21 100 0 
29 100 0 
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The fluorescence detector was operated at attenuation 2.0 gain x 100 and at excitation 
wavelength of 340 nm and emission wavelength of 420 nm. An integrator was operated 
under the following conditions: Attenuation 2, chart speed= 0.5 mm/min, Area of 
rejection= 5000, Threshold= 2.0 and Peak width= 0.04. Prime Multi Channel Data 
Station for Windows TM was also operated in parallel.  
2.6.8. Calibration lines  
 
The peak to area ratio of each analyte to the relevant internal standard was calculated 
and plotted against the concentration of the calibration standards. Calibration lines were 
calculated by the least square linear regression method. Peak integrations and S/N 
calculations were performed using the Prime Multi Channel data station software for 
Windows The method development followed for tGSH and tGSSG and relevant 
calculations are described in detail in chapter 3.  
 
2.7. Bile acid analysis using ESI/LC-MS 
2.7.1. Preparation of bile acid stock solutions 
 
 
All the primary (CA and CDCA) and secondary bile acid standards (DCA, UDCA and 
LCA), conjugates of taurocholic (TCA, TCDCA, TDCA, TUDCA, TLCA) and 
glycocholic acids (GCA, GCDCA, GDCA, GUDCA, GLCA) and the internal standard 
cholic-2, 2, 4, 4-d4 acid were prepared in methanol at a concentration of 1 mg/mL (stock 
solution) individually, and stored in -80ºC. 10 µL of each individual bile acid and 
internal standard solutions were diluted with 990 µL MeOH to prepare working 
standard solutions of 10 μg/ mL separately. These working standard solutions were 
stored in -20ºC. A cocktail of bile acid standard solutions were prepared by mixing 15 
working bile acid standard solutions (10 µg/mL): 10 µL of each bile acid standard (total 
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volume 150 µL) were mixed and the volume was made up to 300 µL by adding 140 µL 
MeOH and 10 µL of 1 µg/mL internal standard. The cocktail was then stored in -20 ºC. 
The final concentration of this composite standard was 0.33 µg/mL/ bile salt.  
2.7.2. Preparation of HPLC solvents  
 
The chromatographic separation of the 15 bile salts were achieved by gradient system 
using two buffers Buffer A (5 mM ammonium acetate in 0.012% formic acid) and 
Buffer B (5 mM ammonium acetate in MeOH and 0.012%formic acid). The flow rate 
was 0.2 µL/min with a total run time of 40 min.  
2.7.3. Bile standards and calibration lines  
 
The peak to area ratio of each bile acid standard to the relevant internal standard was 
calculated and plotted against the concentration of the calibration standards (25 μg- 2.5 
μg/ mL). Calibration lines were calculated by the least square linear regression method.  
2.7.4. Preparation and extraction of bile salts from clinical samples 
 
Approximately, of 1 mL of frozen bile sample was scooped out from each frozen bile 
sample and transferred into a 1.5 mL eppendroff vial. These samples were defrosted on 
ice. 50 μL of each bile sample was then transferred into a clean eppendroff vial, and 
mixed with 940 μL of water, by gentle vortexing. 10 μL of the cholic 2, 2, 4, 4-d4 acid 
(internal standard) (1 μg/mL) was then added to this sample. The samples were kept on 
ice.  
2.7.5. Solid phase extraction  
 
The SPE cartridges were attached to the vacuum manifold and a pressure of 
approximately 5mm Hg was applied. The SPE cartridges were pre-conditioned using 5 
mL methanol adjusting the vacuum to attain a steady drop-wise flow through the 
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cartridge. The flow was stopped just as the meniscus touched the filter taking care not to 
allow any air through. This was judged by constant visual inspection. Then the 
cartridges were washed with 5 mL water adjusting the vacuum to attain a steady drop 
wise flow through the cartridge. The flow was stopped similarly, when the meniscus 
just touched the filter taking care not allow any air through.  
 
The bile samples prepared (as described in section 2.7.4) were transferred to the SPE 
cartridge and allowed to pass through in a drop-wise manner taking care not allow air 
through the filter at any point. The cartridge was then washed with 10 mL water. The 
bile salts were eluted from each cartridge with 5 mL methanol. Care was taken to 
maintain a slow drop-wise flow (under gravity) through the cartridge. The eluent was 
collected in clean, dry extraction glass tubes. At this stage, air was allowed to pass 
though the cartridge for 2 min to ensure the entire methanol extract had been collected.   
2.7.6. Drying and reconstitution of bile salt extract 
 
The drying apparatus were set up as follows: 
Drying apparatus were set with the desired number of needles; the sample extracts 
collected in clean glass vials were placed so that the needle was directly above the 
sample making sure that the needle was not in contact with the solvent. The stream of 
nitrogen gas was to ensure a gentle flow of nitrogen over the surface of the methanol 
causing it to slightly ripple. The flow was periodically readjusted as the methanol 
evaporated. 
Once the tube containing the extracted sample was completely dry, the glass tubes were 
removed from the drying apparatus and the residue was reconstituted in 500 µL 
methanol. This reconstituted sample was then transferred to clean glass vial sealed with 
open screw caps with Teflon septa and stored at -20ºC until analysis.  
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2.7.7. LC-MS analysis 
 
The chromatographic separation of bile salts were achieved by gradient system using 
two buffers buffer A (5 mM ammonium acetate in 0.012% formic acid) and buffer B 
(5 mM ammonium acetate in MeOH and 0.012%formic acid). The flow rate was 0.2 
µl/min with a total run time of 40 min. The gradient was programmed as shown below: 
 
Time (min) % Buffer A % Buffer B 
0 30 70 
20 5 95 
24 5 95 
40 30 70 
 
Ionization was achieved in a negative electrospary ionisation mode (ESI) and data 
acquired using single ion recording (SIR). The optimum conditions for ionization of 
the individual bile acids are shown in the following summary table.  
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Sodium salts of bile acid 
standards  
 
Cone voltage 
(V) 
 
Indicative retention time 
(min) 
 
TCA 82 8.08 
TUDCA 60 5.81 
TDCA 90 11.60 
TCDCA 60 12.57 
TLCA 90 15.82 
GCA 60 8.62 
GUDCA 60 6.17 
GDCA 60 12.08 
GCDCA 60 13.20 
GLCA 60 16.40 
CA 60 12.31 
CDCA 60 10.08 
DCA 60 17.07 
UDCA 60 10.08 
LCA 80 20.72 
CA-d4 internal standard 92 12.26 
 
2.7.8. Limits of detection and quantitation 
 
The limit of detection (LoD) was estimated using signal-to-noise (S/N) ratio of 3. The 
limit of quantitation (LoQ) was determined using a S/N ratio of 10. Peak integrations 
and S/N calculations were performed using the MassLynx TM V4.0 software.  
 
2.7.9. Extraction recovery 
 
In order to assess the recovery of the extraction methodology, bile samples were spiked 
with 10 μL cocktail of standards (330 ng/ mL/ standard), without internal standard. The 
samples were cleaned up by SPE and analysed as described in section 2.7.5. These spiked 
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bile samples were analysed in parallel with unspiked bile samples and the difference in 
the peak-area values was related to the amount of the spike.  
At the same time, standards at the same amount, as used to spike the biological samples, 
were analysed directly by ESI-LC/MS directly. The peak areas of the analyte from the 
spiked, unspiked and directly analysed standards were used to calculate the recovery of 
the spiked standards using the equation: 
 
% Recovery = Peak area of the spiked – Peak area of the unspiked  
                             Peak area of directly analysed standards                          
 
2.8. Statistical Analysis   
All statistical analyses were performed using SPSS v16.00 statistical analysis software 
(SPSS Inc, Cary, NC, USA). Statistical analyses included both parametric and non-
parametric tests. Data were assessed for normality using the Kolmigornov-Smirnov 
(KS) test together with visual inspection of the p-p plots and histograms. Parametric 
data’s was compared using paired sample T-test. Non-parametric data was compared 
data using Mann-Whitney U-test. Pearson’s correlation and Spearman’s rank test was 
used to correlate continuous and non-continuous data respectively. P values <0.05 were 
considered stastically significant.  
 
 
 
 
 
 
 
 
x 100 
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CHAPTER 3: Method development for oxidized and reduced 
glutathione 
3.1. Introduction  
 
Oxidative stress has long been implicated as one of the morbid factors leading to 
various premature cellular complications. This is particularly evident in erythrocytes as 
they are important mobile detoxifiers and carriers of GSH (Dumaswala et al., 2001). 
Given the importance of GSH in many biochemical reactions, there has always been an 
active interest in measuring whole blood GSH concentrations. As whole blood GSH 
concentrations reflect GSH status in other less accessible tissues, measuring both GSH 
and GSSG in whole blood is considered essential as an index of the whole subject 
oxidative status and as a useful indicator of disease risk in humans. 
Under normal physiological conditions, GSH is present in its reduced form and in 
millimolar (mM) levels, while GSSG is present in micromolar (μM) levels. Variations 
in these levels, caused by pathophysiological conditions can make them mediators of 
important functions or parameters of clinical significance. Thus, methods that can 
accurately and specifically measure tGSH and/ or reduced or oxidized GSH levels in 
biological matrix are crucial for understanding the redox status of the cells or the 
tissues. 
The wide spread heterogeneous distribution of GSH and its role against oxidative stress 
and various other vital functions have aroused continuous analytical interest. Accurate 
and precise measurement of GSH or GSSG is not a straightforward procedure for a 
number of reasons. Auto-oxidation is one of the major drawbacks in GSH estimation 
 76
and GSH levels in blood is liable to this. Possible errors that can occur during sample 
collection and preparation can be as follows:  
1. Haemolysis of blood- results in an over estimation GSH, as the GSH levels in red 
blood cells is more than plasma.  
2. Storage at room temperature- if it were stored at room temperature, there would be 
under estimation of GSH, as GSH would undergo auto-oxidation. 
3. Oxidation during acid protein precipitation - oxidation during acid precipitation can 
happen in blood depending on the concentration of heme groups. In blood, oxidants 
formed from oxy-hemoglobin can oxidize GSH (Gallemann and Eyer, 1990) This 
means whatever GSH values acquired, may or may not be reliable. Thus, accurate 
determinations of GSH/GSSG largely depend on proper sample preparation (Mills et al., 
1994). 
 
Numerous methods are available for measuring reduced and oxidized GSH in biological 
samples. Among spectrophotometeric determination, the most popular assay is 
enzymatic recycling, first discovered in 1965 (Owens and Belcher, 1965) and was later 
developed by Tietze (1969). GSH reacts with 5, 5- dithiobis-(nitrobenzoic acid) 
(DTNB) or Ellman reagent. Ellman reagent oxidizes GSH yielding 2-nitro-5-
thiobenzoic acid (TNB) which was spectrophotometrically measured at 412 nm. The 
method also measures GSSG by reducing it with NADPH in the presence of GR. The 
disadvantage was the lack of automation (Tietze, 1969).  
In the intervening periods, these techniques have been further advanced and these 
advancements have been briefly considered. Significant developments were made in 
fluorimetric methods. Pioneering work using OPA, a fluorophore for the determinations 
of reduced GSH were first reported in 1966 (Cohn and Lyle, 1966). The method was 
modified to allow GSH and GSSG determination using OPA as a derivatizing agent to 
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produce highly fluorescent derivatives, which were measured using spectrofluorometer 
(Hissin and Hilf, 1976).  
 
Methods involving capillary electrophoresis have also been described (Serru et al., 
2001). However, considerable oxidation of GSH during analysis was noticed leading to 
loss of GSH. Some of the detection modes coupled with capillary electrophoresis are 
UV-Visible detection, diode array detector, electrochemical detector and mass 
spectrometer (Desiderio et al., 1999, Dankova et al., 1999). Although, some mass 
spectrometric methods for GSH determination have been described (Camera et al., 
2001, Norris et al., 2001), LC/MS is currently not an equipment in many hospital 
laboratories (Steghens et al., 2003). 
 
A majority of assays involved in separation and/ or determination of GSH/ GSSG/ 
tGSH from a given biological matrix are by HPLC systems. However, selecting a 
suitable detection technique for HPLC analysis is one of the most important factors in 
developing an analytical HPLC method. Relatively few HPLC methods for the GSH 
and its congeners with UV-Vis absorbance or diode array detector (DAD) have been 
described (Reed et al., 1980). The authors estimated high amounts of GSSG due to 
oxidation of GSH. Due to low sensitivity and specificity, methods involving UV/ DAD 
are currently out of use. HPLC-ECD (electrochemical detector) analyses of GSH and 
GSSG (Rabenstein and Saetre, 1977) have shown a high oxidation potential and have 
proved to reduce the performance of ECD (Rose and Bode, 1995). 
 
The most common and popular mode of detection employed in the determination of 
GSH in biological matrices is fluorescence. Fluorescence detection provides variable 
excitation and detection wavelengths favouring trace analysis. Further, it is considered 
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more selective and sensitive as only a small number of compounds fluoresce. The 
method of fluorescence detection involves introducing a fluorophore that changes the 
chemical structure of the compound to be studied. The choice of a fluorophore comes 
from the chemical structure that selectively combines and forms a fluorescent product. 
Hence, a fluorophore increases the sensitivity of the assay. The most frequently used 
flurophores in the determination GSH are monobromobiamine (BrB), benzofluron 
derivatives namely 7-flurobenzofurazane-4-sulfonic ammonium salt (SBD-f) and ortho-
phthalaldehyde (OPA).  
 
BrB combines with the functional thiol group in GSH forming GSH-Bimane adducts. 
The adducts formed with high fluorescence allows emission followed by detection even 
at low concentrations (2x 10-8 M). Although, bimane adducts are widely used, studies 
have shown that BrB is not selective for GSH determination (Ivanov et al., 2000). BrB 
being fluorescent by itself undergoes photo-degradation yielding fluorescent products 
that appear as unknown peaks in the chromatograms. SPDf was considered a low-
reactive reagent that requires drastic conditions such as 60º C for approximately 60 min 
to derivatize thiols (Toyo'oka and Imai, 1983).  
 
Unlike BrB, OPA is non-florescent reagent (Neuschwander-Tetri and Roll, 1989, Senft 
et al., 2000, Yan and Huxtable, 1995), capable of reacting with primary amines in the 
presence of thiol, cyanide or sulfite forming a highly fluorescent tricyclic isoindole 
(Yan and Huxtable, 1995, Molnar-Perl, 2001). The reaction between the –SH group and 
OPA is pH dependent. It is widely reported that the reaction between amines and OPA 
takes place in strongly alkaline pH (Svedas et al., 1980). The free thiol group in GSH 
reacts with OPA forming a GSH-OPA adduct (Figure 3.1).  
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Figure 3.1. Structure of GSH-OPA adduct.  
 
3.1.1. Disulfide reduction 
 
Introducing fluorophore does not allow GSSG detection due to the presence of disulfide 
bond. Determination of tGSH or GSSG requires the reduction of all the disulphide 
species in the biological fluid. This reduction can either be enzymatic (Ercal et al., 
2001) by electrolysis (Ivanov et al., 2000) or by chemical reaction (Lenton et al., 1999, 
Yang et al., 1995, Cereser et al., 2001). A number of reducing agents have been 
identified such as 2-mercaptoethanol, TBP, dithiothreitol (DTT) and sodium 
borohydride. Choosing an appropriate reagent is critical for assay performance. 
3.1.2. Thiol scavengers in GSH determinations 
 
One of the innate difficulties is the metal ions (heme in blood) can possibly react with 
sulfhydryl in GSH to yield GSSG during sample preparation. Although, the amount of 
tGSH remains the same, GSSG would be expected to increase under such conditions. In 
order to quantitate intracellular GSSG concentrations accurately, the reduced GSH pool 
has to remain unchanged (without oxidation). A strategy to block changes in GSH in a 
biological sample before protein precipitation, has led to the invention of thiol blockers 
or scavengers.  
Griffith reported 2-vinyl pyridine (2-VP) as an efficient thiol blocker (Griffith, 1980). 
However, the masking reaction with 2-VP required 20-60 min incubation at room 
temperature (Shaik and Mehvar, 2006). This time interval can possibly cause GSH auto-
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oxidation to GSSG at room temperature. There have been two known thiol scavengers 
N-ethylmaleimide (NEM) and indole-3-acetic acid (IAA) since 1969. NEM can 
effectively react with free thiol groups facilitating a GSSG determination (Camera et al., 
2001, Piccoli et al., 1994). Nevertheless, there have always been certain disadvantages 
when the NEM or IAA were used.  
NEM is a potent inhibitor of GR (Griffith, 1980) which is required for GSSG formation 
while IAA acid forms S-carboxymethyl derivatives by nucleophilic substitution 
(Camera et al., 2001, Loughlin AF, 2001, Piccoli et al., 1994). The principle of action 
behind these two thiol scavengers is the same i.e., both of these react with the thiol 
group in GSH. NEM blocks the reduced sulfhydryl group adding a thiol group across 
the double bond of maleimide. 
Lately a more reliable scavenger, a derivative of 2-VP namely 1-methyl-2 
vinylpyridinium trifluoromethane sulfonate (M2VP), a mercaptan scavenger, that 
completely scavenges GSH in less than 1 min has been identified (Fu and Murray, 
2001). The chemical design of the mercaptan scavenger is to bind with the free thiol 
group as shown in the reaction below (Figure 3.2).  
 
 
Figure 3.2. Reaction of M2VP with thiol forming 1-methy l-2-(2-thioethyl)-pyidinium 
salt. 
The aim of the current study therefore, was to develop a reverse phase HPLC method 
for determination of tGSH and GSSG with fluorescence detection using OPA. In order 
to avoid GSH auto-oxidation, GSSG was measured using a mercaptan scavenger 
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M2VP. The concentration of GSH was determined by subtracting tGSH and GSSG 
levels and calculating the ratio GSH/GSSG under normal physiological conditions.  
3.2. Material and methods  
 
The materials used for this study are fully listed in section 2.1.2. The equipment 
conditions are described in section 2.2.2. The sampling procedure has been described in 
method section 2.6.4, whilst the optimised method is described in detail sections 2.6.5 
and 2.6.6. 
3.3. Results  
 
3.3.1. Preliminary tests for glutathione 
 
The initial analysis for the assay involved a simple step of derivatizing GSH with OPA. 
Sodium phosphate solution was added to neutralise the derivatized solution and directly 
taken for HPLC analysis. An isocratic elution with 50 mM sodium acetate with 5% 
acetonitrile was used to analyse the GSH-OPA derivative. The GSH-OPA peak was 
detected at 11 min (Figure 3.3). GSH solution were made in 0.01M HCl. Mild acidic 
condition for the preparation of standards can possibly minimize auto-oxidation of GSH 
and aids to protonate the reactive thiolate anions.  
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Figure 3.3. Sample chromatogram showing GSH peak (10 mM). 
The concentration of GSH present in blood is approximately 10 mM. Hence, a 
calibration line was prepared to cover the entire range of expected concentrations (10 
mM- 1mM) in whole blood (Figure 3.4) (See appendix Table 3.1). 
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Figure 3.4. Representative calibration line for GSH to show the linearity of the assay 
over a range of concentrations (10 mM-1 mM). 
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3.3.2. Internal standard selection 
 
An internal standard is a known amount of standard substance that is added in the assay, 
which can negate some of the problems with changes brought about, by the detector 
response, non-eluting sample constituents and variable injection volume. A number of 
criteria were considered prior selecting an appropriate internal standard. 
 
An internal standard should, completely be resolved from other sample compounds, 
should not be already present in the test sample, should not react/ interfere with other 
components, should not co-elute with compound of interest, should be highly pure and 
readily available and should have similar physiochemical properties as the analyte(s).  
 
As the method involved derivatization with OPA, an internal standard that can also 
derivatized with OPA was chosen. Two compounds were considered as potential 
internal standards and their chromatographic behaviour were studied. These were; 
mercaptopropionylglycine (MPG) and glutathione ethyl ester (GEE).  
However, MPG (α-ketothiol) gave very low fluorescence intensity with OPA (Figure 
3.5) due to low quantum yields of derivatives (Sano and Nakamura, 2001). GEE, on the 
other hand, was considered as a potential internal standard due to its structural 
proximity with GSH. However, GEE-OPA eluted at the same time as GSH-OPA peak 
under isocratic conditions (Figure 3.6).  
 
 
 84
 
                                                                  Time (min) 
Figure 3.5. Sample chromatogram of MPG (100 µM). 
 
                                                     Time (min) 
 
Figure 3.6. Sample chromatogram of GEE (100 µM).  
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3.3.3. Effect of mobile phase pH on the separation of GSH and GEE 
 
To overcome the problem of co-elution and to obtain adequate separation between GSH 
and GEE, a study of buffers with varying pH were undertaken. A very low pH (less 
than pH 5) was avoided as it could possibly lead to alterations in the fluorescent 
properties of the analyte i.e. shift the excitation and emission wavelengths of the 
analyte which, can occur due to stabilization or destabilization of electronic structure 
(Sadek, 1996).  
 
In order to test different pH during the experiments, Buffer A, was 50 mM sodium 
acetate buffer adjusted to pH 5.8 containing and 5% acetonitrile (95: 5) and Buffer B 
was 20 mM sodium acetate buffer containing 50% acetonitrile (50: 50) corrected to pH 
5.8 were made. A gradient was programmed as follows: 
 
Time (min) Buffer A 50 mM sodium acetate 
5% acetonitrile pH 5.8 
Buffer B 20 mM sodium acetate 
50% acetonitrile pH 5.8 
0 90 10 
30 60 40 
31 0 100 
36 0 100 
37 100 0 
45 100 0 
 
 
GSH eluted at 6.2 min and GEE appeared as a shouldering peak with non-derivatized 
OPA at 12.6 min. (Figure 3.7).  
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Figure 3.7. Sample chromatogram showing the separation of GSH from GEE at pH 5.8. 
GEE appearing as tail peak with OPA (Red arrow). 
 
This experiment indicated that the acidity or the pH of the mobile phase was an 
important factor that could possible effect OPA derivatization and GEE separation. As a 
result, buffers with pH 5.8 were discarded. As a solution to this problem, low pH (<5.0) 
and very high pH (> 8.0) were avoided as the pH could possibly cause cleavage of OPA 
and also break down of C18 chains in the stationary phase and damage the stationary 
phase support (Walshe et al., 1995). Studies undertaken by changing the pH of buffers 
beginning from pH 5.0 to pH 5.8 did not produced any conclusive results in terms of 
separating GSH from GEE.  
Time (min) 
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Cereser et al., (2001) used a pH of 6.20 with acetonitrile as the organic modifier for the 
analysis of GSH. Therefore, method development was continued using pH 6.20. 
However, the separation between GSH and GEE was still not achieved even with pH 
6.20. Therefore, further analysis was continued addressing the role of the organic 
modifier with regard to GSH and GEE separation. 
 
3.3.4. Separation of GSH and GEE using a gradient system  
 
Two buffers were made (Buffer A and Buffer B) of sodium acetate 3- hydrate (50 mM) 
with pH 6.2. A number of gradient systems with various percentages of acetonitrile 
(v/v) were tested aiming to separate GSH and GEE. The effect of each of the gradients 
along with comments are discussed below;  
 
Gradient table 1- Buffer A contained acetate buffer with 5 % acetonitrile (950:50), 
while Buffer B contained acetate buffer with 10 % acetonitrile (900: 100) (Figure 3.8).  
 
Time 
(min) 
% Buffer A 
5%  
acetonitrile 
% Buffer B 
10% acetonitrile
RT* of GSH 
(min) 
RT* of GEE 
(min) 
0 100 0 8  17 
20 80 20 
25 0 100 
30 0 100 
32 100 0 
40 100 0 
 
*RT- Retention time  
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Figure 3.8. Sample chromatogram for gradient 1.  
 
Although, GSH and GEE were separated with gradient 1, the time difference between 
GSH and GEE appeared to be vey long and there were unwanted tailing as GEE eluted. 
Further, the run time (40 min) was too long for to be consider for routine analysis. To 
seek a solution, the volume of acetonitrile in both the buffer A and buffer B was 
increased and gradient 2 was programmed as shown below. 
Gradient table 2 
Time 
(min) 
% Buffer A 
10% acetonitrile 
% Buffer B 
50% 
acetonitrile 
RT of GSH 
(min) 
RT of GEE 
(min) 
0 100 0  
8 
 
13 
12 80 50 
20 0 100 
30 0 100 
33 100 0 
40 100 0 
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Time (min) 
GSH GEE 
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Increasing the % acetonitrile in both the buffers resulted in the separation of GSH and 
GEE and the time difference between the GSH (8 min) and GEE (13 min) was 
considerably smaller (Figure 3.9). However, the runtime still considered long.  
 
 
 
Figure 3.9. Sample chromatogram for gradient 2.  
 
 
Gradient table 3 
Further amendments were made in the % acetonitrile used. Buffer A containing 50 mM 
sodium acetate, pH 6.2 with 10% acetonitrile and Buffer B containing 50 mM sodium 
acetate, pH 6.2 with 80% acetonitrile.   
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Time 
(min) 
% Buffer A 
10% acetonitrile 
% Buffer B 
80% acetonitrile
RT of GSH 
(min) 
RT of GEE 
(min) 
0 90 10 4.2 min 11.8 min 
10 80 20 
15 50 50 
16 0 100 
20 0 100 
21 100 0 
29 100 0 
 
Gradient system 3 gave the best results with shorter run time and good separation of 
GSH and GEE (Figure 3.10). Hence, this gradient was used for the estimation of blood 
tGSH and GSSG.  
 
 
Figure 3.10. Sample chromatogram run with gradient 3. GSH peak from blood at 4.2 
min and GEE at 11.8 min.  
 
With the suitable gradient in place, standard calibration lines were constructed over a 
range of concentrations of GSH (10 mM -1 mM) (Figure 3.11). 
GSH 
GEE 
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Figure 3.11. Representative calibration line showing linear range for GSH (10 mM- 1 
mM).  
 
3.3.5. Practical problems with o-phthaldialdehyde reagent  
 
The commercially available OPA reagent showed signs of decomposition in the form of 
peaks co-eluting with GEE. It was suggested that it could be due to inappropriate 
storage conditions and manufacturers recommended, that OPA reagent needed to be 
flushed with nitrogen gas before and after usage. In order to overcome this problem, 
OPA powder was used. A 5 mg/mL OPA solution was made fresh for every time using 
0.4 M potassium borate buffer (pH 9.90).  
3.3.6. Analysis of oxidized glutathione (GSSG) 
 
3.3.6.1. Choice of reducing agent 
 
Under normal physiological conditions, the concentration of GSSG in blood is found in 
micro molar (μM) levels. In order to measure μM levels of GSSG, a calibration line for 
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GSSG was constructed from a 1 mM solution of GSSG prepared in 0.01M HCl. GSSG 
does not react with OPA due to the presence of a disulfide bond. Hence, a reducing 
reagent was needed that would chemically reduce the disulphide bond and free the thiol 
groups making them available for OPA derivatization. This reduction was performed 
using 1, 4 dithiothreitol (DTT). Choosing an appropriate DTT concentration was critical 
for assay performances as incomplete reduction can result in inaccurate data. DTT was 
preferred as it was the choice of most reports (Paroni et al., 1995, Cereser et al., 2001). 
It possesses two thiol groups and two hydroxyl groups (Figure 3.12).  
 
Thiols can be kept in reduced state in presence of having excess of another thiol as 
thiols readily exchange with disulphides (Cleland, 1963). The thiol groups in DTT have 
a pKa value of 9.2 and 10.1 respectively (Singh et al., 1995). Furthermore, DTT can 
reduce disulphides rapidly (Cleland, 1963). At certain concentrations above 1 mM, DTT 
can prevent oxidation of thiols (Kachur et al., 1997, Netto, 1996). With GSH being 
highly prone to oxidation, a reducing agent like DTT was ideal for reduction reaction. 
Also, DTT has low redox potential (-0.33 volts at pH 7), it has the capability of 
maintaining monothiols like GSH in completely reduced state and quantitatively reduce 
disulphides (Cleland, 1963). Hence, DTT was considered very suitable for the reduction 
reaction.   
 
Figure 3.12. Chemical structure of DTT. 
 
3.3.6.2. Choosing appropriate concentration for DTT reaction   
 
In order to identify the optimum concentration of DTT required for reducing the 
disulphide in GSSG, a dose response curve for DTT with GSSG was performed. A 0.5 
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mM GSSG solution was made in 0.01M HCl. Various concentrations of DTT were then 
added (50 mM-10 mM stock solutions). DTT at different concentrations without any 
standards were run in parallel in order to assess the extent of interference with the assay, 
as DTT also possess –SH group (See appendix Table 3.2).  
On analysing results, fluorescence increased up to a concentration of ≥ 25 mM (15 mM 
working solution) before reaching a plateau at or after a stock concentration of ≥ 30 
mM. Furthermore, at higher DTT concentrations, the -SH group in DTT slowly 
interfered with the assay components and with GSH-OPA adduct formation. 
Interferences in the form of unidentified peaks along with peak tailing were also 
observed. Hence, 15 mM of DTT was chosen for routine analysis (Figure 3.13).  
 
 
Figure 3.13. Dose dependent study with DTT to select an appropriate concentration for 
the reduction of GSSG. 
 
Thus, a calibration line for GSSG with 25 mM DTT was constructed at the range of 1 
mM -10 µM (Figure 3.14) (See appendix Table 3.3).  
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Figure 3.14. Calibration line showing linear range for GSSG in the presence and 
absence of DTT (25 mM).    
 
3.3.7. Calibration line for total glutathione 
 
As the present method was an approach to determine tGSH and GSSG in whole blood, a 
calibration line for tGSH was considered. Total glutathione (tGSH) is a mixture of GSH 
and GSSG with concentration of GSH being greater than GSSG. Determination of 
tGSH requires DTT reduction of GSSG present in the biological sample. Hence, a 
calibration line for tGSH was constructed.  
 
A range of different concentrations of standard GSH and GSSG (5 mM - 1 mM) were 
prepared. Equal volumes of GSH and GSSG were thoroughly mixed, reduced with of 25 
mM DTT and derivatized. This mixture of equal volumes of standards was done to 
mimic the condition in the blood. A sample blank was run with only DTT and without 
standard mixture (Figure 3.15) (See appendix Table 3.4).  
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Figure 3.15. Calibration line for tGSH in the presence and absence of DTT.  
 
3.3.8. Choosing a suitable M2VP and NEM concentration for scavenging  
 
In order to achieve a complete scavenging of the thiol moiety, it was critical to choose 
an appropriate concentration of the scavengers to achieve accurate measurement of 
GSSG in the biological samples. To achieve complete scavenging of thiol moieties, a 
series of concentrations of M2VP and NEM were made (1 mM-15 mM). These were 
later, mixed with a series increasing concentrations of GSH (1 mM-10 mM).  
A low concentration of M2VP or NEM mixed with a high concentration of GSH allows 
determination of the un-quenched GSH. As the concentration of the scavengers was 
increased proportionally from 1 mM to 15 mM, GSH, was detected which shows the 
scavenging capabilities of M2VP or NEM.  
On analysing the results, a concentration from 5 mM to 15 mM M2VP stock solution 
was effective in scavenging GSH. Furthermore, increasing concentration of M2VP did 
not show interferences with other assay components (Figure 3.19) (See appendix Table 
3.5).  
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On the other hand, NEM showed slightly different responses when compared to M2VP. 
NEM had similar responses as M2VP at low concentration. However, interferences 
proportionally increased as the concentration of NEM was increased during repeats in 
two individual occasions. At very high concentration of NEM (15 mM), board 
unresolved peaks appeared at the same retention time as GSH with several other 
disturbances in the chromatogram (Data not shown). 
 
Effect of different concentrations of M2VP on GSH
0
20
40
60
80
100
-1 1 3 5 7 9 11 13 15
M2VP (mM)
G
S
H
 (m
M
)
0 mM GSH
1 mM GSH
3 mM GSH
5 mM GSH
8 mM GSH
10 mM GSH
 
 
Figure 3.16. Effect of various concentrations of M2VP on GSH.  
 
3.3.9. A comparative study of two scavengers 
 
The present study was aimed determine tGSSG using a novel mercaptan scavenger 
M2VP. Trapping the thiol moiety of GSH, is considered necessary to measure GSSG. 
NEM is another trapping agent used for thiol moiety. Hence, M2VP and NEM were 
studied in comparison.  
In order to test the efficiency of the scavengers, an analysis was performed with whole 
blood to compare the scavenging capabilities of M2VP and NEM. A 3 mM solution of 
M2VP and NEM were made in water separately. A 100 µL blood sample was collected 
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in vials containing the scavenger, left for 1 min to for the trapping the –SH groups, 
followed by protein precipitation and centrifugation. A 100 µL acidic supernatant was 
mixed with water (to compensate for missing components such as DTT, TRIS) and then 
taken for derivatization with OPA followed by neutralization with phosphate buffer. 
The following figure shows the scavenging effect of M2VP and NEM on trapping blood 
GSH (Figure 3.17).  
 
 
Figure 3.17. Scavenging effect of M2VP and NEM on blood GSH.  
 
Figure 3.17 showed that the scavenging capabilities of M2VP and NEM were different. 
An assay was designed to compare scavenging capabilities of the two scavengers in 
standard solutions.  
A range of different concentrations of standard GSH and GSSG (500 μM - 10 μM) were 
prepared. Equal volumes of GSH and GSSG were mixed, reduced and derivatized in the 
absence of any scavenger to measure tGSH.  
A range of different concentrations of GSSG (500-10 μM) was made and mixed with 
M2VP and NEM separately, reduced with DTT and derivatized to measure GSSG (this 
assay was done with and without DTT). Finally, a single concentration GSSG (250 μM) 
was analysed in the absence of any scavenger. 
A
re
a 
Time (min) 
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Theoretically, this assay should produce five lines when in graph: 
1. tGSH, 2. GSSG in the absence of any scavenger and in the absence/presence of DTT, 
3. tGSSG in the presence of M2VP, 4. GSSG in the presence of NEM and 5. A blank 
(without DTT)  
 
1. Line for tGSH with DTT without any scavenger 
Solutions of various concentrations GSH and GSSG with were assayed for tGSH after 
reduction with DTT. In this assay, there is complete reduction of GSSG to GSH 
followed by determination of GSH equivalents to form tGSH. Thus, the peak area 
obtained for tGSH corresponds to whole blood tGSH.  
 
2. Line for GSSG in the absence of scavenger, with and without DTT 
A solution of GSSG (250 µM) was assayed for GSSG with and without DTT and in the 
absence of any scavenger. Theoretically, result obtained, should roughly be half the 
concentration of tGSH in the absence of any scavenger. The line without DTT is the 
sample blank. 
 
3. Line for GSSG after scavenging with M2VP, reduction with DTT 
Standard solutions of GSH and GSSG at various concentrations were made (500-10 
µM) and mixed in equal proportions (the actual concentration is half of the original 
concentration). M2VP solution (15 mM) was made and mixed with standard mixture, 
reduced and derivatized. They were then assayed for GSSG. Theoretically, M2VP 
should scavenge GSH in the mixture resulting in the determination of GSSG.  
4. Line for GSSG after scavenging with NEM, reduction with DTT 
Standard solutions of GSH and GSSG at various concentrations were made (500-10 
µM) and mixed in equal proportions (the actual concentration is half of the original 
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concentration). NEM solution (15 mM) was made and mixed with standard mixture, 
reduced and derivatized. They were then assayed for GSSG. Theoretically, NEM should 
scavenge GSH in the mixture resulting in the determination of GSSG.  
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Figure 3.18. Comparison of scavenging capabilities of M2VP and NEM. 
 
It was noted from Figure 3.18, that in an equimolar mixture of GSH and GSSG, assayed 
for GSSG in the presence of M2VP and NEM, M2VP rapidly scavenges the thiol group 
of GSH without much interfering with the assay derivatives (red line). This resulted in 
the estimation of GSSG. The amount of GSSG estimated this way was similar to the 
GSSG obtained without adding M2VP (green line). Therefore, M2VP allowed the 
estimation of GSSG and showed complete scavenging of GSH. In addition, M2VP has 
not shown any interference with OPA or DTT during reduction nor has obscured the 
estimation of GSSG. 
NEM, although a potent thiol group scavenger, showed some interference in the form of 
unwanted peaks. NEM binds the –SH group in GSH, slows the scavenging process 
thereby yielding lower quantities of GSSG (blue line) when compared to GSSG 
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obtained without any addition of scavenger (green line). The closer the blue line is with 
green line, more efficient the scavenger is. The line tGSH (pink line) shows 100% 
reduction and a measurement of tGSH.  
 
The line, over lapping/ parallel to the X axis corresponds to GSSG obtained in the 
absence of any DTT. This is a reference line to show that disulphides cannot be 
detected in the absence of a reducing agent. As mentioned elsewhere, without DTT 
reduction, the disulphides are not reduced and there is no derivatization of the 
disulphide with OPA (Figure 3.18) (See appendix Table 3.6). 
 
3.3.10. Comparison of the scavenging capacities of M2VP and NEM 
 
This assay shows scavenging capabilities of the two scavengers with an increasing 
concentration of GSH. A 1 mM GSSG standard solution was made. 15 mM M2VP and 
15 mM NEM solutions were made separately and mixed with a series of increasing 
amounts of GSH standard solutions (5- 2000 µM) separately. This reaction mixture was 
then assayed for GSSG following reduction and derivatization (See appendix Table 
3.7).  
Theoretically, the recovery of GSSG must be constant and quantitative, indicating 
complete quenching of GSH. On comparing the data of the recovered GSSG, it was 
observed that NEM showed a gradual increase in the amount of GSSG detected as the 
concentration of GSH was gradually increased. This possibly shows an incomplete 
scavenging of GSH in presence of NEM. Furthermore, it was also noted that NEM 
interfered with the assay as its concentration was increased. On the other hand, M2VP 
showed a steady scavenging of GSH (Figure 3.19). This illustrates that the recovery of 
GSSG with M2VP scavenging is more consistent when compared with NEM 
scavenging.  
 101
Scavenging ability of M2VP and NEM
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
0 200 400 600 800 1000 1200 1400 1600 1800 2000
GSSG (μM)
A
na
ly
te
 a
re
a/
 IS
GSH:M2VP
GSH:NEM
 
Figure 3.19. Scavenging ability of M2VP and NEM. 
 
3.3.11. Stability of metaphosphoric acid extracts  
 
Blood proteins were precipitated using MPA as reported (Stempak et al., 2001). A 6% 
MPA solution was used to acidify the samples. Proteins were precipitated after 
centrifugation. The MPA extracts stored at stored at 4ºC, -20ºC and at -80 ºC, were 
periodically removed and derivatized with OPA to determine blood GSH for 7 days. 
The GSH concentration in the acidic supernatant was assessed and considered as 100% 
just before storage. Results showed that the GSH acidic supernatants were more stable 
at -80ºC and -20ºC than at 4 ºC for 1week (Figure 3.20).  
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Figure 3.20. Stability of MPA extracts at -80 ºC, -20 ºC and 4 ºC.  
 
3.3.12. Stability of glutathione-o-phthalaldehyde adducts at room temperature, 4ºC 
and at -20 ºC 
 
It was also noted that GEE (internal standard) hydrolysed under inappropriate storage 
conditions (to be stored at -20ºC with para film). The hydrolysed by-product eluted at 
the same time as GSH. Hence, it became mandatory to make GEE solution fresh on the 
day of analysis.  
 
In addition, appropriate stability studies for GSH-OPA adducts were conducted to 
assess this stability. A standard solution of GSH was prepared immediately before 
analysis and this was taken as time 0 and day 1. A 5ml aliquot of the standard solution 
was transferred to pre-labelled eppendroff tubes and then stored under the following 
conditions: RT, 4oC and - 20oC. Analysis was repeated at intervals of day 1 to day 10. 
An analysis after 24 hrs revealed derivatized standards stored at room temperature 
showed significant signs of degradation and were discarded. However, derivatized 
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standards maintained at 4ºC and - 20oC showed slow degradation as time passed (Figure 
3.22). Therefore, derivatization was performed only at the time of analysis.  
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Figure 3.21. Stability of GSH-OPA adducts at -20 ºC and 4 ºC. 
 
3.4. Validation for the analysis of tGSH and GSSG 
 
The assay was validated to determine the linear range, limit of detection (LoD), limit of 
quantitation (LoQ) and the co-efficient of variation. In developing a bio-analytical 
method, it is important to make sure that the method is specific for the objective 
considering the interfering substances in whole blood. Further, with the use of OPA it 
became imperative to select a suitable volume or concentration of components for the 
intended analysis. The specificity of the assay was assessed by carrying out the analysis 
and thoroughly looking for any interfering substances. The retention time of any 
unwanted peak were compared with standards (GSH and GSSG).  
Linearity  
The linearity in this validation study involved the analysis of six calibration points 
prepared for tGSH and GSSG that covered the entire range of expected concentrations 
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including the limit of quantitation. Most importantly, sample blanks were also analysed 
along with calibration points. The assay illustrated excellent linearity from 10 mM to 1 
mM for tGSH (Figure 3.20a) and 1mM -10 µM for GSSG assay (Figure 3. 20b) with 
correlation co-efficient of 0.9953 and 0.991 respectively. The response was directly 
proportional to the analyte concentration as shown in the Figures 3.20a and 3.20b. 
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Figure 3.22a. Sample calibration line showing the linear range for tGSH from 1 mM to 
10 mM. 
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Figure 3.22b. Sample calibration line showing the linear range for GSSG from 10 µM 
to 1 mM. 
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Limit of detection and quantitation 
 
The limit of detection (LoD) and limit of quantitation (LoQ) were established through 
the signal-to-noise (S/N) ratio. Serial dilutions of the GSH solution were prepared, 
derivatized and analysed. The smallest observable peak area of the GSH-OPA 
derivative was identified. The limit of detection (LoD) was calculated using a signal to 
noise (S/N) ratio of 3. The limit of quantitation (LoQ) was considered as the lowest 
concentration of an analyte measured and is determined by using an S/N ratio of 10. 
The limit of detection and quantitation was established at 1µg and 5µg respectively for 
tGSH while that for GSSG was established at 5 ng and 10 ng.   
 
Reproducibility 
The co-efficient of variation (CV%) or relative standard deviation was determined using 
the 500 µM/mL standard GSH. This mid-range standard was injected a total of five 
times in succession and the co-efficient of variation was calculated by dividing the 
standard deviation of the five replicates by the overall mean area and converting the 
value to a percentage. This was measured both intra-assay and inter-assay. The CV/ 
mean RSD were calculated to be less than 5%. 
 
Precision  
The precision was expressed as intra-day co-efficient of variation and inter-day co-
efficient of variation. To assess the precision of this assay method, within day (n=10) 
and between day (n=10) calibration curves with various concentrations of the GSH 
equivalents were calculated. The precision was expressed as within day and between 
days of variation and was expressed as RSD (%). The % RSD for within day precision 
was ±3.51% and ±2.42% for between day precision. 
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No particular experiments were conducted to assess robustness. However, during the 
course of validation experiments unidentified variations in the mobile phase were 
introduced. These variations did not have any conclusive experimental results.  
 
3.5. Application of the assay using whole blood samples 
 
Blood samples were analysed in duplicates. Calibration points for tGSH and GSSG 
were run in the beginning, in between and at the end of sample runs to assess the 
performance of the assay and the instrument on the day of analysis. The following flow 
chart provides detailed information of the assay (Figure 3.21). The results are 
summarized in Table 3.1. The averages of tGSH and GSSG levels in whole blood from 
10 healthy volunteers were as follows: the mean total glutathione was 2.79±0.9 (mM/L); 
the mean values for total oxidized glutathione resulting from the scavenging effect of 
M2VP and NEM were 0.9±0.1 (mM/L) and 3.16±1.88 (mM/L) respectively.  
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Figure 3.23. A flow chart showing the experimental procedure for GSSG and tGSH in 
blood sample determination. 
 
 
 
 
 
 
 
 
 
 
SAMPLE 
GSSG Analysis tGSH Analysis 
10 µL M2VP+100 µL whole blood. Leave 
on ice for 1 min for scavenging GSH 
100µL whole blood + 10 
µL HCl on ice 
50 µL of 100 µM GEE and 100 µL 25 mM DTT +50µL TRIS. Incubate at 4ºC 
for 30 min. Add 400 µL of 6% MPA. Leave on ice for 10-15 min for protein 
precipitation. Centrifuge at 10,000 rpm for 10 min. 
100 µL acidic supernatant taken for derivatization 
100 µL of the sample (acidic supernatant) with 100 µL fresh OPA, mix, leave for 1 
min, add 800 µL of sodium di hydrogen phosphate to neutralize.   
Analyse by RP-HPLC.  
Results GSSG. 
Analyse by RP-HPLC.  
Results tGSH. 
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Table 3.1. Whole blood GSSG and tGSH levels in healthy human subjects (results 
expressed as mmol/L) 
 
Subject 
(n=10) 
tGSH GSSG 
(M2VP) 
GSSG 
(NEM) 
[GSH] a
(tGSH- 
GSSG) 
[GSH] b 
(tGSH- 
GSSG) 
Ratio 
GSH:GSSG a 
Ratio 
GSH:GSSG b
1 2.83 0.93 2.26 1.9 0.57 2.04 0.25 
2 4.75 0.97 2.24 3.78 2.51 3.90 1.12 
3 3.48 1.2 2.15 2.28 1.33 1.90 0.62 
4 3.21 1 2.61 2.21 0.6 2.21 0.23 
5 3.14 0.73 2.23 2.41 0.91 3.30 0.41 
6 1.88 0.79 5.79 1.09 3.91 1.38 0.68 
7 3.79 0.66 2.45 3.13 1.34 4.72 0.55 
8 2.63 0.81 2.14 1.82 0.49 2.25 0.23 
9 2.19 0.82 2.49 1.37 0.3 1.67 0.12 
10 1.35 1.08 2.53 0.75 0.7 0.69 0.28 
Mean±SD 2.79±0.9 0.90±0.1 3.16±1.88 2.07±0.91 0.28±1.72 2.41±1.22 0.23±0.50 
 
a- Ratio obtained after M2VP scavenging 
b- Ratio obtained after NEM scavenging 
 
3.6. Discussion 
 
The present work focussed on developing a method to determine tGSH and GSSG in 
whole blood, subtracted the two to get the concentration of GSH, and calculated the 
ratio GSH/GSSG. A gradient system was used to separate GSH and GEE. As changes in 
the pH of the buffers produced no practical results in terms of separating GSH from 
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GEE, the concentration and the compositions of the buffers were changed. In order to 
achieve an acceptable degree of separation of all the components of interest, a highly 
polar buffer with 50 mM sodium acetate buffer was used with pH 6.20.  
 
Although, the pKa of amine group in GSH was 9.2, was counter-balanced by bringing 
down the pH with the use of acetic acid. The acetate ions in sodium acetate buffer acts 
as a counter ion for R-NH3+, avoiding any further ionisation in the column. Further, to 
favour this, GSH was prepared in 0.01M HCl to protonate the thiolate ions, thus making 
the conditions favourable for appropriate resolution.  
Acetate buffers have a pKa of 4.75 and are the best buffers at a pH close to pK. Further, 
acetate buffers are used within the pH range of 3.0 - 6.0. Low concentration of acetate 
buffers tends to give weak and drifting effect of the peaks. This also helped the column 
performance and avoids column damage. Hence, 50 mM sodium acetate was optimum 
for good peak shape. Acetonitrile was used as an organic modifier as it is relatively less 
polar and suitable for minor adjustments of chromatographic profiles. In the absence of 
any literature support to employ a suitable gradient using GEE as a internal standard 
and acetonitrile as an organic phase, various percentages (v/v) of acetonitrile were 
mixed with acetate buffer with pH 6.2 to a get a good separation of GSH from GEE.  
 
The study focussed in determining GSSG by using a mercaptan thiol scavenger- M2VP. 
The use of thiol scavengers is not a novel approach, as thiol group blockers like NEM, 2-
VP, IAA have been used previously to trap the thiol moiety in GSH (Guntherberg and 
Rost, 1966, Griffith, 1980b). Although NEM, a reactive thiol alkylating agent, can 
effectively react with free thiol group (Camera et al., 2001, Piccoli et al., 1994), the 
reaction rate is quiet slow (Shaik and Mehvar, 2006) allowing GSH oxidization in the 
biological samples and resulting in overestimation of GSSG. Owing to the fact that redox 
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changes can potentially happen during sample collection, precautions were taken to 
minimise auto-oxidation of GSH. Samples were collected in EDTA coated vials as 
EDTA, apart from serving as an anticoagulant, serves as a heavy metal complex that can 
possibly catalyse oxidation of GSH (Rabenstein and Saetre, 1978).  
 
M2VP and NEM share the same principle of scavenging the thiol moiety (-SH) in GSH. 
However, no previous HPLC assay for the determination of GSSG using M2VP as a 
scavenger has been reported. Analyses for tGSH and GSSG in whole blood were 
performed using a HPLC pre-column derivatization with OPA. OPA was an attractive 
choice due its mild reactive conditions with both sulfhydryl and primary amino group 
with less derivatization time. Further, HPLC separation of the derivatized compound 
enhanced with improved hydrophobicity with a fluorescence compound, is performed in 
most cases in reverse phase mode (Camera and Picardo, 2002).  
 
Accurate measurement of GSSG has always been complicated as the amount of GSSG in 
whole blood is low under normal physiological conditions. The determination of GSSG is 
directly dependent upon the efficiency of the scavenger used. In order to demonstrate the 
scavenging capabilities of M2VP over NEM, a standard mixture solutions (500-10 μM) 
were assayed for tGSH and GSSG (with and without scavengers). It was found, that 
M2VP scavenging was more efficient and quicker than NEM scavenging. The 
superimposition of GSSG obtained as a result of M2VP scavenging with GSSG obtained 
without any scavenger suggests that there was no possible oxidation of GSH in blood 
during the experimental procedure.  
NEM, although a potent thiol group blocker is non-specific with thiols (Asensi et al., 
1994, Rossi et al., 2002, Giustarini et al., 2003). No doubt, NEM binds the –SH group in 
GSH but also has a potential to slowly bind to the amino group in the glutamyl moiety in 
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GSH, thus making the scavenging process slow. There are also possibilities that NEM 
can bind with the amine groups, which in turn can contribute to the loss of NEM making 
it less available for scavenging thiol group. Thus, NEM directed GSSG estimation from 
the standard mixture (500-10 μM) seems to be low when compared to GSSG estimated 
without any scavenger.  
DTT was used as a reducing agent. DTT reduces the disulphide, followed by OPA 
derivatization. DTT, can react with OPA and interfere with GSH-OPA adduct formation 
(Cereser et al., 2001). Thus, selecting a suitable DTT concentration is a compromise 
between the DTT concentration and effective disulphide reduction. The experiment 
conducted in the present study gives way to select a suitable DTT concentration that can 
completely reduce GSSG without interfering with side reactions with OPA or forming 
unidentified peaks. At 25 mM DTT concentration the disulphide reaction is complete 
thus facilitating disulphide reduction.  
 
Quantitation of GSH has always been subject to studies, aiming to prevent its auto-
oxidation. In order to prevent thiol-disulphide exchange reactions and improve the thiol 
scavenging, it is very crucial to choose an appropriate concentration of scavenger. There 
are studies done using various concentrations of NEM (Giustarini et al., 2003, Kand'ar et 
al., 2007).  
M2VP is used in a commercially available scavenger in a assay kit and although easy to 
use are expensive and are not good value for money for routine analysis of large number 
of samples. To choose an appropriate M2VP concentration, a series of GSH 
concentrations were allowed to quench with varying M2VP concentrations. A final 
concentration of 3 mM completely quenched GSH. The present study also includes 
evidence that concentration from 3 mM to 15 mM M2VP did not seem to interfere with 
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GSH/GSSG assay. However, it has been reported that a concentration above 50 mM may 
show some interference (Fu and Murray, 2001).  
 
Results from the present study have shown interference of NEM as the concentration was 
increased. Furthermore, trapping the thiol group with NEM although prevents oxidation, 
it has been reported that this trapping makes the GSH unavailable for derivatization 
process (Cereser et al., 2001, Cohn and Lyle, 1966). No doubt NEM is considered a 
better scavenger among other thiol blocking agents such as 2-VP and IAA, however, 
NEM directed scavenging in the present study has shown higher GSSG (3.16±1.88) 
levels in whole blood when compared to the literature (Gough, 1990). 
 
In conclusion, we have developed a simple, rapid and sensitive method for tGSH and 
GSSG determination in whole blood using M2VP as scavenger for GSH. Sample 
collection plays an important role in the determination, as oxidation of GSH can be very 
rapid. Collecting samples in tubes held on ice does not prevent oxidation of GSH. Thiol 
trapping agent like M2VP prevents further oxidation. An ideal thiol trapping agent should 
scavenge almost all the thiol and aid in GSSG determination. Therefore, the present 
method could be used for clinical analysis. Data obtained from the this assay was 
compared with various reported studies (Camera et al., 2001, Cereser et al., 2001, Paroni 
et al., 1995, Pastore et al., 2001, Sakhi et al., 2006) and were found to be comparable. 
The method could be used for the determination of tGSH and GSSG to assess redox 
imbalance in under normal and diseased conditions.  
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CHAPTER 4. Sulfur amino acids in acute pancreatitis 
4.1. Introduction  
 
The sulfur containing amino acids - Cys, Hcy, Cys-Gly and GSH have been implicated in 
various functions in the body including redox homeostasis via transsulfuration. Briefly, 
transsulfuration reactions (Refer to Figure 1.3) result in the transfer of an Hcy–SH group 
to a serine residue to form cystathionine, following an irreversible reaction to form Cys. 
Therefore, Cys can be synthesized from Met and serine. Hence, Cys is not an essential 
amino acid, but is conditionally essential due to limited production rate of Met and serine 
under certain circumstances (Laidlaw and Kopple, 1987), when Cys requirement is 
increased. It is reported that cells such as rat hepatocytes favour Cys directed GSH 
synthesis rather than its precursor Met (Stipanuk et al., 1992).  
 
Under normal physiological conditions, Cys regulates the main step of GSH 
biosynthesis and is considered to be the limiting amino acid for GSH synthesis (Meister 
and Anderson, 1986). Under certain conditions like in oxidative stress, Cys biosynthesis 
is altered and hence may affect the synthesis of important downstream metabolites (Yu 
et al., 1993, Finkelstein, 1990, Malmezat et al., 2000). Several hypotheses have 
supported altered amino thiol metabolism in human pathology (Boushey et al., 1995, 
Kang et al., 1992, Ueland, 1995). The association between amino thiol concentration 
and oxidative stress in AP has received much attention (Yuzbasioglu et al., 2008). It is 
stated that despite an increased Cys flux it appears that this does not compensate for the 
enhanced GSH turnover (Finkelstein, 1990, Vina et al., 1992, Malmezat et al., 2000). 
Hence, it appears that the GSH biosynthetic pathway may be defective at a number of 
levels during the course and severity of inflammatory insult. It is reported that severe 
GSH depletion is a consistent feature of AP and this is also associated with progression 
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to severe attacks (Rahman et al., 2004). Therefore, to further investigate GSH 
biosynthesis during AP, the temporal relationship between the plasma amino thiols Cys, 
Hcy and Cys-Gly, total reduced erythrocyte GSH concentrations were evaluated and 
related with the severity of attack. The plasma from these patients was collected soon 
after the onset of abdominal pain (Day 1 or 24 hrs) upon admission to the hospital. 
Subsequently, the plasma samples were also collected consecutively on day 3 (72 hrs). 
Not all diseases in a clinical setting present all the clinical elements and / or symptoms 
at once. Some disease states (including AP) evolve over time. The time points 24 and 72 
hours in the present study were chosen according to clinicians recommendations.  
 
Research into plasma amino thiols has been receiving growing interest ever since their 
importance in cell chemistry has been interpreted and altered metabolism implicated in 
human pathology. Assaying the total amino thiols or individual amino acids is 
increasingly becoming a clinical practice in laboratory medicine (Andersson et al., 1993, 
Bald and Glowacki, 2005, Deyl et al., 1986, Walker and Mills, 1995). Amino thiol levels 
in the plasma and/ or in the urine reflect the metabolic and/ or the nutritional status of 
total or individual amino acids.  
Hence, quantification of individual amino acids is important in monitoring the therapeutic 
intervention by way of dietary manipulations and/ or vitamin supplement therapy. A 
comprehensive profile of sulfur amino acids is of immense significance in clinical and 
diagnostic laboratories. The importance of –SH group containing amino acids and their 
relation in various disorders/ pathologies, has led to a spurt of interest in the development 
of analytical methods. Immuno, (Frantzen et al., 1998), enzymatic assays (Refsum et al., 
1989), electrochemical (Robenstein and Yamaahita, 1989) have limited use to detect a 
given amino acid or any –SH group containing amino acid. RP-HPLC is a frequently 
used analytical technique for the determination of amino thiols with fluorescent detection 
after its reduction with trialkylphosphines followed by derivatization with 7-flurobenzo-
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2-oxa-1,3-diazole-4-sulfonate (SBD-f) (Krijt et al., 2001). Trialkylphosphines are 
powerful reducing agents. They stoicmetrically and irreversibly reduce disulfides in an 
aqueous solution;  
 
 
The phosphine nucleophilic attack on the disulfide bond determines the rate of the 
reaction (Burns et al., 1991).  
For brevity, experimental design involved, treatment of the plasma sample from the 
patients prior to application on the analytical column included a reduction reaction with 
TBP, protein precipitation with TCA followed by derivatization with SBD-f and 
incubation. A modified version of reverse phase-HPLC–fluorescence assay (Fortin and 
Genest, 1995, Vester and Rasmussen, 1991) was employed to profile Cys, Hcy, Cys-
Gly and GSH in these patients.  
In an attempt to explore the effects of sulfur amino acid deficit in these patients, the 
sulfur amino acid levels were correlated with the results obtained for plasma C-reactive 
protein (CRP) acute physiology score (APS) and γ-GT. CRP is an acute phase protein 
and a marker of inflammation that is synthesised by hepatocytes. Serum levels of CRP 
have been known to rise within 24 hours of onset of AP and reach peak levels at about 
72-hours (Yadav and Agarwal, 2002). APS is a subcomponent of APACHE-II scoring 
system (See section 2.3.1.1 for details). The clinicians determine APS at 48 hrs from the 
onset of abdominal pain in order to estimate the magnitude of the systemic 
inflammatory response (Larvin and McMahon, 1989). γ-GT is present in the cell 
membranes of many tissues including the kidneys, bile duct, pancreas, liver, spleen, 
heart, brain, and seminal vesicles (Goldberg, 1980). The enzyme is involved in the 
transfer of amino acids across the cellular membrane (Meister, 1974). Abnormal activity 
of the enzyme appears to be specific for liver, biliary tract and pancreatic diseases .  
R’3P + RSSR + H2O    R’ 3P=O + 2RSH 
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Therefore, the aim of this study was to experimentally address the temporal relationship 
between plasma amino thiols in these patients and correlate with the physiological and 
biochemical parameters such as APS, CRP and γ-GT levels. 
4.2 Materials and methods  
 
The materials for this study are fully listed in section 2.1.1. The equipment conditions 
are described in section 2.2.2. The sampling procedure has been described in method 
section 2.3.1 and methodology in 2.5.  
4.3. Results  
4.3.1. Sulfur amino acid assay 
Sulfur amino acids in the plasma from the patients were derivatized with SBD-f. 
Separation of the four sulfur amino acids and the internal standard were achieved using 
a gradient method (See section 2.5.3.7 for details). Injecting single standards of each 
amino acid and comparing the retention time confirmed the sulfur amino acid identities.  
Cys eluted at 4.6 min, Hcy at 5.8 min, Cys-Gly at 6.6 min, GSH at 8.3 min and the 
internal standard (MPG) at 19.8 min. Quantification of sulfur amino acids was achieved 
using calibration lines of known concentrations (120-3.75 μM). Further, at least three 
different concentrations of the calibration line were derivatized and run on each day of 
plasma sample analysis. The concentration of sulfur amino acids from the patients were 
directly read from the chosen three-point calibration line of the day. The peak-area ratio 
of every amino acid to the internal standard (MPG) were calculated and plotted against 
the concentration of the calibration standards (120-3.75 μM) (Figure 4.1). All results 
are expressed as μM /mL. Typical chromatograms of a combined standard of S-amino 
acid (7.5 μM) along with a plasma control sample are shown in Figures 4.2a and 4.2b.   
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Figure 4.1. Calibration lines for Cys, Hcy, Cys-Gly and GSH.  
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Figure 4.2a. A typical chromatogram of the HPLC analysis of S-amino acid combined 
standard (7.5 µM).  
 
 
Figure 4.2b. A typical chromatogram of the HPLC analysis of S-amino acid from 
plasma control.  
Cysteine (Cys), Homocysteine (Hcy), Cysteinyl-Glycine (Cys-Gly), glutathione (GSH) 
and mercaptopropionyl glycine (MPG) (internal standard).  
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4.3.2. Sulfur amino acid profile in patients with acute pancreatitis 
 
In total 42 patients with AP (30 mild and 12 severe) and 12 healthy controls were 
studied. Attacks of AP were classified as “mild” and / or “severe” retrospectively in 
accordance with the Atlanta criteria of 1992 (Bradley, 1993), however within this frame 
work, a severe attack was that which was associated with organ failure, pancreatic 
necrosis, and / or sepsis. Mild disease was defined as that associated with minimal 
organ dysfunction and an uneventful recovery. 
 
Age and gender were similar in all the groups (Table 4.1) (Rahman et al., 2009). The 
Acute Physiology and Chronic Health Evaluation (APACHE-II) (Larvin and McMahon, 
1989, Yeung et al., 2006) scores at 48 hrs were found to be significantly higher in 
patients with severe attack compared to those with mild attacks (p< 0.001) (Table 4.1) 
(Rahman et al., 2009). The cause of the mild attack of AP was gallstones in 29 patients 
(69%) and ethanol in 9 patients (21.4 %) respectively (Table 4.1).  
 
In the remaining 4 patients, AP was either due to hyperlipidemia (n=1), pancreas 
divisum (n=1) or idiopathic (n=2) and these were collectively referred to as “Other” in 
Table 4.1. Amongst the patients with severe attack, 7 had persistent organ failure, 2 
with pancreatic necrosis without organ failure and 3 with both pancreatic necrosis and 
organ failures. Overall mortality in the severe group was 2 of 12 patients (18%).  
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Table 4.1. Clinical and demographic details of the study group. (AP: Acute pancreatitis:  
CRP: C-reactive protein, APACHE- Acute Physiology and Chronic Health Evaluation).  
 
*Significant difference between patients with mild and severe attacks of acute 
pancreatitis. p<0.001. Mann-Whitney U-test.  
 
 
 
 
 
 
 
 
 
 
 
Parameters Control 
N=12 
Mild AP 
N=30 
Severe AP 
N=12 
All AP 
N=42 
Alcohol - 20% 25% 21.4% 
Gall stones - 66% 75% 69% 
Other - 14% 0% 9.6% 
Median age (range) 58.5 (18-
92) 
55.5 (17-95) 65 (20-91) 57.5 (17-95) 
Male: Female ratio 1.0 0.9 1.0 0.9 
APACHE-II Score - 5 (0-10) 9 (5-26)* 6 (0-26) 
Peak (0-72 h) CRP 
(g/dL) Median 
(range) 
- 195 (3-357) 339 (132-444)* 221 (3-444) 
24h APScore - 1(0-5) 5.5(3-20)* - 
72h APScore - 0(0-4) 3.5(1-12)*  
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4.3.3. Sulfur amino acid and clinical disease severity  
In order to determine individuals with high/low levels of plasma sulfur amino acid 
metabolite concentrations, the distribution of data for the all the four plasma sulfur amino 
acids was analysed at 24 and 72 hrs respectively. The Met metabolites: Cys, Hcy, Cys-
Gly and GSH showed varied difference from 24 and 72 hrs between mild and severe 
attacks (Table 4.2)(Rahman et al., 2009).  
 
After the onset of abdominal pain, plasma Hcy was found to be significantly increased in 
patients with mild attack at 24 hrs (p=0.002) (Figure 4.3), however no significant 
difference was observed in the plasma Cys pool at 24 hrs mild attack. However, as the 
disease progressed from 24 to 72 hrs after a mild attack, plasma Hcy decreased while Cys 
levels increased (p=0.03) (Figure 4.3 and 4.4). These increased levels in Cys however, 
remained within normal range (Table 4.2). Analyses for correlation between amino thiols 
Cys and Hcy seemed positive (r=0.77, p<0.001). The ratio Hcy: Cys was elevated at 24 
hrs (p <0.001) appearing to normalise reaching control values at 72 hrs.  
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Table 4.2. Plasma Hcy, Cys, Cys-Gly and total erythrocyte glutathione (GSH) concentration, γ-glutamyl transferases (γGT) activity and 
disease severity markers (APS=acute physiology score; CRP= C-reactive protein) in patients with AP and healthy controls. Values 
represent medians and (range). # p<0.05, ## p<0.001 comparing data to control; * p<0.05, ** p<0.01 comparing 72 h to 24 h. Mann-
Whitney U-test.  
                                         Control        
                                         N=12 
 
                     Mild AP                                                  Severe AP 
                       N=30                                                         N=12 
          24 h                       72h                              24h                            72h  
 
 
Plasma HCy (µM)              10.5                     13.4#                 10.6*                              11.7                                12.9#* 
                                           (6-15)                  (3-23)                (7-21)                             (8-40)                             (7-14) 
 
Plasma Cys (µM)                164                      150.9                172*                              161.5                                174 
                                      (111-222)               (28-204)          (96-306)                         (110-241)                           (83-223) 
 
Plasma Cys-Gly (µM)        25.9                     38.1##                112.9##**                  40.8##                              154###* 
                                         (16-39)                 (18-63)               (54-162)                      (29-101)                              (110-225) 
 
Erythrocyte GSH             3685                       420##                 639##**                     423##                                372##      
(nmol/g protein)         (2460-6262)            (305-3560)             (344-978)                  (168-942)                           (168-539) 
 
Serum γGT (IU/L)           28                          239##                  238##                         338##                                186##* 
                                     (12-43)                  (40-1504)            (50-1171)                    (42-506)                               (60-314) 
 
APS Score                       0                              1##                      0.0#**                            5##                                   3## 
                                                                      (0-4)                     (0-4)                            (3-20)                                (1-11) 
 
Plasma CRP                <5.0                           118##                  152##*                        309##                                  325## 
(mg/L)                                                          (3-324)               (10-226)                       (161-416)                            (238-339) 
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Figure 4.3. Hcy levels after the onset of abdominal pain in mild and severe attacks at 24 
and 72 hrs corresponding to control * p<0.05, **p<0.001. 
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Figure 4.4. Cys levels after the onset of abdominal pain in mild and severe attacks 
corresponding to control at 24 and 72 hrs. *p<0.05.  
 
Plasma Cys and Hcy levels seemed slightly higher compared to healthy controls in the 
early stages of severe AP at 24 hrs. However, as the disease progressed to 72 hrs 
following a severe attack there seemed no further changes in Cys levels but an increase 
in Hcy levels was apparent, possibly indicating Hcy flux through the transsulfuration 
pathway. Hcy flux through transsulfuration concurs with an increase in Hcy levels from 
24 to 72 hrs as disease progressed.  
An analyses for correlations between Hcy and Cys was strong and positive at 24 hrs in 
severe attacks (r=0.86, p<0.001) although this became less significant at 72 hrs. 
Following severe attacks, the ratio Hcy: Cys was elevated above healthy control values 
at both 24 (p<0.001) and 72 hrs (p=0.049) respectively (Figure 4.5).    
Control Mild attack Severe attack 
 *
  24 hrs 72 hrs 
Pl
as
m
a 
C
ys
 (μ
M
) 
Population group 
 126
 
 
Figure 4.5. Correlation Hcy: Cys in mild and severe attacks at 24 and 72 hrs.  
 
Hcy, Cys and Cys-Gly are all metabolically inter-related (Mansoor et al., 1992). Plasma 
Cys and Cys-Gly are of interest in understanding the biological interrelationship for the 
disease progression in AP (Bates et al., 2002). In the present study, all the measured 
and calculated fractions of plasma Cys-Gly, a dipeptide metabolite of GSH.Cys-Gly, 
which re-synthesise GSH in many intracellular reactions, were elevated in both mild 
and severe AP attacks (p<0.001) and increased further as the disease progressed (Table 
4.2). Levels of Cys-Gly were significantly higher in patients with severe attacks 
compared to the mild attacks (p=0.002) (Figure 4.6). In addition, Cys-Gly and total 
glutathione levels were significantly different at 72 hrs between two attacks (p=0.03). A 
scatter plot showed an inverse relationship of the amino thiols Cys-Gly with GSH (r= - 
0.99, p=0.01) respectively (Figure 4.7). 
24 hrs 
72 hrs 
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Figure 4.6. Cys-Gly levels in mild and severe attacks at both 24 and 72 hrs compared to 
control. (**p<0.001). 
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Figure 4.7. Correlation between Cys-Gly and GSH in mild and severe attacks at 24 and 
72 hrs.  
 
4.3.4. Erythrocyte glutathione levels and disease severity  
 
Marked changes were observed in the erythrocyte glutathione concentrations in the 
patients suffering from acute pancreatitis. The median erythrocyte glutathione 
concentration in healthy controls was shown to be 3685 nmol/g of total erythrocyte 
protein (Table 4.2). 
At 24 hrs after the onset of abdominal pain, the erythrocyte GSH concentration was 
found to be significantly reduced in patients with mild (median: 420 nmol/g [Range: 
305 – 3560 nmol/g, p < 0.001], and severe attacks (median: 423 nmol/g [Range: 168 – 
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942 nmol/g, p < 0.001], compared to the control group. However, there were no 
observed differences in GSH concentration between mild and severe attack (p = N.S.). 
At 72-hrs, erythrocyte GSH concentration continued to be significantly lower in patients 
with mild (median: 639 nmol/g [Range: 344 – 978 nmol/g] and severe attacks (median: 
372 nmol/g [Range: 168 – 539 nmol/g], compared to healthy controls (p < 0.001) 
(Figure 4.9) (Table 4.2). 
At 72 hrs, erythrocyte GSH concentration was significantly higher in patients with mild 
attack compared to those who subsequently developed severe attacks (p = 0.006). The 
72 hrs GSH increased in patients with mild attacks relative to 24 hrs GSH (p = 0.012), 
but no significant change was observed among patients with a severe attack.  
 
Figure 4.8. Comparison of erythrocyte GSH concentration (nmol/ g protein) in mild and 
severe acute pancreatic attacks at 24 and 72 hrs compared to normal (** p<0.001). 
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Cys is the limiting amino acid for GSH synthesis. The ratio Cys: GSH was significantly 
higher in both mild and severe attacks (p<0.001) when compared with the healthy 
volunteers. Although levels were similar at 24 hrs in mild and severe diseases (p=0.74), 
at 72 hrs this ratio tended to decrease over the course of mild attacks (p<0.05) while it 
remained elevated after severe attacks. 
It should also be noted that, according to UK recommendations, severity stratification is 
done on all the patients on admission with AP (Anon, 2005, Anonymous, 1998). Hence, 
the plasma sulfur amino acid levels from the present study were compared with some of 
the physiological (APS) and biological (CRP) parameters, to validate the severity of the 
disease referring only to S-amino acids.   
Many potential markers for predicting the severity of acute pancreatitis act as systemic 
inflammatory markers. CRP is a well-established marker of inflammation produced in 
the liver by cytokines from the site of inflammation (Johnson et al., 2004). Values of 
150 mg/L at 48 hrs after the onset of symptoms are now accepted as a proven indicator 
of severity of pancreatitis (Yadav and Agarwal, 2002). To determine whether the 
individuals with low or high amino thiol levels also had relatively low or elevated 
levels CRP, a comparison was carried out to relate values provided, among the different 
individuals at 24 and 72 hrs. Elevated levels of CRP can possibly reflect the disease 
progression/ severity in AP. CRP acts as a part of systemic inflammatory response 
marker (Anon, 2005). Stratifying the data to disease severity, it was observed that there 
was significant changes in C-reactive protein (p=0.43) (Table 4.2). Further, an increase 
in Hcy levels, also increased the CRP significantly (p<0.05)  
The physiological scores (based on the acute physiology and APACHE II scoring 
systems), a correlation of Met metabolites was carried out at respective time points to 
stratify disease severity. The amino thiol Cys-Gly (p=0.025) correlated with APS 
(r=0.37, p=0.025) and serum CRP at 24 and 72 hrs (r= 0.59, p=0.003). However, an 
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inverse correlation was demonstrated with GSH at 72 hrs suggesting that low GSH 
levels (r= - 0.49, p=0.046) concurs with high APS and hence more physiologically the 
unwell the patient is. The erythrocyte glutathione also showed an inverse correlation 
with APACHE-II score (r= - 0.50, p=0.026) respectively.  
4.3.5. γ-Glutamyl transpeptidase 
The plausible potential cause of pancreatic GSH loss was addressed by the study of the 
enzymes of γ-glutamyl cycle, most importantly γ-glutamyl transpeptidase (γ-GT), the 
only known enzyme to initiate the breakdown of GSH. It is well established that γ-GT 
is essential for GSH precursor uptake and involved in amino acid reabsorption and Cys 
transport (Hanigan and Ricketts, 1993, Hanigan, 1995). However, γ-GT directed 
catabolism of GSH is the only major source of circulating Cys (Lieberman et al., 1996). 
This infers that, without γ-GT initiated reutilization of Cys, a dietary intake or cleavage 
of cystathionine forming Cys are insufficient to compensate for its loss as GSH 
(Lieberman et al., 1996)  
 
In the present study, the serum γ-GT levels was compared in both mild and severe 
pancreatic attacks. The serum γ-GT activity was increased in both mild and severe 
attacks at both time points when compared with healthy control (p< 0.001) (Table 4.2). 
As already mentioned, there was an immediate change in the GSH pool at 24 hrs 
(decrease) mild and severe attacks (p<0.001). Concomitantly, there was no significant 
increase/ decrease in serum γ-GT levels at 24 hrs mild attacks. However, there was a 
significant decrease in serum γ-GT levels following severe attacks at 72 hrs (p=0.012). 
This decrease in serum γ-GT directly reflects GSH levels at 72 hrs (p=0.002) (Figure 
4.11).  
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Figure 4.9. Serum γ-glutamyl transpeptidase levels in patients with acute pancreatitis.  
(*p<0.05, **p<0.001).  
 
4.4. Discussion 
 
The overall outcome of the sulfur amino acid profiling in patients suffering from AP in 
both mild and severe attacks from 24 hrs to 72 hrs can be can be summarized as 
follows; 
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1) Mild attack 
                                                Progression to 72 hrs 
 
 
2) Severe attack 
                                             Progression to 72 hrs 
   
 
 
 
 
 
 
 
 
 
Figure 4.10. Summary of sulfur amino acid profile at 24 and 72 hrs in patients suffering 
from AP. 
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The Met transsulfuration pathway supplies the key amino acid Cys (source of GSH), 
through the metabolism of Met via Hcy. It is reported that Hcy flux through 
transsulfuration increases during oxidative stress conditions (Mosharov et al., 2000), 
certain systemic injuries and /or trauma like sepsis  and burns (Yu et al., 1993). Hcy is 
an important key intermediate in both transmethylation and transsulfuration pathways. 
Hence, Hcy plays a key role in the maintenance of the cellular GSH pool.  
 
The results from the present study provide an interesting insight into the differences in 
transsulfuration capacities of certain cells in an event of pathophysiology such as AP. 
At 24 hrs during a mild attack, an increase in Hcy possibly provides a meaningful 
correlation for an elevated plasma Hcy. This metabolic demand for transsulfuration 
under certain pathological conditions directly or indirectly reflects oxidative stress and 
demonstrates, probably, a diminishing pool of GSH. Hence, transsulfuration can be 
described as an auto corrective response leading to an increased GSH synthesis via Cys 
in the cells challenged by oxidative stress.  
 
It must be noted, that Cys elevated slightly during mild or severe attacks. Plasma Cys 
concentrations were surprisingly similar to healthy controls in both mild and severe AP. 
A fall in plasma Hcy concentration was noted at a later stage of the disease. Elevated 
levels of Hcy reported in the present study correlated with another study who also 
showed changes in plasma Hcy levels in patients with AP (Yuzbasioglu et al., 2008). 
The latter study suggested that hyperhomocysteinemia was due to disturbed 
methylations.  
 
The transsulfuration pathway supplies the key amino acid Cys for GSH synthesis. It has 
been shown in rat pancreatic acinar cells, that the exocrine pancreas synthesizes GSH 
from precursor amino acids and that the transsulfuration pathway is functionally intact 
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in the pancreas and may serve as an important source of pancreatic Cys (Neuschwander-
Tetri et al., 1997). In the present study, despite elevated levels of Hcy, its conversion to 
Cys was limited. Although, there can be many potential riposte for this, the present 
hypothesis contemplated on an insufficient utilization of Hcy for Cys synthesis in 
response to an increase in demand. This insufficiency has probably led to GSH deficit 
within 24 hrs of onset of the disease.  
 
Nevertheless, given that Hcy and Cys concentrations were maintained within the normal 
range irrespective of disease severity, the results suggest that Cys bioavailability does 
not appear to be impaired in AP. It is cited that there could be Met flux among patients 
with acute inflammatory disorders, without an apparent change in serum Hcy or Cys 
levels (Vina et al., 2001). Yu et al (1993) studied a group of patients with severe burns 
and showed that rates of Hcy remethylation and Met oxidation all increased without 
changes in Cys levels (Yu et al., 1993). This reflected in the current study as 
demonstrated by the increased Hcy: Cys ratio in both mild and severe attacks without an 
apparent change in Cys concentration. 
 
Ostensibly, in mild attacks the Cys: GSH ratio fell significantly (p<0.05) as the disease 
progressed, despite increases in the Cys concentration. This can be attributed to an 
increase in erythrocyte GSH, suggesting that intra and extra-cellular recycling of GSH 
is sufficient to meet the demand for Cys in mild attacks. However, following a severe 
attack, the Cys: GSH ratio was unchanged and the Hcy: Cys ratio remained elevated 
despite an increase in plasma Cys-Gly levels. This suggests that in severe AP attacks 
defects in GSH biosynthesis may occur downstream of Cys biosynthesis, and are 
unlikely to be attributed to altered cystathionine activity (Vina et al., 1992, Rao et al., 
1990).  
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A persistent observation has come from the array of data, which has allowed uncovering 
the anticipated decrease in GSH levels within 24 hrs after the onset of a pancreatic 
attack. This decrease has been consistent and continued to 72 hrs following severe 
attacks. This perhaps explains a common thread connecting the progression of the 
disease and oxidative stress, which through free radical generation and/ or accumulation 
leads to depletion of GSH levels.  
Reduced cellular GSH levels have also been observed in critically ill and septic patients 
and has shown to correlate with increased organ damage and mortality (Rahman et al., 
2004, Mishra et al., 2005, Lyons et al., 2001, Hammarqvist, 1997). It appears therefore, 
that oxidative stress is associated with the progression of clinical AP, and this is 
highlighted by the observed inverse correlation between GSH concentration and the 
systemic physiological response to AP.  
 
This result has in fact served to underscore the intimate coupling between GSH and the 
enzyme involved in GSH metabolism viz γ-GT. Hypothetically, γ-GT activation 
intracellularly can lead to inappropriate GSH degradation (Stark, 1991). A diminished 
extracellular activity of γ-GT can result in decreased GSH precursor uptake 
(Neuschwander-Tetri et al., 1992). As mentioned elsewhere, the enzyme is expressed 
and exposed to the extracellular milieu. At 24 hrs mild attack, the cells, despite depleted 
levels of GSH try to export GSH into the extracellular milieu to combat oxidative stress 
and prevent cell damage. However, as time progresses, the cells unable to divert Hcy 
through transsulfuration have depleted GSH levels.  
GSH catabolism by the membrane bound γ-GT enzyme at 24 hrs yield Cys-Gly, a 
dipeptide metabolite of GSH. A concomitant decrease in GSH with an increase in Cys-
Gly levels at 72 hrs concurs with decreased levels of γ-GT. Despite increased Cys-Gly 
levels, the membrane bound enzyme is unable to transport Cys back to the cell for the 
reasons unrecognized.     
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The enzymes of the transsulfuration pathway are vulnerable to oxidative stress as shown 
by studies on hepatocytes poisoned by paracetamol (Davis et al., 1986). The two 
penultimate rate limiting enzymes in GSH biosynthesis, namely γ-glutamyl cysteine 
synthetase and glutathione synthetase participate in the downstream biosynthesis of Cys 
(Biolo et al., 2007, Dickinson and Forman, 2002). Mitochondrial dysfunction and 
depletion of ATP have been linked to intracellular antioxidant (reduced GSH) depletion 
in critically ill patients (Liaw et al., 1980, Tresadern et al., 1988, Gasparetto et al., 1983) 
and this may further directly affect the activity of γ-glutamyl cysteine synthase and 
glutathione synthase, which are both ATP dependent rate-limiting enzymes subjected to 
feedback inhibition by GSH.  
 
Furthermore, reduced levels of GSH could result in lack of feedback inhibition of γ-
glutamyl cysteine synthase leading to accumulation of γ-glutamyl cysteine that may be 
metabolised to glutamic acid via the γ-glutamylcyclotransfereses and oxoprolinase 
reactions, thereby potentiating cellular acidosis (Benedetti et al., 1980, Vander Jagt et 
al., 1997, Kaplowitz, 1980). Similarly, impaired GR activity or the excessive production 
of GSSG in the face of oxidative stress or xenobiotic challenge, may impair protein 
function by reacting with protein sulfhydryl via a mixed disulfide reaction (Walker and 
Gilbert, 1995). GSSG and glutathione-S-conjugates may in such circumstances be 
removed from cells through ATP-dependent processes mediated by the multidrug-
resistance (MRP) family (Singer and Brealey, 1999). Therefore, increased GSH 
oxidation may affect the cellular capacity to recycle GSH (Vina et al., 2001, Rao et al., 
1990, Singer and Brealey, 1999).  
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CHAPTER 5 Analysis of bile salts in cholestatic hepato-biliary diseases 
5.1. Introduction 
 
Bile acids are a family of molecules derived from cholesterol and form the major 
components of the bile. They are a complex group of acidic steroids forming a large 
heterogeneous group of water-soluble compounds characterized by steroid scaffolding 
with a carboxylic acid group located in the side chains (Figure 5.1). The most abundant 
primary bile acids in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). 
All primary bile acids appear to have three common features; i) they are the major end 
products of cholesterol metabolism, ii) secreted in to the bile in a conjugated form, iii) 
the conjugates are membrane impermeable, water-soluble, amphiphilic molecules 
(Danielsson, 1973, Hoffman, 1994). Briefly, the steps leading to the formation of the 
primary bile acids involve hydroxylation at C7 in the steroid ring of cholesterol or at 
C24, C25 or C27 position thus shortening the steroid ring. The terminal step in bile acid 
biosynthesis, involves conjugation with the amino acids glycine and taurine and that is 
aided by the hepatic microsomal, mitochondrial and lysosomal enzymes. Their 
conjugation increases the aqueous solubility of the bile salts under physiological 
conditions. The primary bile acids are further metabolized by the aid of intestinal 
bacterial flora that remove the hydroxyl group at position 7 to form the secondary bile 
acids: lithocholic acid (LCA) is formed from chenodeoxycholic acid (CDCA) and 
deoxycholic acid (DCA) is formed from cholic acid (CA) and ursodeoxycholic acid 
(UDCA) (Perwaiz et al., 2001). The latter two secondary bile acids constitute 70-80% 
of total bile acid pool in humans.  
These five bile acids namely CA, CDCA, DCA, UDCA and LCA form the most 
abundant bile acids in the human body. These acids differ from each other by the number 
and position of hydroxyl or keto groups and by the presence of double bonds in the 
steroid ring (Figure 5.1). They can either occur as free bile acids (unconjugated forms) or 
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as amide conjugates of carboxylic groups with glycine (NH2CH2CO2H) and taurine 
(NH2CH2CH2SO3H) via amidation on C24 forming taurocholic and glycocholic acids 
(Perwaiz et al., 2001, Tagliacozzi et al., 2003).  
Oxygen on the sulfur of the taurocholic acid and the terminal carbon of the glycocholic 
acid are ionized at physiological pH. Together with planar structure of the bile acid and 
the ample hydroxyl groups on the rings renders the bile salt (the ionized form) very 
amphipathic. Further, conjugation also reduces the pKa, for example: cholic acid binding 
with glycine reduces the pKa from 6.4 to 4.4. This change in the pKa ensures complete 
ionization and increases solubility. However, the hydrophobicity of the bile acids is 
inversely related to the number of –OH groups and linked with the intrinsic toxicity of 
the bile acids. For example: LCA has only one –OH group and is highly hydrophobic and 
toxic (Little et al., 1990).   
 
Upon their release into the small intestine, the majority of the bile acid conjugation 
involve re-conjugation of the unconjugated bile acids of previously secreted bile acids 
(Combes etal 1999). They are then used to solubilise dietary lipids such as cholesterol 
and triacylglycerides, aiding their absorption into the bloodstream. Thereafter, bile 
acids are reabsorbed from the portal blood by hepatocytes and re-excreted into bile for 
reuse. 
 
Thus, both primary and secondary bile acids are reabsorbed by the intestine and re-
delivered back to the liver via the portal circulation for uptake and re-secretion into the 
bile thus, recycling about 95% of the bile acids via the enterohepatic circulation. Any loss 
in the bile acid pool (through faeces), is compensated by the de novo synthesis to 
maintain the bile acid pool size in the body (Heaton, 1972, Hoffman, 1977). 
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Figure 5.1. Chemical structure of the parent bile acid along with side chain structure of 
six major bile acids with their taurine and glycine conjugates.  
R1, R2, R3 and R4 are shown with their respective chemical groups in the glycine and 
taurine conjugates. CA-cholic acid, CDCA-chenodeoxycholic acid, UDCA-
Ursodeoxycholic acid, DCA-Deoxycholic acid, LCA-Lithocholic acid. 
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In normal physiological conditions, only small quantities of bile acids are found in 
peripheral circulation (Perwaiz et al., 2001). The bile acid level in the peripheral 
circulation is in the micromolar (μM) range (Burkard et al., 2005). However, blood bile 
acid levels rise when bile flow is reduced or blocked as in cholestasis thereby escaping 
into the bloodstream.  
 
Circulating bile acids levels in plasma are rapidly cleared by the liver. Decreased liver 
function results in elevated plasma bile acid concentrations (Salen and Batta, 1999), 
thus there is less efficient removal of bile salts from circulation causing the bile acid 
levels to rise in the peripheral circulation. Bile acid levels in pathological conditions 
can be efficient in early diagnosis of many diseases associated with liver and intestine 
(Roda et al., 1998, Scalia, 1995). Further, it has been investigated that altered bile acid 
levels are more sensitive indices in the diagnosis of liver disease when compared to 
conventional liver function tests (Kaplowitz, 1973).  
 
Hepatobiliary, intestinal dysfunction and related gastro-intestinal diseases disturb the 
bile acid synthesis, metabolism and its clearance by the liver. Hence, the bile acid pools 
in various compartments in the body like serum, gall bladder, liver, urine and faeces are 
affected quantitatively. A comprehensive analysis of bile acids in various biological 
matrices requires their isolation and separation from the given sample. Primary or 
conjugated bile acid levels vary in their concentration dependent on the source they 
obtained from. 
As bile acids differ broadly in their physiochemical properties such as lipophilicity and 
polarity, a complete and accurate separation requires the use of chromatographic 
techniques (Roda et al., 1983). Major advances have been made in analytical 
methodologies for the determination of bile acids in various biological matrices and 
physiological fluids.  
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Gas chromatography (GC) was extensively used for bile acid analysis before any other 
analytical assay was developed. However, extensive samples clean up prior GC analysis 
have ostensibly reduced the use of GC in bile acid analysis. GC coupled with mass 
spectrometer (MS), has been more useful in the elucidation of bile acid profile in 
biological fluids. Nevertheless, a routine GC-MS analysis of bile acids mainly in plasma 
required a laborious sample preparation involving enzymatic and/ or chemical 
deconjugation, prior derivatization (Bootsma et al., 1999) 
 
Mass spectrometry is a valuable method for providing qualitative information about 
metabolite identification. LC-MS methodologies for bile salts, both primary and 
conjugated, acids are promising. Specifically, LC-MS with an ESI interface, offers rapid 
and efficient methodology amenable for the both conjugated and non-conjugated bile 
acids in biological samples (Alnouti et al., 2008) 
 
Although several analytical methods have been described to determine bile acids levels, 
only a few publications have specified individual bile acid concentrations in a single 
run. Thus, the aim of the present study was to develop a LC-MS technique to assay the 
profile of 15 bile acids in a cohort of patients suffering from various degrees of 
cholestatic hepato-biliary diseases. Based on the chemistry of the bile acids and in 
agreement with the literature (Grattagliano et al., 2005), electrospary ionization (ESI) 
was used as the method for ionisation.  
5.2. Materials and methods  
 
The materials used for this study are fully listed in section 2.1.3. The equipment 
conditions are described in section 2.2.3. The sampling procedure has been described in 
method section 2.3.3, whilst the extraction procedure is explained in detail in section 
2.7.  
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5.3. Results 
5.3.1. Optimisation of conditions for ionisation  
 
ESI with a combination of high voltage and heat was used to generate ions at 
atmospheric pressure from the biological sample prior its transfer to the mass analyser. 
Furthermore, ESI was operated in both positive [M+H] + and negative [M-H] – modes 
for the bile standards. Positive-ion mode analysis resulted in a spectrum with low signal 
strength and with ample background noise. Hence, based on the signal strength and the 
dominant ionic species present, negative mode [M-H] – was selected for further 
optimisation. The negative ion formation has enabled low concentration detection. 
Further, the presence of –COOH (acid group) and abundant –OH groups in almost all 
the bile acids favoured negative ion selectivity in the detection process. 
 
In order to optimise the conditions for ionisation in ES-, all the 15 bile acid standards 
were prepared in MeOH at a concentration of 1 mg/mL (stock solution) individually and 
stored in -80ºC. 10 µL of the individual sodium salt of bile acid standards were diluted 
with 990 µL MeOH (10 µg/mL, working standard). Optimization was achieved by both 
direct infusion into the mass spectrometer through a syringe pump (10 µL/mL) and with 
corresponding HPLC mobile phase (0.2 μL/ min). The coupling of LC allowed the 
separation of isobaric components.  
 
Full scan spectra for all the 15 bile standards were acquired over the mass range of m/z 
300-550. The operating parameters of the ESI source were optimised with regard to 
maximum signal intensity with source and desolvation temperature of 120ºC and 
200ºC. The capillary voltage was maintained at 3.50 kV, the dwell time was 0.2s with 
an interscan delay of 0.1s. The optimised conditions for the formation, detection and 
recording of a single ion species forms the basis of an analytical protocol using single 
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ion recording (SIR). All relevant information is summarized in Table 5.1 A and B. The 
corresponding ESI spectra for bile acids are shown in Figures 5.2 a to o.   
Table 5.1 A and B. Summary of the optimized mass spectrometer conditions for the 
bile acid standards. 
 
A) 
Sodium salts of bile 
acid standards  
Relative 
molecular 
mass 
 
Parent-ion 
[M-Na]- 
 
Cone voltage  
(V) 
 
TCA 537 514 82 
TUDCA 521 498 60 
TDCA 521 498 90 
TCDCA 521 498 60 
TLCA 505 482 90 
GCA 487 464 60 
GUDCA 471 448 60 
GDCA 471 448 60 
GCDCA 471 448 60 
GLCA 455 432 60 
 
B) 
Bile acids Molecular 
weight 
Parent-ion 
[M-H]- 
Cone voltage 
(V) 
CA 408 407 60 
CDCA 392 391 60 
DCA 392 391 60 
UDCA 392 391 60 
LCA 377 376 80 
CA-d4* 412 411 92 
*Internal standard  
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Figure 5.2a) Structure and ESI-MS spectra for sodium taurocholate (TCA) (10 μg/mL).  
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Figure 5.2b). Structure and ESI-MS spectra for sodium tauroursodeoxycholate (TUDCA) 
(10 μg/mL).  
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Figure 5.2c) Structure and ESI-MS spectra for sodium taurochenodeoxycholate (TCDCA) 
(10 μg/mL).  
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Figure 5.2d) Structure and ESI-MS spectra for sodium taurodeoxycholate (TDCA) (10 
μg/mL). 
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Figure 5.2e) Structure and ESI-MS spectra for sodium taurolithocholate (TLCA) (10 
μg/mL). 
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Figure 5.2f) Structure and ESI-MS spectra for sodium glycocholate (GCA) (10 μg/mL). 
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Figure 5.2g) Structure and ESI-MS spectra for sodium glycoursodeoxycholate 
(GUDCA) (10 μg/mL). 
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Figure 5.2h) ESI-MS spectra and structure for sodium glycochenodeoxycholate 
(GCDCA) (10 μg/mL). 
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Figure 5.2i) ESI-MS spectra and structure for sodium glycodeoxycholate (GDCA) (10 
μg/mL). 
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Figure 5.2j) ESI-MS spectra and structure for sodium glycolithocholate (GLCA) (10 
μg/mL). 
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Figure 5.2k) ESI-MS spectra and structure for cholic acid (CA) (10 μg/mL). 
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Figure 5.2l) ESI-MS spectra and structure for chenodeoxycholic acid (CDCA) (10 
μg/mL). 
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Figure 5.2m) ESI-MS spectra and structure for deoxycholic acid (DCA) (10 μg/mL). 
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Figure 5.2n) ESI-MS spectra and structure for ursodeoxycholic acid (UDCA) (10 
μg/mL). 
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Figure 5.2o) ESI-MS spectra and structure for lithocholic acid (LCA) (10 μg/mL). 
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5.3.2. Choice of internal standard 
 
The compound 5-β cholanic acid, 3α, 12α-diol 3 acetate methyl ester was tested as a possible 
internal standard. The compound showed weak signal in both negative mode and in positive 
mode. However, when the standard was made in ammonium acetate: MeOH solution, it 
showed a strong signal in positive mode and no signal in negative mode (Figure 5.3). 
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Figure 5.3. Structure and ESI-MS spectra of 5-β cholanic acid, 3α, 12α-diol 3 acetate 
methyl ester (10 μg/mL).  
Deuterated analogues of bile acids behave almost identically to the corresponding non-
labelled analytes differing only in their mass to charge ratio. Thus, cholic-2, 2, 4, 4-d4 
acid was tested. A stock solution of 1 mg/mL was made by dissolving 1 mg of the 
internal standard in 1 mL MeOH. A 10 µg/mL working solution was then prepared. The 
internal standard was monitored by the formation of the ion. Parameters for the SIR 
assay and a sample spectrum are shown in Figure 5.4 and Table 5.1B.   
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Figure 5.4) ESI-MS spectrum and structure for internal standard cholic-2, 2, 4, 4-d4 
acid. (10 μg/mL). 
5.3.3. LC-MS method development 
 
Individual bile standards were serially diluted (50 µg-100 ng/mL) and analyzed 
chromatographically. The column was maintained at ambient temperature. The sample 
injections were performed with the sample chamber temperature set at 8oC. This 
temperature was suitable to avoid sample evaporation as all the samples were 
dissolved/ reconstituted in MeOH. A needle wash was programmed in between each 
runs to avoid any cross-contamination in the injector system. A sample chromatogram 
of 15 resolved bile acids (66 µg/mL) is shown (Figure 5.5).  
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Figure 5.5. Representative chromatogram of ESI-LC/MS analysis of bile salt standards 
(33 µg/mL).                                                                      
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1. Taurocholic acid (TCA), 2. Tauroursodeoxycholic acid (TUDCA), 3. 
Taurochenodeoxycholic acid (TCDCA), 4. Taurodeoxycholic acid (TDCA), 5. 
Taurolithocholic acid (TLCA), 6. Glycocholic acid (GCA), 7. Glycoursodeoxycholic acid 
(GUDCA), 8. Glycochenodeoxycholic acid (GCDCA), 9. Glycodeoxycholic acid (GDCA), 
10. Glycolithocholic acid (GLCA), 11. Cholic 2, 2, 4, 4-d4 acid (internal standard) 12. Cholic 
acid (CA), 13. Chenodeoxycholic acid (CDCA), 14. Deoxycholic acid (DCA), 15. 
Ursodeoxycholic acid (UDCA), 16. Lithocholic acid (LCA).  
 
5.3.4. Calibration lines, linearity, detection and quantitation limits  
 
The composite standard was used to obtain a six point calibration curve with internal 
standard at the range of 25 µg-2.5 µg/mL. Linear regression and was estimated using the 
response ratio of the analyte to internal standard. These were then plotted against the 
concentration of the calibration standards (Figures 5.6 a to o). Indicative retention times, 
linear regression equation, correlation coefficient (R2), limit of detection (LoD) and limit 
of quantitation (LoQ) for each standard is shown in Table 5.2.  
TCA m/z  514
0
50
100
150
200
250
300
350
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
a) 
 
 
 
 
 
 
 
 166
TUDCA m/z  498
0
50
100
150
200
250
300
350
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
b) 
 
 
TCDCA m/z 498
0
50
100
150
200
250
300
350
400
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
c) 
 
 
TDCA m/z 498
0
50
100
150
200
250
300
0 10 20 30 40 50 60
Conc (μg.ml)
Ar
ea
/IS
 
d) 
 
 
 167
TLCA m/z  482
0
100
200
300
400
500
600
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
e) 
 
 
GCA m/z  464
0
100
200
300
400
500
600
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
f) 
 
 
GUDCA m/z  448
0
100
200
300
400
500
0 10 20 30 40 50 60
Conc. μg/ml
Ar
ea
/IS
 
g) 
 
 
 
 
 
 168
GCDCA m/z  448
0
50
100
150
200
250
300
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
 
h) 
 
GDCA m/z  448
0
50
100
150
200
250
300
350
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/is
 
i) 
 
 
GLCA m/z  432
0
100
200
300
400
500
600
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
j) 
 
 
 
 
 169
CA m/z  408
0
5
10
15
20
25
30
0 10 20 30 40 50 60
Conc (μg/ml)
A
re
a/
IS
 
k) 
 
 
CDCA m/z  392
0
5
10
15
20
0 10 20 30 40 50 60
Conc (μg/ml)
A
re
a/
IS
 
l) 
 
 
DCA m/z  392
0
5
10
15
20
25
30
35
40
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
m) 
 
 
 170
UDCA m/z  391
0
100
200
300
400
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
n) 
 
 
LCA m/z  376
0
5
10
15
20
25
30
35
40
45
0 10 20 30 40 50 60
Conc (μg/ml)
Ar
ea
/IS
 
o) 
 
 
Figure 5.5 a to o. Calibration lines for individual bile salts/ acid. 
 
The calibration lines for the bile acids are in the following order:  
a) Taurocholic acid (TCA), b) Tauroursodeoxycholic acid (TUDCA), c). 
Taurochenodeoxycholic acid (TCDCA), d) Taurodeoxycholic acid (TDCA), e). 
Taurolithocholic acid (TLCA), f). Glycocholic acid (GCA), g). Glycoursodeoxycholic acid 
(GUDCA), h). Glycochenodeoxycholic acid (GCDCA), i). Glycodeoxycholic acid (GDCA), 
j). Glycolithocholic acid (GLCA), k). Cholic acid (CA), l) Chenodeoxycholic acid (CDCA), 
m) Deoxycholic acid (DCA), n) Ursodeoxycholic acid (UDCA), o) Lithocholic acid (LCA). 
Calibration line for internal standard is not shown. 
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Table 5.2. Indicative retention times, linearity, LoD, LoQ of the ESI-LC/MS of bile 
salts. 
 
Bile acid 
Standards  
 
Equations R2 LoD 
(ng) 
 
LoQ  
(ng) 
Retention 
time 
TCA y=5.48x+49.4 0.960 7 25 8.08 
TUDCA y=5.62x+55.4 0.935 5 25 5.81 
TCDCA y=5.186x+51.03 0.951 1 50 11.60 
TDCA y=3.673x+85.36 0.984 8 25 12.57 
TLCA y=8.699x+77.51 0.948 1 50 15.82 
GCA y=7.68x+95.2 0.936 5 25 8.62 
GUDCA y=7.39x+90.1 0.919 7 25 6.17 
GCDCA y=4.63x+46.96 0.962 7 50 12.08 
GDCA y=5.25x+58.95 0.965 3 25 13.20 
GLCA y=9.92x+49.4 0.972 2 50 16.40 
CA y=0.423x+4.05 0.942 9 100 12.31 
CDCA y=0.271x+2.42 0.954 2 100 10.08 
DCA y=0.526x+6.81 0.912 5 100 17.07 
UDCA y=5.45x+57.8 0.969 3 100 10.08 
LCA y=0.658x+7.87 0.916 1 100 20.72 
 
5.3.5. Reproducibility 
 
To ensure method reliability and reproducibility, inter and intra day accuracy and precision 
were determined and this was determined by using six quality control concentrations 
distributed throughout the calibration range for each analyte. Each of these six QC points 
were analysed in replicates for three days to determine the inter-day and between (intra) 
days variations.  
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Inter-day accuracy and precision was calculated by dividing the standard deviation of the 
three replicates by the overall mean area and converting the value to a percentage relative 
standard deviation (%RSD= SD/mean) respectively. The inter-day precision for all the 
analytes were less than 15% and is shown in Table 5.3. 
 
A mid-range concentration (30 ng) was selected and injected for a total of five times in 
succession and the co-efficient of variation was calculated by dividing the standard 
deviation of the five replicates by the overall mean area and converting the value to a 
percentage to give the between (inter) day accuracy and precision. The calibrating solutions 
were freshly prepared from the individual bile acid stock solutions stored at -80ºC. The co-
efficient of variation for intra-day precision was less than 5% (except for GDCA). The 
intra-day precision is summarized in Table 5.4. 
 
5.3.6. Recovery 
 
 
The average recoveries ranged from 86 to 105 %. The results are summarized in Table 
5.4. 
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                  QC1                                     QC2                                  QC3                        QC4                           QC5                                   QC6 
Conc.    0.16                                    1.6                                   3.3                             16                                 33                                      50 
             µg/mL      %RSD               µg/mL     %RSD               µg/mL     %RSD      µg/mL     %RSD           µg/mL     %RSD            µg/mL       %RSD 
 
TCA           11           13.4                    26              8.1               86               2.9             179           8.6                 233          9.1                      333             3.8 
TCDCA     4.3          13.5                    16             12.7               26              17              153           14.3               207          3.6                      288              7.4      
TDCA        7.7          11.7                    17.7           3.3                35.3           13              169           15.9               217          9.8                      257             2.5 
TUDCA     5.3           9.8                     74             6.6                 91              5.8             166           6.9                 233          8.5                      277             7.0 
TLCA        8.8           3.8                     132           1.6                 172            5.8             226           1.3                  336         9.0                       495            5.2 
Nominal   0.06                                  0.16                                 1.6                           3.3                                16                                        33 
Conc.      µg/mL     %RSD              µg/mL    %RSD            µg/mL   %RSD      µg/mL      %RSD             µg/mL     %RSD             µg/mL       %RSD 
 
GCA         2.4            8.6                   20.7          7.4                  125         5.0              141          5.8                  261              3.2               367                  5.2  
GCDCA   1.7            12.4                  3.1           3.2                  15.2        8.4               86            5.2                133              3.7                179                  9.8 
GDCA      2.0            1.5                    26             13.8                 66           6.1             39           11.5                145             8.6                244                  8.5   
GUDCA   2.0            7.3                    34             12.8                 144         7.7            144         11.8                249             13.5                332                 9.6 
GLCA     4.9             10.6                 28              9.2                   57           10.5           41.3        13.3              174.7           15.7                321                  7.4 
 
Nominal    0.06                               0.16                                   1.6                           3.3                                 16                                      33 
Conc.     µg/mL       %RSD            µg/mL     %RSD               µg/mL     %RSD      µg/mL     %RSD           µg/mL     %RSD              µg/mL        %RSD 
 
CA         0.15            9.9                 1.43           14.5               4.2                8.2             4.5           14               16.6           14                      17.3            8.1 
CDCA   0.45            9.7                  3.1              6.1                3.6               2.6             16.8         7.6                8.0           8.5                     11.0            3.5 
DCA      0.73           3.6                  1.9              9.6                 7.1               13.8           13.1         2.1              19.5          11.3                    22.9            10.7 
UDCA   4.2             4.9                  0.0              0.0                 18.0             11.0           191          1.7              166           2.4                      235             1.6 
LCA      0.65           3.2                  1.7              4.0                 11.6              5.8            14.2          0.55           19.3           9.6                      26.7           15.0 
 
 
Table 5. 3. Inter-day accuracy and precision for the ESI-LC/MS assay of bile salts. 
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Table 5.4. Intra-day accuracy and precision recovery of bile acids. Mean recovery rate 
of the extraction procedure presented as of % recovery (n=3, ± SD). The average peak 
areas of the extracted analyte were compared with the one for the non-extracted 
standard from which the % recovery was calculated.  
 
Bile acids Intra-day 
CV (%) 
Recovery (%) 
TCA 3.6 90.05±2 
TUDCA 5.4 99.10±9 
TCDCA ND 90.21±6 
TDCA 3.9 99.6±6 
TLCA 5.4 87.77±9 
GCA 3.7 104.76±5 
GUDCA 4.7 96.24±7 
GCDCA ND 92.70±7 
GDCA 6.1 85.52±3 
GLCA 2.5 89.47±7 
CA 4.1 87.67±12 
CDCA 5.0 97.36±1 
DCA 2.2 87.39±2 
UDCA 4.5 92.06±2 
LCA 4.0 83.12±13 
 
 
 
ND-Not detected.   
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5.3.7. Bile salt analysis in clinical samples 
 
The bile salts were extracted from the bile as described in Section 2.7.4. (see methods 
section). Typical chromatograms for the analysis of clinical samples from patients 
suffering from cholestatic hepato-biliary diseases are shown in Figure 5.6. The results of 
the analysis of conjugated and unconjugated acids from patients suffering from cholestatic 
hepato-biliary disease are shown in Table 5.5.  
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Figure 5.6. Representative mass chromatogram of bile salts from bile sample.  
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Taurine and glycine conjugates (m/z 498 and m/z 448) co-elute in the bile sample only. The 
bile acids elute in the following order: 
1.Taurocholic acid (TCA), 2. Tauroursodeoxycholic acid (TUDCA), 3. 
Taurochenodeoxycholic acid (TCDCA), 4. Taurodeoxycholic acid (TDCA), 5. 
Taurolithocholic acid (TLCA), 6. Glycocholic acid (GCA), 7. Glycoursodeoxycholic acid 
(GUDCA), 8. Glycochenodeoxycholic acid (GCDCA), 9. Glycodeoxycholic acid (GDCA), 
10. Glycolithocholic acid (GLCA), 11. Cholic 2, 2, 4, 4-d4 acid (internal standard) 12. Cholic 
acid (CA), 13. Chenodeoxycholic acid (CDCA), 14. Deoxycholic acid (DCA), 15. 
Ursodeoxycholic acid (UDCA), 16. Lithocholic acid (LCA).  
 
* TCA eluted 2 minutes early than the expected standard retention time.  
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Table 5.5. Bile acid levels in bile samples from patients suffering from cholestatic 
hepato-biliary diseases (mean of three separate analysis). Values shown represent 
concentrations (µg/mL) analysed from bile collected from six patients with cholestatic 
hepato-biliary diseases. Each value represents the average of three individual 
determinations run along with the standards in parallel. TCDCA; TDCA and GCDCA; 
GDCA co-eluted in all the samples. ND, not detected.  
Taurine 
Conjugates 
Clinical 
Condition  
TCA 
Co-elute 
 
TCDCA              TDCA 
 
TUDCA 
 
TLCA 
µg/mL  m/z 514 m/z498 m/z 498 m/z 498 m/z 482 
Bile Sample 1 Gall Pne 381 3539 0 36 16 
Bile Sample 2 Biliary Colic 2182 3753 0 83 60 
Bile Sample 3 
Sever AP 
pseudo cyst 463 1269 0 102 2 
Bile Sample 4 Mild GS AP 2431 6251 0 423 11 
Bile Sample 5 Mild GS AP 3323 6488 0 81 179 
Bile Sample 6 
Nero endocrine 
liver 1975 2931 0 126 178 
Glycine 
Conjugates 
 
 
GCA 
Co-elute 
 
GCDCA              GDCA 
 
GUDCA 
 
GLCA 
µg/mL  m/z 464 m/z448 m/z 448 m/z 448 m/z 432 
Bile Sample 1 Gall Pne 970 2202 0 37 43 
Bile Sample 2 Biliary Colic 2841 6744 0 128 97 
Bile Sample 3 Sever AP 
pseudo cyst
1862 326 0 488 12 
Bile Sample 4 Mild GS AP 5673 18667 0 1919 12 
Bile Sample 5 Mild GS AP 773 5970 0 406 404 
Bile Sample 6 
Nero endocrine 
liver 5835 8196 0 196 222 
Primary 
Bile Acids 
 
 
CA 
 
CDCA 
 
DCA 
 
UDCA 
 
LCA 
µg/mL  m/z 408 m/z392 m/z 392 m/z 391 m/z 376 
Bile Sample 1 Gall Pne 0.35 2.47 1.69 0.10 2.29 
Bile Sample 2 Biliary Colic 1.56 ND 0.08 0.10 2.66 
Bile Sample 3 
Sever AP 
pseudo cyst 2.41 2.26 1.42 0.16 2.66 
Bile Sample 4 Mild GS AP 1.66 4.46 2.56 0.12 4.33 
Bile Sample 5 Mild GS AP 1.76 1.00 2.68 0.09 3.79 
Bile Sample 6 
Nero endocrine 
liver 0.23 0.01 0.23 0.02 0.36 
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5.4. Discussion 
 
A resurgence of interest in bile acids over the years as a result of their use in various 
treatments and their involvement in the aetiology of a number of diseases has led to the 
development of specific analytical techniques.  
The present method has detected and determined the profile of 15 bile acids in a single 
run. Mass spectrometric conditions have been specifically optimised for each analyte 
(each bile salt). As acidic function is always present in these compounds, they yielded 
ions in the negative mode (Warrack and DiDonato, 1993, Evans et al., 1993). Further, the 
use of ESI has enabled a robust method for bile acid screening in human bile. The elution 
gradient was optimised for the simultaneous separation of unconjugated and conjugated 
(taurine and glycine conjugated) bile acids. Furthermore, ammonium acetate was used in 
the LC separation and was preferred over ammonium formate as it yielded more signal 
strength and is more volatile, therefore giving better sensitivity (Alnouti et al., 2008, 
Setchell and Vestal, 1989, Iida and Murata, 1990). Volatile electrolytes like ammonium 
acetate readily promote ion-molecular reaction in almost neutral pH (Iida and Murata, 
1990). Further, using a low concentration of ammonium acetate (5 mM) was useful to 
minimize the formation of ammonium adducts and the molecular ions remained intact. 
The signal strength of molecular ions was highest in negative mode. Moreover, 0.012% 
formic acid, added as a buffer additive (to control ion formation) was suitable for 
chromatographic behaviour and enhanced for MS sensitivity.  
 
Broad differences in the physiochemical properties of bile acids such as polarity and 
lipophilicity, required particular care in choosing stationary and mobile phases. A C18 
ODS column allows good separation of 15 bile acids using a methanol gradient. To 
account for any loss of the analyte(s), the quantification of bile acids was based on 
using deuterium labelled internal standard. The bile samples were semi-purified using 
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SPE cartridges. The SPE allowed a simple efficient and cost effective of all analytes and 
internal standard. The deuterated internal standard behaved identically to the analytes 
(Burkard et al., 2005). All the standard curves were linear in both calibration ranges for 
all bile acids summarized in Table 5.2. The data obtained from this method in terms of 
precision and accuracy demonstrated the reproducibility of the assay (See Table 5.4). 
The mean recovery rates of the extraction procedure were between 86 and 105 %. 
Glycine conjugates showed better recoveries than the taurine conjugated bile acids. The 
unconjugated bile acid LCA, in particular showed poor recovery perhaps the 
lipophilicity could possibly interfere with extraction process. The LoD and LoQ are 
summarized in Table 5.4.  
 
A crucial parameter in this method development was the chromatographic separation of 
glycine and taurine conjugates of UDCA, CDCA and DCA as they all possess same 
parent ion (m/z 498 for taurine conjugates and m/z 448 for glycine conjugates) (see Table 
5.1). Hence, it was considered prudent to obtain sufficient peak resolution for 
chromatographic analyses.  
 
It was also noted that, taurine conjugated bile acids eluted earlier than the glycine 
conjugates (See Figure 5.4). The glycine conjugates eluted earlier than the primary and 
secondary bile acids. It was noted from the chromatogram (Figure 5.6) that TCA peak 
(m/z 514) from the bile sample, eluted two minutes before the expected retention time (as 
in TCA standard, See Figure 5.4). This probably can be attributed to the detection of a 
possible isoform of TCA in the bile sample. This need to be further elucidated. 
 
Furthermore, two of the taurine and glycine conjugates co-eluted in all the patients’ 
samples (Figure 5.6) thus making the levels of these bile acids indistinguishable in 
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patients. The rest of the conjugated and primary bile acids were sufficiently resolved. At 
this late juncture, it was not possible to fabricate new and better resolving gradient 
programmes to separate the co-eluting conjugates.   
 
The bile acid levels measured from the patients were quantitated using the standard 
calibration lines. As evident from Table 5.5, the concentrations of the major endogenous 
primary bile acids (CA, CDCA, DCA UDCA and LCA) in these patients showed 
considerable variations. The concentrations of the glycine conjugates were higher 
compared with taurine conjugates. In addition, very low levels of UDCA were detected 
in the patients in the present study (Table 5.5). Perhaps low levels of UDCA reflected 
greater extent of conjugation with glycine rather than with taurine. CA, CDCA and 
DCA varied in the concentration while LCA remained elevated in all the patients, 
compared to other primary and secondary bile acids. As it can be seen from the Table 
5.5, primary bile acids seemed to be conjugated in most of the patients resulting in 
elevated levels of taurine and glycine.  
 
An increased proportion in LCA and a reduction in UDCA and CDCA in all the patients 
was observed. LCA is formed either by 7-β-dehydroxylation of UDCA or by 7-α-
dehydroxylation of CDCA. UDCA is poorly absorbed in the GI tract but undergoes 
significant biotransformation to hydrophobic bile acids CDCA and LCA (Cecilia et al., 
1995). This might possibly explain the high concentration of LCA among these patients. 
It is suggested that LCA is the most toxic bile acid while CDCA is the least toxic bile 
acid (Staudinger et al., 2001). The levels CA in two of the patients was decreased 
compared to normal, which perhaps suggest failure of 12α-hydroxylation in the bile 
synthetic pathway. This decrease in the CA was also noted in cirrhotic patients 
(McCormick et al., 1973).  
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Taurine and glycine are the main conjugates of the primary bile acids and their ratio 
vary with age and in various liver disorders. An accurate measurement of their ratio 
perhaps is of biological and clinical significance. It is reported that UDCA in its 
conjugated form could prevent liver cell injury and cholestatic in animal model (Kanai 
and Kitani, 1983).   
 
In conclusion, this part of the project was a pilot study with a small cohort of patients with 
varying cholestatic hepato-biliary disease. Nevertheless, the study concluded lower levels 
of primary bile acids. However, the results suggested that the summation of all the di and 
tri-hydroxy C27 bile acids can possibly be overall indicators of cholestatic hepato-biliary 
diseases.    
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CHAPTER 6 General discussion and future work 
 
Oxidative stress is a perpetual theme throughout the body of this thesis. Overwhelming 
free radical production in the presence of limited free radical neutralization leads to 
accumulated oxidative stress resulting in various injuries in the cell/ tissue/ organ. This 
has been a constant conjunction in the pathophysiology of AP. One of the aspects the 
present study was concentrated in evaluating the pathophysiology augmented by 
oxidative stress in AP in the absence of depleting thiol status.    
6.1. Transsulfuration and acute pancreatitis  
 
Ample supplies of data, whether it is pharmacokinetic or biochemical have suggested 
that oxidative stress was a plausible damaging mechanism in both acute-or-chronic 
pancreatitis (Braganza, 1990). The role of ROS in the pathogenesis of pancreatic 
inflammation has been studied almost exclusively in animal models and has received 
relatively little attention in human patients. This is perhaps due to a high variability in 
aetiology, severity and clinical course of AP in human patients.  
Depletion of thiols in the pancreas was seen as an early feature in experimental AP 
(Neuschwander-Tetri et al., 1992, Luthen and Niederau, 1995). In an attempt to 
investigate thiol status, analysis of sulfur amino acids was carried out in the plasma of 
patients suffering from AP. Clearly, the results suggested that impaired GSH 
biosynthesis occurs within 24 hrs of onset of abdominal pain associated with AP. 
Although loss of GSH is perpetual either in acute or chronic pancreatitis, the rationale 
for this loss is still ambiguous. The following evidences can be germane and possibly 
explain the reasons for loss of GSH during AP.   
Cys is extremely unstable and rapidly auto-oxidises to cystine, generating potentially 
toxic oxygen radicals that can further augment oxidative stress. Furthermore, Cys is 
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avidly taken up by pancreas, it is cited that pancreas is relatively low in transsulfuration 
enzymes (Mudd et al., 1965). Therefore, the acinar cells must depend on GSH for a 
continuous supply of Cys for synthesis of GSH. From the present data, despite ample 
Cys supply, GSH synthesis is deficient. This possibly explains GSH being severely 
compromised with a large load of oxygen radicals generated by Cys auto-oxidation.    
 
Further, Hcy has also been shown to cause oxidative stress on cells directly by the 
production of H2O2 (Jhee and Kruger, 2005). Severe oxidative stress may overcome the 
ability of the cell to reduce GSSG, thus deplete cellular GSH (Benedetti et al., 1980, 
Vander Jagt et al., 1997). Decreased levels of GSH in plasma are reported, but 
paradoxically an increased GSH levels may also be found as a result of outshoot after 
enhanced synthesis due to oxidative stress or conjugation of toxic compounds, as has 
been reported in different disorders (Gut et al., 1995, Plummer et al., 1981, Deneke and 
Fanburg, 1989).  
 
GSH conjugation with xenobiotic electrophiles is rapidly excreted from the cells, 
(Orrenius, 1984) although vitally protective, results in permanent loss of GSH. Under 
heavily oxidative stress conditions, a cell may not be able to replace this disrupted thiol 
status. This mechanism, depending on the aetiology, can possibly reflect the state of 
pancreatic acinar cells during a pancreatic attack. Considering all these above-described 
points, it is perhaps not surprising that abrupt depletion of GSH, itself may seem to 
initiate changes in AP.  
6.1.2. Role of γ-Glutamyl transpeptidase in disease progression  
The data originated from the γ-GT expression poses a possible hypothesis for 
aggravated and/ or progression during pancreatitis. Low GSH levels and γ-GT 
illustrated a significant correlation at 72 hrs (See section 4.3.5 for results, Table 4.2). As 
 186
cited earlier, γ-GT is an abundant ectoenzyme, whose major function is to maintain the 
catabolism of GSH (Hanigan and Pitot, 1985). An important apparent activity of γ-GT is 
that γ-GT can act as GSH oxidase (Tate, 1979), giving rise to free radicals (Stark, 1991). 
Considering the following reactions: 
 
1. Formation of Cys-Gly (CG-SH) from GSH by GGT 
2. Facile dissociation of CG-(SH) into thiolate anion due to low pKa (SH) 
3. Direct reduction of iron and formation of a thiyl radical 
4. Recycling of iron and formation of superoxide 
5. Dismutation of superoxide to hydrogen peroxide 
6.  Formation of a thiolate anion radical 
7. Formation of superoxide from thiolate anion radical and molecular oxygen 
8. Possible termination: formation of Cys-Gly disulfide.    
 
 
Scheme 1. Generation of oxygen and thiyl radicals from the oxidation of GSH. 
(Adopted from (Stark et al., 1993). 
 
 
 
1. γ-Glu-Cys-Gly + R-NH2    γ-Glu-HN-R + Cys-Gly   
 
 
 
 
2. 2RSH  2RS- + 2H+ 
   
3. 2RS- + 2Fe+3  2RS + 2Fe+2 
4. 2Fe+2 + 2O2              2Fe+3 + 2O2- 
 
5. 2O+2    +   2H+     H2O2 + O2 
 
6. RS- + RS   RSSR 
 
7. RSSR + O2               RSSR + O2- 
 
8. RS + RS     RSSR  
SH
γ-GT
   SH 
(RSH) 
pKa (SH) 6.4 pKa (SH) 8.6
•
•
• SOD
• - •
- • •
• •
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During this auto-oxidation of thiols, thiyl radicals can also propagate radical chain 
reactions by reacting directly with unsaturated bond in lipids and/ or abstract hydrogen 
from alcohols yielding carbon-centred radicals. These carbon-centred radicals can 
further react with oxygen to yield oxygen-centred radicals (Ito et al., 1988, Stock et al., 
1986, Schoneich et al., 1989). This premise could possibly explain disease progression 
at 72 hrs following a mild AP attack. To add weight to this argument, non-enzymatic 
auto-oxidation of Cys-Gly in the presence of iron yields superoxide and H2O2 and the 
auto-oxidation proceeds via, thiolate anion intermediates (Misra, 1974).  
As previously explained, oxygen radicals mediate an important step in the initiation and 
progression of AP, the potential source for enhanced oxygen radicals’ production 
however, remains unexplained. Continuing the hypothesis, auto-oxidation and 
dissociation of GSH at high pH yields O2- radical (Richmond and Halliwell, 1982). As 
explained earlier, γ-GT cleaves the γ-glutamyl bond in GSH releasing Cys-Gly, another 
abundant thiol, that has received little attention so far.  
The conversion of GSH to Cys-Gly results in readily dissociating species, facile auto-
oxidation and radical formation at physiological pH (Stark, 1991). An inefficient 
metabolism of Cys-Gly and/ or the radicals, the action of γ-GT on GSH, may lead to 
oxidative damage (Stark et al., 1988, Stark, 1991, Stark et al., 1993), which may also 
explain the aggravated pancreatic attack at 72 hrs. To add to this present conception, 
free radicals own ample energy and are unstable. Hence, it is implicit that some 
radicals’ have extremely short half-life period, which prevents them from leaving the 
site of its generation. This could explain depletion of GSH at 72 hrs leading to disease 
progression.  
 
Oxidative damage does happen in a pancreatic attack but its mode of action is still 
unclear. Efforts to demonstrate the participation of free radical association during a 
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pancreatic attack has not been fully successful in human patients despite considerable 
body of information being available from the animal models. Nevertheless, 
experimental effectiveness on animal models does not mirror the clinical reality because 
patients are admitted to the hospital only after the onset of the disease/ attack. This 
reflects that the disease is fully established and the mechanisms taking place during this 
time gap has not been identified so far in human patients. It must be stressed, that to-
date no direct evidence for these proposed mechanisms is available and it is impossible 
to prove that GSH depletion, coupled with oxidant stress, underlies the development of 
AP in humans (Wallig, 1998). From a clinical point of view, the above-explained 
arguments may seem controversial. However it is, important to realise that these 
preponderances are an “association”, and may/ may not reflect on the theoretical 
advantage of the present study. Nevertheless, oxidative damage exerted by the GSH and 
γ-GT system can be considered as a contributing factor to AP attacks.  
 
Of interest AP is an inflammatory disease associated with auto-digestion of the 
pancreas, intra-hepatic activation and release of digestive enzymes. Current perspectives 
favour evidence that pancreatic ischemia also plays an important role in AP 
(Yuzbasioglu et al., 2008). The current consensus is that a disturbance of pancreatic 
microcirculation leads to the formation of thrombus in the capillaries, following 
activation of leukocytes, release of proteolytic enzymes and formation of ROS and/ or 
proinflammatory cytokines. Evidences also suggested that there is a relationship 
between pancreatitis and homocysteinuria, possibly being secondary to occlusive 
vascular disease of the pancreas (Makins et al., 2000). Thus, elevated Hcy levels may be 
a cause of AP with endothelial dysfunction and impaired micro vascular circulation 
(Yuzbasioglu et al., 2008).  
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Folate deficiencies depress remethylation of Hcy to Met. Met is an essential amino acid 
and is avidly taken up by pancreas (Mann et al., 1989) and has a key role in maintaining 
the integrity and proper functioning of the pancreas (Girish et al., 2010). It was reported 
that in alcohol-induced relapse of pancreatitis, leukocyte Met levels exceeded those in 
controls while GSH remained largely oxidized (Martensson and Bolin, 1986). Their 
study suggested that oxidative stress within the gland interferes with Met metabolism at 
a point distal to SAM, causing amino acid flux into plasma. Collectively, their results 
indicated the extension of free radical pathology from the pancreas to the peripheral 
blood during an attack. Reduced plasma Met levels have been observed in patients with 
chronic pancreatitis (Girish et al., 2010)  
 
6.2. Redox regulation and glutathione 
 
The concept of redox regulation is suffering much popularity, mainly because of the 
redox couples functioning to maintain the redox homeostasis and to add to this 
popularity, redox regulation is an “emerging concept”. There will always be a struggle 
to quantify oxidative stress because the redox couples in the body are not in constant 
state of equilibrium (Smith, 2005). Furthermore, there are no data (at present), available 
to show that individuals with increased oxidized (GSSG) redox ratio are at a risk of 
developing any kind of disease and / or any clinical interventions could possibly 
normalize this increased oxidized ratio could provide a beneficial effect. However, 
common quantitative standards would advance the clinical utility of biomarkers of 
oxidative stress. Based upon available data, the redox state of GSH/GSSG ratio would 
provide a reasonable place to begin.  
A comprehensive compilation of references is available to quantify GSH. Information 
on GSSG quantification are however scanty. The second aspect of the present study was 
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to transfer a proficient methodology to determine tGSH and GSSG in whole blood and 
subtract the two to get the GSH present. The fact that one can assess oxidative stress in 
vivo in plasma by measuring GSH/GSSG in animal (rodent) models was established 
several years ago (Adams et al., 1983). However, application of the same approach to 
human studies has been limited due to enhanced oxidation of GSH that allows 
erroneous errors during its measurements.  
 
The novelty of the present method comes from the use of a mercaptan scavenger M2VP 
to scavenge GSH and quantify GSSG in whole blood, which no earlier studies have 
done using M2VP in a HPLC setting. Unfortunately, at this late juncture, this developed 
method could not be applied on the blood samples from sepsis patients, which may have 
provided grounds for GSH loss in the pancreatic study. Nevertheless, the method 
developed as described in detail in chapter 3 allowed suitable venture for GSSG 
determination.  
 
6.3. Estimation of bile salts in human bile using liquid chromatography-mass 
spectrometry  
 
There has been steady progress in the bile acid science (cholanology), aimed at 
elucidating their physiological functions and developing pharmacological applications.  
Mass spectrometric methods have become indispensable for the analysis of bile acids to 
quantify either free or conjugated bile acids. Further, the emergence of soft ionization 
technique such as ESI has considerably simplified bile analysis. ESI was well suited for 
polar, non-volatile and thermo liable compounds.  
The present study has identified the bile salt levels in a small cohort of patients 
suffering from various cholestatic-hepatobiliary diseases and in an attempt has tried to 
explain different responses/ behaviour of bile salts using LC-MS. This method is simple 
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and provides high sensitivity and specificity to perform quantitative-profiling of 
individual bile salts. Negative ion mass spectra were characterized by intense [M-H]- 
ions and product ions due to consecutive loss of Na+/ water corresponding to number of 
hydroxyl groups present. Quantifying bile acids in these patients with the use 
isotypically labelled internal standard is an improvement and novel in this method. 
Deuterated bile acid analogs behave identically to their analytes and differ in their mass-
to-ratio (m/z) (Burkard et al., 2005). 
 
A number of hepato-biliary diseases have been identified which are caused by defects in 
bile acid biosynthesis. Current perspectives upon a comprehensive evaluations of six 
patients in this study favour evidence for the existence of high levels of hydrophobic bile 
salts in conjugation with deoxycholic acid (tauro and glyco conjugates) in all the patients. 
It is suggested that retention of hydrophobic bile like taurine and glycine conjugates of the 
secondary bile salt deoxycholate is the main cause of hepatotoxicity (Grattagliano et al., 
2005). This is often associated with impaired mitochondrial metabolism, heightened 
oxygen radical production and oxidative damage (Krahenbuhl et al., 1994, Sokol et al., 
1994).  
 
The current study is far too small to provide a meaningful interpretation for 
hepatobiliary diseases. However, the small cohorts of six patients have demonstrated 
valuable observation in terms of their levels in diseased state. The use of LC-MS has 
resulted in a resurgence of interest in the determination of bile acids, accurate 
identification and quantification of bile acids in hepatobiliary diseases.  
Finally, a comprehensive exploration of bile acid in patients with various cholestatic-
hepatobiliary diseases in large numbers will probably be a clinical intervention with 
new therapies in future. It is claimed that UDCA is extensively used in therapy for 
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biliary diseases (Combes et al., 1999). However, relatively little information is available 
on the effect of UDCA in compensating for low primary bile acids levels.  
 
6.4. Future work 
 
The present work has focussed on oxidant stress leading to depleted thiol status, 
focussing on GSH status, in an auxiliary inflammatory condition called AP. Although 
various theories have been pin-pointed for the depleted GSH status, it still remains 
blurred, whether the current data, pose that oxidative stress and GSH depletion play a 
significant role in the development of severe pancreatitis and whether the maintenance 
of intracellular GSH concentration has beneficial therapeutic implication.  
 
The corollary that ancillary antioxidant systems (vitamin C, vitamin E or GPx), exert a 
GSH-sparing facility has been exploited by way of supplementing antioxidants (Uden et 
al., 1990). However, the question whether antioxidant therapy is beneficial or 
functionally redundant remains unanswered to date. Although data produced by the use 
of GSH analogues in sepsis remains controversial due to conflicting results (Spies et al., 
1994, Peake et al., 1996), their use in AP cannot be advocated without a better 
understanding of GSH metabolism in this disease. If GSH depletion is the principal 
mediator of disease progression, a better understanding of its kinetics in clinical 
pancreatitis needs to be ascertained to reduce the chances of treatment failure.  
 
In addition, future work needs to address cellular loss of GSH and the biochemical 
processes that separate mild from severe attacks of pancreatitis. This may fall into three 
broad categories: reduced synthesis (either due to inadequate amino acid availability or 
decreased activity of key regulatory enzymes), reduced recycling of GSSG (disulfide 
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pool), or increased cellular GSH loss (through oxidative stress, reduced recycling, or 
xenobiotic conjugation).  
 
It may be inferred that a fall in GSH reflects a build up of GSSG (GSSG may 
accumulate in the face of oxidative stress), and a number of experimental studies 
supports this notion. Hence, measuring GSSG along with sulfur amino acids would 
provide useful information about the GSH/GSSG ratio in patients suffering from AP.  
Plasma Met, SAM, folate, vitamin B12 levels determination upon admitting AP patients 
would provide useful information about transsulfuration intermediates. In addition, 
conjugation of GSH through mercapturic acid pathway would possible estimate loss of 
GSH. In addition, urinary excretion of oxoproline can suggest the loss of GSH. Hence, 
an estimation of this loss would be valuable indicator of redox balance.  
 
Pancreas is low in transsulfuration enzymes (Wallig, 1998) in normal physiological 
conditions, an inflammation in the organ, can explain if transsulfuration enzymes are 
expressed during AP. Cogent with these statements, the catabolism of intracellular GSH 
by other mechanism cannot be ruled out. Although, GSH is considered resistant to 
normal pancreatic intracellular enzymes, an inappropriate release (characteristic of 
pancreatic attacks) of digestive enzymes that could yet play an anonymous role in GSH 
loss. This can potentially provide subject of further studies. 
 
The γ-GT expression during inflammatory conditions are tantalising but unproven 
during AP progression. Only a well-designed clinical study will provide a meaningful 
interpretation of γ-GT expression during AP. As stated elsewhere, GCL is a heterodimer 
and takes part in the synthesis of GSH. The activity of two subunits can be 
compromised during an oxidative stress. The stress response model as described by 
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(Yang et al., 2002), can possible be correlated to humans and during a stress response 
like in AP. The cellular pathway approaches towards oxidative stress are significantly 
complex than originally envisioned. Hence, any pharmacological interventions will only 
or probably be promising when they target the regulatory pathways linked to these 
diseases. This perhaps, can potentially ameliorate pancreatic injury caused by free 
radicals.  
 
The present study also reported bile acid levels in cohort of patients suffering from 
various degrees of cholestatic hepato-biliary disorders. The data reported increased 
levels of LCA compared to other primary and secondary bile acids. Increased levels of 
LCA are toxic in normal physiology. Further studies can explain the toxicity of LCA in 
cholestatic hepato-biliary diseases. In addition, further studies can be focussed on 
increasing the resolution of taurine conjugates and perhaps identify a probable isoform 
of TCA eluting 2 min earlier than the normal standard retention time (see Figure 5.6). In 
the present study, poor peak shape resulted in varied limits of LoD and chromatograms. 
Future studies can perhaps enhance these limitations.    
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APPENDICES 
Table 3.1. Calibration line for GSH  
 
 
Conc. of 
GSH 
mM 
GSH 
(µL) 
MPA 
(µL) 
Water 
(µL) 
Volume 
Taken(µL) 
 
OPA  
(µL) 
phosphate 
(µL) 
10  100 400 500 100 100 800 
8  100 400 500 100 100 800 
6 100 400 500 100 100 800 
4 100 400 500 100 100 800 
2 100 400 500 100 100 800 
1 100 400 500 100 100 800 
 
 
 
Table 3.2. Choosing appropriate concentration for DTT reduction   
 
 
Conc. 
of 
DTT 
(mM) 
 
GSSG 
(μL) 
0.5 
mM 
GEE 
(μL) 
 
Water 
(μL) 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
Volume 
taken 
(μL) 
OPA 
(μL) 
Phosphate 
(μL) 
50 100 50 300 100 50 400 100 100 800 
35 100 50 300 100 50 400 100 100 800 
30 100 50 300 100 50 400 100 100 800 
25 100 50 300 100 50 400 100 100 800 
20 100 50 300 100 50 400 100 100 800 
10 100 50 300 100 50 400 100 100 800 
50 0 50 550 0 0 400 100 100 800 
35 0 50 550 0 0 400 100 100 800 
30 0 50 550 0 0 400 100 100 800 
25 0 50 550 0 0 400 100 100 800 
20 0 50 550 0 0 400 100 100 800 
10 0 50 550 0 0 400 100 100 800 
Blank 100 50 300 100 50 400 100 100 800 
Blank 0 0 450 100 50 400 100 100 800 
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Table 3.3. Calibration line for GSSG with and without DTT 
 
 
Conc. 
of 
GSSG 
(μM) 
 
GSSG 
(μL) 
GEE 
(μL) 
Water 
(μL) 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
Volume 
Taken 
(μL) 
OPA 
(μL) 
Phosphate  
(μL) 
1000 100 50 300 100 50 400 100 100 800 
500 100 50 300 100 50 400 100 100 800 
300 100 50 300 100 50 400 100 100 800 
100 100 50 300 100 50 400 100 100 800 
50 100 50 300 100 50 400 100 100 800 
10 100 50 300 100 50 400 100 100 800 
5 100 50 300 100 50 400 100 100 800 
1000 100 50 450 0  400 100 100 800 
500 100 50 450 0  400 100 100 800 
300 100 50 450 0  400 100 100 800 
100 100 50 450 0  400 100 100 800 
50 100 50 450 0  400 100 100 800 
10 100 50 450 0  400 100 100 800 
50 100 50 450 0  400 100 100 800 
Blank 0 50 400 100 50 400 100 100 800 
Blank  0 0 600 0 0 400 100 100 800 
 
 
Table 3.4. Calibration line for tGSH  
 
 
Initial 
conc. 
standard 
mixture 
GSH+GSSG 
 
Final  
Conc. 
(mM) 
Mix 
(μL) 
GEE 
(μL) 
Water 
(μL) 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
V
ol
um
e 
Ta
ke
n 
(μL
) 
OPA 
(μL) 
Ph
os
ph
at
e 
(μL
) 
1 0.5 100 50 300 100 50 400 100 100 800 
2 1 100 50 300 100 50 400 100 100 800 
4 2 100 50 300 100 50 400 100 100 800 
5 2.5 100 50 300 100 50 400 100 100 800 
           
1 0.5 0 50 400 100 50 400 100 100 800 
2 1 0 50 400 100 50 400 100 100 800 
4 2 0 50 400 100 50 400 100 100 80 
5 2.5 0 50 400 100 50 400 100 100 800 
Blank  0 0 50 400 100 50 400 100 100 800 
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Table 3.5. Choosing a suitable M2VP and NEM concentration for scavenging  
 
 
C
on
c.
 o
f 
sc
av
en
ge
r 
(m
M
) 
M2VP 
(μL) 
NEM 
(μL) 
GSH 
(μL) 
GEE 
(μL) 
Water 
(μL) 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
V
ol
um
e 
 
Ta
ke
n 
 μL
) OPA  
(μL) 
Ph
os
ph
at
e 
(μL
) 
Blank 0 10 0 50 290 100 50 400 100 100 800 
15 10 0 100 50 290 100 50 400 100 100 800 
10 10 0 100 50 290 100 50 400 100 100 800 
8 10 0 100 50 290 100 50 400 100 100 800 
5 10 0 100 50 290 100 50 400 100 100 800 
3 10 0 100 50 290 100 50 400 100 100 800 
1 10 0 100 50 290 100 50 400 100 100 800 
0 0 0 100 50 300 100 50 400 100 100 800 
15 0 10 100 50 290 100 50 400 100 100 800 
10 0 10 100 50 290 100 50 400 100 100 800 
8 0 10 100 50 290 100 50 400 100 100 800 
5 0 10 100 50 290 100 50 400 100 100 800 
3 0 10 100 50 290 100 50 400 100 100 800 
1 0 10 100 50 290 100 50 400 100 100 800 
0 0 0 100 50 300 100 50 400 100 100 800 
Blank 0 10 0 0 290 100 50 400 100 100 800 
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3.6. Comparison of scavenging capabilities of M2VP and NEM. 
 
Initial 
Conc. 
(μM) 
 
Actual 
Conc. 
(μM) 
 
M2VP 
Or 
NEM 
MIX 
(μL) 
GEE 
(μL) 
Water 
(μL) 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
Volume 
taken 
(μL) 
OPA 
(μL) 
Ph
os
ph
at
e 
(μL
) 
tGSH            
500 250 0 100 50 300 100 50 400 100 100 800 
300 150 0 100 50 300 100 50 400 100 100 800 
100 50 0 100 50 300 100 50 400 100 100 800 
50 25 0 100 50 300 100 50 400 100 100 800 
10 5 0 100 50 300 100 50 400 100 100 800 
0 0 0 0 0 450 100 50 400 100 100 800 
            
GSSG  M2VP          
500 250 10 100 50 300 100 50 400 100 100 800 
300 150 10 100 50 300 100 50 400 100 100 800 
100 50 10 100 50 300 100 50 400 100 100 800 
50 25 10 100 50 300 100 50 400 100 100 800 
10 5 10 100 50 300 100 50 400 100 100 800 
0 0 0 100 50 300 100 50 400 100 100 800 
Blank 0 0 0 0 450 100 50 400 100 100 800 
  NEM          
500 250 10 100 50 300 100 50 400  100 800 
300 150 10 100 50 300 100 50 400 100 100 800 
100 50 10 100 50 300 100 50 400 100 100 800 
50 25 10 100 50 300 100 50 400 100 100 800 
10 5 10 100 50 300 100 50 400 100 100 800 
0 0 0 100 50 300 100 50 400 100 100 800 
Blank 0 0 0 0 450 100 50 400 100 100 800 
            
GSSG            
250 250 0 100 50 300 100 50 400 100 100 800 
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Table 3.7. Comparison of scavenging capabilities of M2VP and NEM with 
increasing concentration of GSH 
 
Conc. 
Of 
GSH 
(μM) 
M2VP 
15 
mM 
(μL) 
NEM 
15 
mM 
(μL 
GSH 
(μL) 
GSSG 
(μL) 
GEE 
(μL) 
Water 
(μL)r 
DTT 
(μL) 
TRIS 
(μL) 
MPA 
(μL) 
V
ol
um
e 
Ta
ke
n 
(μL
)
OPA 
(μL) 
Ph
os
ph
at
e 
(μL
 
2000 10 0 100 100 50 190 100 50 400 100 100 800 
1000 10 0 100 100 50 190 100 50 400 100 100 800 
450 10 0 100 100 50 190 100 50 400 100 100 800 
100 10 0 100 100 50 190 100 50 400 100 100 800 
50 10 0 100 100 50 190 100 50 400 100 100 800 
30 10 0 100 100 50 190 100 50 400 100 100 800 
25 10 0 100 100 50 190 100 50 400 100 100 800 
20 10 0 100 100 50 190 100 50 400 100 100 800 
10 10 0 100 100 50 190 100 50 400 100 100 800 
5 10 0 100 100 50 190 100 50 400 100 100 800 
             
2000 0 10 100 100 50 190 100 50 400 100 100 800 
1000 0 10 100 100 50 190 100 50 400 100 100 800 
450 0 10 100 100 50 190 100 50 400 100 100 800 
100 0 10 100 100 50 190 100 50 400 100 100 800 
50 0 10 100 100 50 190 100 50 400 100 100 800 
30 0 10 100 100 50 190 100 50 400 100 100 800 
25 0 10 100 100 50 190 100 50 400 100 100 800 
20 0 10 100 100 50 190 100 50 400 100 100 800 
10 0 10 100 100 50 190 100 50 400 100 100 800 
5 0 10 100 100 50 190 100 50 400 100 100 800 
Blank 0 0 0 100 50 300 100 50 400 100 100 800 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
